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IschemIa reperfusIon Injury of the kIdney
A 69-year-old patient walked into the hospital without any complaints and was scheduled 
to undergo elective open abdominal aneurysm repair. The operation required 40 minutes 
of suprarenal clamping of the aorta, temporarily obstructing the renal blood flow and 
therefore causing the patient to develop renal failure. As a result, the elective intervention 
tragically sentenced this man to lifelong dependency on haemodialysis. This dramatic 
clinical presentation of the patient in the intensive care unit provides the starting point 
of our interest in ischemia-reperfusion injury of the kidney. 
The type of renal damage described above can occur in aorta surgery, kidney 
transplantation, iodine contrast administration for imaging, sepsis, kidney operations, 
and in major operations with large hemodynamic changes. The pathophysiology of this 
type of renal damage is well understood: the blood flow is the most important regulatory 
guardian of the fundamental needs of the human (renal) cell, which depends on a strict 
range of parameters for its viability, such as temperature, electrolyte balance, nutrition 
and oxygenation. Compensating mechanisms enable the cell to cope with minor changes 
in these parameters, but larger disturbances can have devastating effects, such as cell 
death, tissue damage, loss of organ function, organ failure, and even death. The specific 
type of renal damage described in the case above is called ischemia-reperfusion injury 
(IRI) and is caused by the temporary obstruction of or lower blood flow to the organ 
or tissue. The degree of damage is determined by the duration of the obstruction or 
lower blood flow and the type of tissue involved, as tissues differ in susceptibility to IRI. 
In addition to the brain and heart, the kidney is particularly vulnerable to IRI because of 
its high energy demand and intricate microvascular network. This high energy demand is 
illustrated by the fact that apart from the heart, the kidney contains the highest number 
of mitochondria in the body. The primary tasks of the kidney involve continuous cellular 
processes with large energy and oxygen consumption, including maintaining electrolyte, 
acid-base and osmolality balance, excreting waste products and reabsorbing vital 
nutrients [1]. Blood flow to the kidney is high, with approximately 20% of the cardiac 
output running through both kidneys. However, the anatomy of the renal vasculature 
leads to low oxygen concentrations in specific parts of the kidney, which are just sufficient 
under normal physiological circumstances. This results in a narrow range of supply and 
demand of oxygen and nutrient concentrations, making the kidney highly susceptible 
to IRI [2]. The typical period of renal ischemia that causes irreversible damage is longer 
than 30 minutes [3]. 
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In order to attenuate the detrimental effects of IRI, it is essential to understand its 
underlying pathophysiological mechanism. In the past thirty years, our understanding 
of the molecular pathways in IRI has greatly increased. It is assumed that mitochondria, 
the energy producing organelles in cells, play a pivotal role in IRI. In the absence or 
severe reduction of blood circulation, the cell becomes deprived of oxygen, switching its 
energy cycle from the aerobic citric acid cycle (the producer of adenosine triphosphate; 
ATP) to anaerobic metabolism. The latter generates H+, pyruvic acid and lactate, thereby 
lowering the intracellular pH. Simultaneously, ATP depletion leads to ATP-dependent ion 
transporters dysfunction, disrupting the intracellular ion homeostasis. Due to the acidic 
intracellular environment, the cell transports H+ outside the cell in exchange for Na+. 
This increase in intracellular Na+ reverses the activity of the Na+/Ca2+ exchanger, causing 
an influx of Ca2+. The subsequent rise in intracellular and mitochondrial calcium levels 
induces cell swelling and eventually cell death [4].
Restoration of the circulation is essential to discontinue the harmful effects of ischemia. 
However, paradoxically, reperfusion is also detrimental to the ischemic tissue and greatly 
contributes to the total degree of IRI. For instance, in animal models of myocardial 
infarction, reperfusion injury accounts for 50% of the total infarct size [5]. Reperfusion 
injury is caused by the induction of prolonged opening of the mitochondrial permeability 
transition pore (mPTP), which is located in the inner mitochondrial membrane. The 
opening of the mPTP leads to depolarisation of the mitochondrial membrane and an 
increase in its permeability, causing disruption of the mitochondria and eventually 
cell death. The extent of the mPTP opening determines whether the cell can recover, 
undergo apoptosis, or undergo necrotic cell death. Two pathophysiological processes 
following reperfusion affect the opening of the mPTP. First, the acidic environment 
during the ischemic period prevents the opening of mPTP. After reperfusion, abrupt 
restoration of intracellular pH occurs due to the re-activation of Na+/H+-exchanger and 
Na+/HCO3-transporter, which result in mPTP opening. Second, abrupt restoration of 
oxygen levels causes this oxygen to react with enzymes and metabolites of anaerobic 
metabolism, forming reactive oxygen species (ROS) that cause oxidative stress, lipid 
peroxidation, damage to membrane of cells, and prolonged opening of the mPTP [6-9]. 
Because of its pivotal role in IRI, the pharmacological inhibition of mPTP-opening has 
been proposed as a promising strategy to reduce IRI. However, despite the identification 
of some substructures of the mPTP, its exact anatomical structure remains unclear [10, 
11]. It is therefore not yet possible to specifically target the mPTP with pharmacological 
agents [12]. 
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IschemIc condItIonIng strategIes
The current strategy to reduce renal IRI is to shorten the ischemic period and, in 
transplantation surgery, to cool the organ. However, these strategies are often insufficient 
or not possible. Another method that has been shown to diminish IRI is local ischemic 
preconditioning (LIPC). LIPC is the application of short, harmless periods of ischemia 
to a certain tissue in order to reduce IRI caused by a subsequent long, harmful period 
of ischemia [13]. In 1986 Murry et al. [14] were the first to describe LIPC in a canine 
myocardial infarction model. A protocol of 4x5 minutes of ischemia and reperfusion 
proved highly successful in reducing myocardial infarct size upon 40 minutes of index 
ischemia and reperfusion (Figure 1.1). However, the same LIPC protocol was not 
successful in reducing IRI after three hours of index ischemia and reperfusion [14], 
indicating that protection can only be accomplished with a selected conditioning protocol 
and that its efficacy is dependent on the severity of IRI. Since this landmark study, LIPC 
has been shown to induce protection against IRI in many organs. Although the first study 
investigating the protective effects of LIPC for renal IRI, published in 1997 [15], showed no 
protection, later studies did show highly successful reduction of renal IRI [16] (Figure 1.1).
Figure 1.1. Infarct size in a canine heart model of Murry et al. in 1986 and serum creatinine concentrations 
in the study of Islam et al. after 48 hours, 45min IRI, in control and 4x 4min LIPC mice, figure adapted from 
[14, 15].
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It was not until decades after the discovery of LIPC that the mechanism of action in 
LIPC was explored. Since then, thousands of studies have reported over 100 different 
molecules related to the mechanism underlying LIPC [17]. Despite this vast amount of 
data, the precise mechanism through which LIPC prevents IRI remains unclear. However, 
some pieces of the puzzle have been identified. With the mitochondrion being the key 
in IRI, the same organelle provides the basis for the protective mechanism of LIPC. More 
specifically, inhibiting mPTP opening prevents IRI [18] and LIPC inhibits the opening 
of mPTP [19, 20]. Since mPTP opening occurs in the first minutes of reperfusion, the 
protective agent of LIPC has to be active in this timeframe, making appropriate timing 
of the LIPC stimulus crucial [21]. In animals, protective effects of LIPC have been found 
in studies where the LIPC protocol was applied a few minutes or hours before IRI, the 
so-called early window of protection, as well as in studies with a long interval of days 
or even weeks between LIPC and IRI, the late window of protection. 
The signalling pathways underlying LIPC can be divided into two main categories. In 
the first category, LIPC directly inhibits mPTP opening by activating specific signalling 
cascades, including the Reperfusion Injury Salvage Kinase (RISK) and Survivor Activating 
Factor Enhancement (SAFE) pathways (Figure 1.2) [22-24]. In the second category, LIPC 
indirectly inhibits mPTP opening by attenuating a number of the intracellular changes 
caused by ischemia and reperfusion. These intracellular changes include four distinctive 
mechanisms of action: 1) reduction of reactive oxygen species (ROS) formation [25, 
26]; 2) opening of the ATP-dependent mitochondrial K+ channels, which reduces the 
mitochondrial Ca2+ overload, thereby inhibiting mPTP opening [24, 27-29]; 3) reduction 
of the ATP consumption and/or preservation of ATP production during ischemia and 
reperfusion [30, 31]; and 4) delaying the restoration of the intracellular pH, thereby 
maintaining the acidic environment and inhibiting the opening of mPTP [32]. The precise 
mechanism of the two main pathways is not yet fully understood, and the direct and 
indirect effects of LIPC on the mPTP can act simultaneously and have a certain overlap 
in their working mechanism [23, 24]. 
Overall, there is sufficient evidence to suggest that, with a specific LIPC protocol and a 
determined IRI period, LIPC is effective in reducing IRI in a wide range of animal models, 
in different organs [33]. Although there is growing evidence of how LIPC works, it is not 
yet possible to predict the most effective application of LIPC for a specific species, organ 
or tissue; there is no overview of all animal studies performed. Such a meta-analysis 
could identify characteristics that determine the effectiveness of LIPC protocols and could 
give answers to the translational difficulties between animal studies and human trials.
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After the discovery of LIPC in 1986 [14], Pryzklenk et al. conducted their landmark study in 
1993: an ischemic preconditioning (IPC) stimulus applied to the circumflex coronary artery 
diminished IRI that was caused by a 60 minute occlusion of the left anterior descending 
coronary artery [35]. These coronary arteries supply different areas of the cardiac muscle, 
without anastomoses between the two. The protective effect of IPC on a distant tissue 
undergoing ischemia and reperfusion is called remote ischemic preconditioning (RIPC). 
Later studies reported that various remote organs and tissues can be preconditioned 
Figure 1.2. The Reperfusion Injury Salvage Kinase (RISK, in yellow) and Survivor Activating Factor 
Enhancement (SAFE, in red) pathways [17].
Akt indicates protein kinase B; AMPK, cyclic adenosine monophosphate–activated kinase; BNP, brain 
natriuretic peptide; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; 
COX, cyclooxygenase; Cx 43, connexin 43; DAG, diacylglycerol; EGFR, epidermal growth factor receptor; 
ERK, extracellular regulated kinase; FGF, fibroblast growth factor; Gs/Gi/q, stimulatory/inhibitory G protein; 
GPCR, G protein-coupled receptor; gp130, glycoprotein 130; GSK3β, glycogen synthase kinase 3 β; H2S, 
hydrogen sulfide; H11K, H11 kinase; HIF1α, hypoxiainducible factor 1α; IGF, insulin-like growth factor; 
iNOS, inducible NO synthase; IP3, inositoltrisphosphate; JAK, Janus kinase; KATP, ATP-dependent potassium 
channel; Na+/H+, sodium/proton-exchanger; NPR, natriuretic peptide receptor; pGC, particulate guanylate 
cyclase; p38, mitogen-activated protein kinase p38; NO, nitric oxide; eNOS, endothelial nitric oxide synthase; 
PI3K, phosphatidylinositol [4,5)-bisphosphate 3-kinase; PKC, protein kinase C; PKG, protein kinase G; PLC, 
phospholipase C; PTEN, phosphatase and tensin homolog; PTK, protein tyrosin kinase; ROS, reactive oxygen 
species; sGC, soluble guanylate cyclase; SR, sarcoplasmic reticulum; STAT, signal transducer and activator of 
transcription; and TNFα, tumor necrosis factor α. The NO/PKG pathway is displayed in green, the RISK pathway 
in yellow, and the SAFE pathway in red.
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to protect the heart from IRI [36]. Furthermore, other organs including the kidney can 
also be protected by RIPC (Figure 1.3) [59].
Thus, RIPC seems applicable to many organs or body parts and produces a universal 
protective signal throughout the body, and its mechanism of action appears to resemble 
that of local IPC. Although not as extensively investigated, available literature shows that 
the protective effect of RIPC is initiated by similar pathways and that a similar degree 
of protection is achieved [38]. Recent evidence suggests that the signal is transmitted 
either humorally, immunologically or neurogenically, or via a combination of these 
pathways [17, 39].
Figure 1.3. A demonstration of the noncardiac organs and tissue in which RIPC may offer protection against 
IRI. In each organ and tissue, there are a number of clinical settings in which RIPC has been or is currently 
being investigated [59].
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Compared to local IPC, RIPC has major advantages in terms of translation to the clinical 
setting. An IPC stimulus applied directly to the kidney is often highly invasive, since it 
requires laparotomic or laparoscopic access to the renal vasculature, and clamping 
introduces risks of complications, such as damage to the vasculature, bleeding and 
infection. A commonly used method to apply RIPC on the other hand, is the inflation 
of a blood pressure cuff around an extremity, at a pressure beyond the systolic blood 
pressure (Figure 1.4). Using an extremity is favourable, since skeletal muscle can 
tolerate an interruption of blood flow for periods up to several hours without suffering 
irreversible damage. Remote conditioning protocols typically consist of cycles of three 
to five minutes of ischemia, during which damage due to compression of vessels and 
nerves in the extremity is negligible. Even in patients with atherosclerosis and peripheral 
vascular disease, it appears to be safe to occlude the vasculature by blood pressure cuff 
to apply RIPC [40]. Furthermore, the procedure can be performed without anaesthesia, 
is inexpensive, and effortless. Although clinical trials investigating the protective effect of 
RIPC on renal IRI initially showed positive results [41], these were not always replicated 
in later trials [40]. A systematic review and meta-analysis of all clinical trials is helpful to 
summarize all available evidence on the protective effect of RIPC on renal IRI in patients, 
identify possible adverse effects and improve the design of future clinical studies by 
analyzing the influence of decisive variables of these trials.
The currently used RIPC protocols in clinical trials are still the same protocols that were 
used by Murry et al. in his LIPC experiment in 1986 [14]. All trials use a similar two to four 
cycles of five to ten minutes protocol to precondition the target organ. With accumulating 
Figure 1.4. An anesthetised Sprague-dawley rat undergoing remote ischemic conditioning by bilateral 
occlusion of the hind limbs with blood pressure cuffs.
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disappointing results, exploring different IPC protocols could optimize the effectiveness 
of IPC for the human kidney. There is, for instance, evidence that repeating the RIPC 
stimulus over several days (RepRIPC) protects the heart from IRI [42]. A possible indication 
of the positive effect of RepRIPC is the improvement of the endothelial function of the 
vasculature [43]. Although there is no evidence for beneficial effects of RepRIPC in renal 
IRI models, our hypothesis is that RepRIPC could also increase the RIPC effectiveness 
in renal IRI models.
Apart from renal surgery and transplantation, contrast induced nephropathy is a field 
in which RIPC could be applied to reduce renal damage in patients. Iodine contrast 
administration causes acute kidney injury, known as contrast induced nephropathy 
(CIN). Although the precise mechanism underlying CIN remains unknown, evidence 
exists that contrast media have direct toxic effects on the tubular cells, resulting in 
altered mitochondrial function and apoptosis. Moreover, compelling evidence exists 
from experimental models that renal ischemia, resulting from contrast induced 
vasoconstriction, plays a key role in the pathogenesis of CIN [44, 45]. The outer part 
of the medulla has an area with high oxygen demand and is therefore vulnerable to 
contrast induced vasoconstriction of the vasa recta. When vasoconstriction resolves 
and the oxygen supply is restored, post-ischemic cells produce free oxygen radicals. The 
formation of free radicals contributes, at least in part, to the renal tubular cell injury 
[46]. This part can be explained by IRI, and can therefore possibly be diminished by RIPC. 
Results of RIPC significantly reducing CIN have already been shown in a small study in 
high-risk patients [47]. A second study in patients with medium risk of CIN showed no 
significant protection [48]. It remains unclear whether patients who are, according to 
the Dutch guidelines, at risk of CIN can benefit from RIPC. 
Despite the advantages of RIPC compared to LIPC, these preconditioning strategies cannot 
be used in patients for whom the moment that IRI occurs is not predictable, such as 
renal IRI in an acute ruptured aneurysm. A solution for this problem was found in 2003 
by Zhao et al. [50]; applying a brief local ischemic stimulus within minutes after index 
ischemia protected the tissue from IRI to the same extent as IPC. This phenomenon is 
referred to as ischemic postconditioning (IPostC), and was first reported to reduce renal 
IRI in 2007 [51]. In analogy to preconditioning, the postconditioning stimulus can be 
successfully applied to either the target organ (LIPostC) or to a remote organ (RIPostC). 
It may seem counter-intuitive to protect tissue from IRI after restoration of the blood 
flow, but because IRI is largely effectuated after reperfusion, a swift protective signal 
appears to reduce IRI.
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Although the underlying mechanism is only partly understood, most molecules involved 
in IPC signalling have also been implicated in LIPostC and RIPostC signalling, and the 
inhibition of mPTP opening appears to be the key factor of the protective effect as well 
[32, 52, 53]. Despite the fact that strategies have been shown to influence the status 
of the mitochondrial permeability transition pore, it has been postulated that LIPostC 
prevents opening of the mPTP by delaying the normalization of the intracellular pH [54]. 
RIPostC on the other hand, is believed to cause the release of various signalling molecules, 
such as adenosine, opioids, and cytokines, which act on the mitochondrial permeability 
transition pore through the activation of the cyclic guanosine monophosphate, Protein 
Kinase G (cGMP/PKG), RISK, or SAFE pathway [55]. Therefore a combination of LIPostC 
and RIPostC could be more effective in reducing renal IRI, and this has not yet been 
tried before. 
Similar to RIPC, preclinical studies on IPostC have yielded contradictory results and it is 
unclear which characteristics influence IPostC efficacy, and which conditioning protocols 
are most effective. Meta-analysis and systematic review of preclinical studies have 
proven useful in optimizing the design of both preclinical and clinical studies [56], but 
are not available for IPostC. Conducting such analyses could make it possible to analyze 
the influence of different variables, thereby improving future study design. For human 
trials on IPostC only limited data is available, herein protective effects have only been 
observed in subgroups or on secondary endpoints [57, 58]. 
RATIonALE And AIMS oF ThIS ThESIS
This thesis focusses on ischemic conditioning strategies and their value in reducing renal 
IRI. In order to achieve successful translation of these strategies to the clinical setting, 
we have employed animal models, systematic reviews and meta-analyses of preclinical 
and clinical data, and conducted a clinical trial. The objectives of this thesis are:
The efficacy of IPC in animal models
• To evaluate the available evidence on the efficacy of local and remote IPC against 
experimental renal IRI, to assess treatment efficacy, and to identify variables that 
influence efficacy.
• To optimize the efficacy of the IPC protocol in an animal model for renal IRI.
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The effectiveness of RIPC in patients 
• To evaluate the efficacy of RIPC in patients undergoing major cardiac or vascular 
surgery in order to reduce renal IRI based on existing evidence from clinical trials. 
• To investigate the efficacy of RIPC in patients undergoing procedures using iodine 
containing contrast agents to reduce renal IRI.
ouTLInE oF ThE ThESIS
Chapter 1 provides an outline of the clinical problem and an introduction to the 
pathophysiology of renal IRI and proposed mechanisms of local and remote IPC and 
IPostC. This introduction is followed by systematic reviews and meta-analyses on (R)IPC 
(Chapter 2) and (R)IPostC (Chapter 3) against renal IRI, providing a detailed overview of 
the current preclinical evidence. The next step is to fill gaps in the current literature on 
animal studies to optimize the efficacy of IPC in reducing renal IRI in an animal model. 
Optimization could be achieved by a combination of successful IPC stimuli. In the first 
animal study, we hypothesized that LIPC in combination with RIPC could enhance the 
protective effect (Chapter 4) and in the second animal experiment (Chapter 5), we studied 
the optimization of RIPC by repeating the RIPC stimulus over seven days. Repeating RIPC 
is an extensive combination of the protective effects of the early and late window of 
protection. In the next chapters, the efficacy of RIPC to reduce renal IRI is investigated 
in humans. In Chapter 6, a systematic review and meta-analysis describe the effects 
of RIPC on renal IRI in all available randomized controlled trials studying renal IRI after 
major cardiac or vascular surgery. Chapter 7 and 8 address a randomized controlled 
trial using RIPC to reduce contrast-induced nephropathy. Chapter 9 provides a general 
discussion of the thesis and future perspectives, and Chapter 10 summarizes the main 
findings of this thesis.
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ABSTRACT
Ischemic preconditioning (IPC) is a potent renoprotective strategy which has not yet been 
translated successfully into clinical practice, in spite of promising results in animal studies. 
We performed a unique systematic review and meta-analysis of animal studies to 
identify factors modifying IPC efficacy in renal ischemia/reperfusion injury (IRI), in order 
to enhance the design of future (clinical) studies. 
An electronic literature search for animal studies on IPC in renal IRI yielded fifty-eight 
studies which met our inclusion criteria. We extracted data for serum creatinine, blood 
urea nitrogen and histological renal damage, as well as study quality indicators. Meta-
analysis showed that IPC reduces serum creatinine (SMD 1.54 [95% CI 1.16, 1.93]), blood 
urea nitrogen (SMD 1.42 [95% CI 0.97, 1.87]) and histological renal damage (SMD 1.12 
[95% CI 0.89, 1.35]) after IRI as compared to controls. Factors influencing IPC efficacy 
were the window of protection (<24 hours = early vs. ≥24 hours = late) and animal species 
(rat vs. mouse). No difference in efficacy between local and remote IPC was observed. 
In conclusion, our findings show that IPC effectively reduces renal damage after IRI, with 
higher efficacy in the late window of protection. However, there is a large gap in study 
data concerning the optimal window of protection, and IPC efficacy may differ per animal 
species. Moreover, current clinical trials on RIPC may not be optimally designed, and our 
findings identify a need for further standardization of animal experiments.
Chapter_2_Theo.indd   24 6-9-2017   10:22:40
25
Ischemic preconditioning in animal models: a systematic review and meta-analysis
2
INTRODUCTION
Ischemic preconditioning (IPC) is a potent protective strategy in which application of 
a brief episode of ischemia and reperfusion (I/R) results in tolerance to subsequent 
ischemia/reperfusion injury (IRI) [1–3]. The conditioning stimulus has been shown to be 
effective when applied either to the target organ itself (local IPC; LIPC [4]) or to a remote 
organ or tissue (remote IPC; RIPC [5]). LIPC and RIPC were both originally discovered in 
the dog heart, and have been successfully reproduced in a variety of animal species, 
using various organs, e.g. heart, intestine, brain, liver and kidney. There is a large variety 
in the IPC protocols used: the preconditioning stimulus may be one continuous ischemic 
period, or it may be comprised of two or more cycles of brief ischemia. Moreover, the 
interval between the preconditioning stimulus and the index ischemia may vary, and 
positive results in animals have been found for both short intervals of a few minutes or 
hours (the so-called early window of protection), as well as for long intervals of days or 
even weeks (late window of protection). 
Thus, IPC poses a promising alternative to existing treatments for IRI in humans, since 
current strategies to reduce this important and common clinical problem are inad-
equate. Next to the heart, the kidney is one of the major organs of interest for clinical 
application of IPC. Its high energy demand and intricate microvascular network render 
the kidney especially sensitive to IRI, which is a major cause of kidney injury in e.g. 
renal artery stenosis and renal surgery [6, 7]. Furthermore, renal IRI is a major cause of 
cardiovascular morbidity and mortality, and is associated with delayed graft function 
after transplantation, renal damage in cardiac and aortic surgery, and shock [8–11]. In 
animal models, both LIPC and RIPC have been shown to be effective tools to protect 
the kidney (e.g. [12, 13]).
Where do we stand in terms of the translation of IPC to beneficial treatment for patients? 
LIPC has not been studied in the human kidney, but several clinical studies have been 
conducted in the heart: a number of studies have investigated LIPC in patients undergoing 
coronary artery bypass grafting (CABG) surgery, which collectively show that LIPC reduces 
inotrope requirements, ventricular arrhythmias, and shortens intensive care unit stay 
[14]. For RIPC, several clinical trials have been performed for cardiac as well as renal 
IRI, but their outcome is not clear-cut: many studies report protective effects of RIPC 
after CABG surgery, heart valve surgery, or abdominal aortic aneurysm repair, but not 
all findings have been positive ([15–18] and recently reviewed in [19]). 
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Thus, even though the protective effect of LIPC and RIPC on renal IRI has been shown in 
many animal studies, translation of IPC to the clinic has, as yet, not been successful. The 
variety of IPC protocols used in clinical trials may be one of the reasons for this ambiguity, 
i.e. in some studies, the stimulus could have been suboptimal or incorrectly applied. 
There is no consensus on how many ischemic stimuli should be applied, and what the 
duration of the ischemic and intermediate reperfusion periods should be. It isunclear 
whether the early or late window of protection is most effective. Furthermore, it is 
unknown which patient-related factors such as age, gender or co-morbidities play a role. 
Meta-analysis and systematic review of preclinical (animal) studies have previously been 
used to optimize experimental animal models and to improve the design of clinical trials 
[20–22]. In the case of IPC, meta-analysis on animal study data may provide valuable 
indicators to optimize the IPC protocol, as well as the window of protection in humans. It 
has been shown that proper analysis of animal experiments can also improve the decision 
making in whether or not to start a clinical trial. In addition, this approach can be used 
to perform a quality assessment of the current literature, including measures to avoid 
bias (e.g. randomization, concealment of allocation and blinded outcome assessment).
As such, meta-analysis of existing literature on animal models may improve future animal 
research in the field, thereby contributing to the Refinement and Reduction of animal 
experiments, as proposed by the Animal Research: Reporting in vivo Experiments [23] 
and Gold Standard Publication Checklist [24] guidelines. 
This report presents innovative methods in reviewing animal studies, i.e. a systematic 
review and meta-analysis of the efficacy of IPC in experimental models of renal IRI. We 
set out to 1) provide a complete and systematic overview of all literature available on 
the effects of IPC (both local and remote) on renal IRI; 2) report summary estimates of 
efficacy based on meta-analysis; 3) identify factors modifying the efficacy of IPC in renal 
IRI, to inform the design of future clinical trials; and 4) provide insight in the quality of 
literature in the field of IPC and renal IRI in animal models.
ANAlySIS
literature search strategy, inclusion and exclusion criteria 
The present review was based on published results of animal studies on the effects of 
IPC on renal IRI, which were identified via a systematic computerized search in PubMed 
and Embase. The inclusion criteria and method of analysis were specified in advance 
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and documented in a protocol. The databases were searched for published articles up 
to October 19th 2011. The full search strategies for PubMed and EMBASE are included 
in Appendix S1, and involved the following search components: ‘‘animal’’ [25, 26], 
‘‘kidney’’, ‘‘ischemia reperfusion injury’’ and ‘‘preconditioning’’. Studies were included 
in the systematic review if they fulfilled all of the following criteria: 1) the study assessed 
the effect of remote or local IPC on renal IRI; 2) the study was performed in animals in 
vivo; 3) the study was an original full paper which presented unique data. Studies were 
excluded if 1) the renal IRI model involved cold storage of the kidney or 2) the study 
was performed only in genetically modified animals. Study selection was performed 
independently by two reviewers (TM and KW) on the basis of title and abstract. In case 
of doubt, the whole publication was evaluated. Differences were clarified by discussion 
with a third investigator (MW). No language restrictions were applied. If necessary, 
papers in languages other than English were translated by scientists (native speakers 
for that particular language) within the Radboud University Nijmegen Medical Centre.
Study characteristics and data extraction
The following study characteristics and data items were extracted from the studies 
included: animal species, strain, sex, number of animals in treatment and control 
groups, measures of randomization, measures of blinding, number of animals excluded 
for statistical analysis, reason for exclusion of animals, reported outcome measures 
and results. Bibliographic details such as author, journal, and year of publication were 
also registered. Three outcome measures were assessed: serum creatinine, BUN and 
histological renal damage. For histology, data could be extracted if the authors used 
the Jablonski [27] score for renal damage, or an adapted version of this scoring system. 
Data were extracted if raw data or group averages, standard deviation (SD) or standard 
error (SE), and number of animals per group (n) were reported, or could be recalculated. 
For 30 articles, relevant outcome measures or study details were not reported. We 
therefore contacted these authors via e-mail and received response from eight authors, 
six of which provided additional data. For two papers, authors reported using six to 
eight animals per group and we included these data using n=6 animals [28, 29]. If the 
number of animals was stated less specific (e.g. >3 animals or 4–8 animals), and the exact 
numbers could not be retrieved by contacting the authors, data were not included. If SE 
was reported, this was converted to SD for meta-analysis. If a study contained separate 
groups for each gender, or several preconditioning protocols, these groups were analyzed 
as if they were separate studies. If two or more identical groups existed, the data were 
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pooled for these groups. If outcomes were measured at several time points, we chose 
the time point at which efficacy was greatest. In eight out of 11 cases, this was 24 hours 
post ischemia, which was also the most common time of measurement overall (see Table 
S2.1). When data were presented only graphically, we contacted authors to obtain the 
numerical values. If these were not available, data were measured using digital image 
analysis software (ImageJ; http://rsbweb.nih.gov/ij/).
Assessment of methodological quality
We designed a 16-point rating system to assess the methodological quality of the included 
publications (see Table S2.2 and legend for details). Concerning the number of excluded 
animals, we assumed that there had been no exclusion if the number of animals per 
group mentioned in the materials and methods section was identical to the number 
stated in the figure legends or results section. 
Data synthesis and statistical analyses 
Data were analyzed using Review Manager Version 5.1 (Copenhagen, The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2011). Meta-analysis was performed for 
the outcome measures serum creatinine, BUN and histology score, by computing the 
standardized mean difference (SMD; the mean of the experimental group minus the 
mean of the control group divided by the pooled SD of the two groups). To account for 
anticipated heterogeneity, we used random effect models in which some heterogeneity 
is allowed. Subgroup analyses were predefined and performed for all outcome measures, 
and were used to assess the influence of variables on IPC efficacy, as well as to explore 
possible causes for heterogeneity. The five subgrouping variables were: timing of index 
ischemia (late or early window of protection), preconditioning protocol (fractionated or 
continuous), site of preconditioning (LIPC, RIPC or both), animal species (rat or mouse) 
and gender (male, female or both). Differences between subgroups were determined by 
calculating the difference between the respective SMDs (ΔSMD) and confidence interval 
(CI) of the difference. Furthermore, subgroup interaction analysis was performed in an 
attempt to further explain the expected study heterogeneity: we compared smaller sets 
of experiments by combining two subgrouping variables, e.g. early-RIPC vs. early-LIPC. 
Unless indicated otherwise, data are presented as SMD and 95% CIs. 
For each outcome measure, we assessed the possibility of publication bias by visually 
evaluating the possible asymmetry in funnel plots. Finally, we investigated whether study 
methodology influenced the results of our meta-analysis. Pre-specified sensitivity analysis 
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was performed to assess whether the chosen cut-off point for early vs. late window of 
protection influenced the outcome of this subgroup analysis.
RESUlTS
Study selection and characteristics  
The electronic search strategy retrieved 253 records from PubMed and 270 articles from 
EMBASE, 310 of which were unique. Seventy-seven papers met our inclusion criteria. On 
the basis of predefined criteria, 19 reports were excluded and the remaining 58 articles 
were retrieved in full (see Figure 2.1).
The characteristics of the included studies are summarized in Table S2.1. There was a large 
variation in study characteristics. In 76% of the 58 included studies, the delay between 
the preconditioning stimulus and the index ischemia was 24 hours, which we considered 
to be the early window of protection. Eleven studies (19%) assessed protection in the 
late window of protection (timing of index ischemia ≥24 hours after IPC), and three 
studies (5%) reported data for both late and early window(s) of protection. For the early 
window of protection, the delay between IPC and index ischemia was four to 40 minutes 
(average 967 minutes). For the late window of protection, this was 24 hours up to 12 
weeks (average 17 ± 23 days). In 28 of the 58 studies (48%), the ischemic preconditioning 
protocol consisted of one continuous stimulus. Twenty-two studies (38%) used only 
fractionated protocol(s), i.e. two to five cycles of brief ischemia and reperfusion, whereas 
eight studies employed both fractionated and continuous stimuli. The majority of studies 
focussed on the protective effects of LIPC on renal IRI. However, five studies assessed the 
effects of RIPC, using hind limb, intestine, liver or subphrenic aortic occlusion as remote 
stimuli. In four studies, both LIPC and RIPC of one kidney to its contralateral counterpart 
were performed (either intentionally, or as a result of a bilateral preconditioning stimulus 
and a unilateral index ischemia). Out of all 58 included studies, 14 were conducted in 
mice (24%), 34 in rat (59%), and ten in other species, namely rabbit (7%), dog (5%) and 
pig (5%). Eight out of 58 studies (14%) were performed in female animals, 37 in males 
(64%), and four studies used animals of both genders (7%). Nine studies did not report 
the gender of the animals.
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Methodological quality of studies
The results of the quality assessment of the 58 studies included in this systematic 
review are shown in Table S2.2 and Figure 2.2. On average, studies reported nine out of 
16 characteristics (59 ± 10%). The lowest score was five out of 15 items (33%), and the 
highest scoring studies reported 12 items out of 14 (80%). In the quality assessment of 
Figure 2.1. Flow chart of study selection.
The number of studies in each phase is indicated between brackets.
or mouse) and gender (male, female or both). Differences between
subgroups were determined by calculating the difference between
the respective SMDs (DSMD) and confidence interval (CI) of the
difference. Furthermore, subgroup interaction analysis was
performed in an attempt to further explain the expected study
heterogeneity: we compared smaller sets of experiments by
combining two subgrouping variables, e.g. early-RIPC vs. early-
LIPC. Unless indicate otherwise, data are presented as SMD and
95% CIs.
For each outcome measure, we assessed the possibility of
publication bias by visually evaluating the possible asymmetry in
funnel plots. Finally, we investigated whether study methodology
influenced the results of our meta-analysis. Pre-specified sensitivity
analysis was performed to assess whether the chosen cut-off point
for early vs. late window of protection influenced the outcome of
this subgroup analysis.
Results
Study selection and characteristics
The electronic search strategy retrieved 253 records from
PubMed and 270 articles from EMBASE, 310 of which were
unique. Seventy-seven papers met our inclusion criteria. On the
basis of predefined criteria, 19 reports were excluded and the
remaining 58 articles were retrieved in full (see Figure 1).
The characteristics of the included studies are summarized in
Table S1. There was a large variation in study characteristics. In
76% of the 58 included studies, the delay between the
preconditioning stimulus and the index ischemia was ,24 h,
which we considered to be the early window of protection. Eleven
studies (19%) assessed protection in the late window of protection
(timing of index ischemia $24 h after IPC), and 3 studies (5%)
reported data for both late and early window(s) of protection. For
Figure 1. Flow chart of study selection. The number of studies in each phase is indicated between brackets.
doi:10.1371/journal.pone.0032296.g001
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clinical trials, randomization, blinding, and description of withdrawals are key quality 
measures. However, only 40% of the animal studies included in this systematic review 
reported randomization of the animals across treatment groups. Out of the 39 studies in 
which renal histology was an outcome measure, 74% reported blinding of the outcome 
assessment. No study reported blinding for any other outcome measure. Only 29% of the 
studies reported the number of animals excluded, 64% of which did not state the reason 
for exclusion. Although the strong influence of body temperature on renal damage has 
been shown in both large and small animal models, 36% of the studies did not report 
whether the body temperature of the animals was controlled.
Meta-analysis of outcome measures
Results for the outcome measure serum creatinine are summarized in Table S2.3 and 
Figure 2.3. Thirty-two articles studied the effect of one or more IPC protocols on serum 
creatinine after renal IRI. The analysis contained 62 experiments, including data for 512 
control animals which underwent renal IRI only, and 492 animals that underwent IPC + 
renal IRI. In 36 experiments, the SMD and 95% CI indicated that IPC significantly reduced 
the IRI-induced rise in serum creatinine. One study reported a negative effect of IPC on 
serum creatinine [30]. Overall analysis showed that IPC reduced serum creatinine after 
IRI (1.54 [1.16, 1.93], p<0.00001). Overall study heterogeneity was high (83%).
Subgroup analysis showed a beneficial effect of IPC for all subgroups, except for female 
(notably, this subgroup contained only two experiments and was therefore excluded from 
further statistical analysis). We also found a subgroup effect of the variable ‘window of 
protection’ (Table S2.2, filled squares). The ΔSMD and CI of the difference for early vs. 
Figure 2.2. Quality assessment score, averaged per item.
Many studies scored poorly on key characteristics of scientific practice, and measures to avoid bias, such as 
characteristics of the subject population, randomization, blinding and exclusion criteria.
the early window of protection, the delay between IPC and index
ischemia was 4 to 40 min (average 967 min). For the late window
of protection, this was 24 h up to 12 wk (average 17623 d). In 28
of the 58 studies (48%), the ischemic preconditioning protocol
consisted of one continuous stimulus. Twenty-two studies (38%)
used only fractionated protocol(s), i.e. 2 to 5 cycles of brief
ischemia and reperfusion, whereas 8 studies employed both
fractionated and continuous stimuli. The majority of studies
focussed on the protective effects of LIPC on renal IRI. However,
5 studies assessed the effects of RIPC, using hind limb, intestine,
liver or subphrenic aortic occlusion as remote stimuli. In 4 studies,
both LIPC and RIPC of one kidney to its contralateral
counterpart were performed (either intentionally, or as a result
of a bilateral preconditioning stimulus and a unilateral index
ischemia). Out of all 58 included studies, 14 were conducted in
mice (24%), 34 in rat (59%), and 10 in other species, namely rabbit
(7%), dog (5%) and pig (5%). Eight out of 58 studies (14%) were
performed in female animals, 37 in males (64%), and 4 studies
used animals of both genders (7%). Nine studies did not report the
gender of the animals.
Methodological quality of studies
The results of the quality assessment of the 58 studies included
in this systematic review are shown in Table S2 and Figure 2. On
average, studies reported 9 out of 16 characteristics (59610%).
The lowest score was 5 out of 15 items (33%), and the highest
scoring studies reported 12 items out of 14 (80%). In the quality
assessment of clinical trials, randomization, blinding, and
description of withdrawals are key quality measures. However,
only 40% of the animal studies included in this systematic review
reported randomization of the animals across treatment groups.
Out of the 39 studies in which renal histology was an outcome
measure, 74% reported blinding of the outcome assessment. No
study reported blinding for any other outcome measure. Only
29% of the studies reported the number of animals excluded, 64%
of which did not state the reason for exclusion. Although the
strong influence of body temperature on renal damage has been
shown in both large and small animal models, 36% of the studies
did not report whether the body temperature of the animals was
controlled.
Meta analysis of outcome measures
Results for the outcome measure serum creatinine are
summarized in Table S3 and Figure 3. Thirty-two articles studied
the effect of one or more IPC protocols on serum creatinine after
renal IRI. The analysis contained 62 experiments, including data
for 512 control animals which underwent renal IRI only, and 492
animals that underwent IPC + renal IRI. In 36 experiments, the
SMD and 95% CI indicated that IPC significantly reduced the
IRI-induced rise in serum creatinine. One study reported a
negative effect of IPC on serum creatinine [30]. Overall analysis
showed that IPC reduced serum creatinine after IRI (1.54 [1.16,
1.93], p,0.00001). Overall study heterogeneity was high (83%).
Subgroup analysis showed a beneficial effect of IPC for all
subgroups, except for female (notably, this subgroup contained
only two experiments and was therefore excluded from further
statistical analysis). We also found a subgroup effect of the variable
‘window of protection’ (Table S2, filled squares). The DSMD and
CI of the difference for early vs. late was 2.43 [1.29, 3.57],
indicating that the late window of protection of IPC was more
effective in reducing serum creatinine than the early window.
Subgroup analysis indicated a higher IPC efficacy in studies
conducted in mouse vs. rat (Table S2, triangles; DSMD 1.7 [1.5,
1.90]). For other species (dog, pig, rabbit) subgroups were too
small to perform reliable subgroup analysis. No difference in IPC
efficacy was observed for continuous vs. fractionated; DSMD 0.46
[20.30, 1.22]), or males only vs. groups of mixed gender (DSMD
0.38 [20.60, 1.36]). For site of preconditioning, no differences
were found when comparing the subgroups LIPC vs. RIPC
(DSMD 0.06 [20.98, 1.10]), LIPC vs. LIPC +RIPC (DSMD 1.01
[20.44, 2.46]) or RIPC vs. LIPC+RIPC (DSMD 0.95 [20.73,
2.63]).
Results for the outcome measure BUN are summarized in
Table S4 and Figure 4. Seventeen articles studied the effect of one
or more IPC protocols on BUN after renal IRI. In 20 out of 29
experiments, the IRI-induced rise in BUN was significantly
reduced in animals undergoing IPC, when compared to a control
group that underwent IRI only (overall effect size 1.42 [0.97,
1.87]; p,0.00001). Overall study heterogeneity was high (76%).
Subgroup analysis showed that the beneficial effect of IPC on
BUN was present in all subgroups. Between-subgroup analysis
revealed a higher IPC efficacy in mouse vs. rat (Table S3, triangles;
DSMD 2.12 [0.48, 3.76). No effect was found for the window of
protection (early vs. late; DSMD 1.25 [20.05, 2.55]) or the IPC
protocol (continuous vs. fractionated; DSMD 0.96 [20.03, 1.95]).
Furthermore, the site of preconditioning did not influence IPC
efficacy: LIPC vs. RIPC, LIPC vs. LIPC +RIPC and RIPC vs.
LIPC+RIPC, respectively DSMD 0.2 [20.69, 1.09]), DSMD 0
Figure 2. Quality assessment score, averaged per item. Many studies scored poorly on key characteristics of scientific practice, and measures
to avoid bias, su h as characteristics of the subject population, randomization, blinding and exclusi n criteria.
doi:10.1371/journal.pone.0032296.g002
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Figure 2.3. Effect of IPC on serum creatinine after renal IRI.
Left side favours control (renal IRI only), right side favours IPC. An overall beneficial effect of IPC on serum 
creatinine was observed (1.54 [1.16, 1.93]). Data presented as SMD and 95% CI.
Figure 3. E fect of IPC on seru creati i ft . Left side favours control (renal IRI only), right side favours IPC. An overall beneficial
effect of IPC on serum creatinine was observed (1.54 [1.16, 1.93]). Data presented as SMD and 95% CI.
doi:10.1371/journal.pone.0032296.g003
Ischemic Preconditioning in the Animal Kidney
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late was 2.43 [1.29, 3.57], indicating that the late window of protection of IPC was more 
effective in reducing serum creatinine than the early window. Subgroup analysis indicated 
a higher IPC efficacy in studies conducted in mouse vs. rat (Table S2.2, triangles; ΔSMD 
1.7 [1.5,1.90]). For other species (dog, pig, rabbit) subgroups were too small to perform 
reliable subgroup analysis. No difference in IPC efficacy was observed for continuous 
fractionated; ΔSMD 0.46 [20.30, 1.22]), or males only groups of mixed gender (ΔSMD 0.38 
[20.60, 1.36]). For site of preconditioning, no differences were found when comparing 
the subgroups LIPC vs. RIPC (ΔSMD 0.06 [20.98, 1.10]), LIPC vs. LIPC +RIPC (ΔSMD 1.01 
[20.44, 2.46]) or RIPC vs. LIPC+RIPC (ΔSMD 0.95 [20.73, 2.63]). 
Results for the outcome measure BUN are summarized in Table S2.4 and Figure 2.4. 
Seventeen articles studied the effect of one or more IPC protocols on BUN after renal IRI. In 
20 out of 29 experiments, the IRI-induced rise in BUN was significantly reduced in animals 
undergoing IPC, when compared to a control group that underwent IRI only (overall effect 
size 1.42 [0.97, 1.87]; p<0.00001). Overall study heterogeneity was high (76%).
Figure 2.4. Effect of IPC on BUN after renal IRI.
Left side favours control (renal IRI only), right side favours IPC. An overall beneficial effect of IPC on BUN was 
observed (1.42 [0.97, 1.87]). Data presented as SMD and 95% CI.
[21.03, 1.03] and DSMD 0.2 [20.82, 1.22]. Subgroup analysis
could not be performed for the variable ‘gender’, because of
insufficient data.
Results for the outcome measure renal histology are summa-
rized in Table S5 and Figure 5. Twenty-six experiments from 15
studies reported the effect of IPC on the Jablonski score for renal
histology. Eight studies using a histology score not comparable
with Jablonski’s were excluded from analysis. Data included
contained 205 control and 191 IPC-treated animals. Overall, IPC
had a significant renal protective effect of 1.12 [0.89, 1.35].
Overall study heterogeneity was 63%.
Subgroup analysis showed that the beneficial effect of IPC on
histology was present in all subgroups. Between-subgroup analysis
could only be performed for the variables window of protection,
IPC protocol, gender and animal species, because of insufficient
numbers of experiments in the other subgroups. No significant
differences between subgroups were found (early vs. late, DSMD
1.8 [20.07, 3.67]; continuous vs. fractionated, DSMD 0.3 [20.50,
1.10]; males vs. mixed gender, DSMD 0.25 [20.58, 1.08]; rat vs.
mice, DSMD 0.55 [20.14, 1.24]).
Subgroup interaction analysis
In an attempt to further explain the expected study heteroge-
neity, subgroup interaction analysis was performed for all
subgroup interactions which contained three or more experiments.
Study heterogeneity was not notably reduced by combining
subgroup variables and remained on average 8066% for serum
creatinine, 62623% for BUN and 47630% for renal histology.
The analyses revealed no significant differences in the interaction
between subgroups, and did therefore not alter the results of the
subgroups analysis. Interestingly, for serum creatinine, the
subgroup interactions early-RIPC and continuous-RIPC did not
show an overall effect of IPC, whereas early-LIPC and continuous-
LIPC did show the protective effect. This may indicate that the
positive effect of an early window of protection, or the benefits of a
continuous IPC protocol are less pronounced for RIPC than for
LIPC. However, because of the small number of experiments in
these subgroups interactions (six and three experiments, respec-
tively), these results must be interpreted with care.
Publication bias
The presence of publication bias was assessed for all outcome
measures. Visual analysis of funnel plots revealed that small,
negative studies appeared to be underrepresented (data not
shown). This was especially true for serum creatinine and BUN,
and to a lesser extent for renal histology data.
Sensitivity analysis
To assess the robustness of our findings, we undertook a
sensitivity analysis by redefining the cut off-point for the early
window of protection at a later time point (,48 h) or an earlier
time point (,6 h). This did not significantly alter the outcome of
any of the outcome measures (data not shown).
Figure 4. Effect of IPC on BUN after renal IRI. Left side favours control (renal IRI only), right side favours IPC. An overall beneficial effect of IPC on
BUN was observed (1.42 [0.97, 1.87]). Data presented as SMD and 95% CI.
doi:10.1371/journal.pone.0032296.g004
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Subgroup analysis showed that the beneficial effect of IPC on BUN was present in all 
subgroups. Between-subgroup analysis revealed a higher IPC efficacy in mouse vs. rat 
(Table S2.3, triangles; ΔSMD 2.12 [0.48, 3.76). No effect was found for the window of 
protection (early vs. late; ΔSMD 1.25 [20.05, 2.55]) or the IPC protocol (continuous vs. 
fractionated; ΔSMD 0.96 [20.03, 1.95]). Furthermore, the site of preconditioning did not 
influence IPC efficacy: LIPC vs. RIPC, LIPC vs. LIPC +RIPC and RIPC vs. LIPC+RIPC, respectively 
ΔSMD 0.2 [20.69, 1.09]), ΔSMD 0 [21.03, 1.03] and ΔSMD 0.2 [20.82, 1.22]. Subgroup 
analysis could not be performed for the variable ‘gender’, because of insufficient data.
Results for the outcome measure renal histology are summarized in Table S2.5 and 
Figure 2.5. Twenty-six experiments from 15 studies reported the effect of IPC on the 
Jablonski score for renal histology. Eight studies using a histology score not comparable 
with Jablonski’s were excluded from analysis. Data included contained 205 control and 
191 IPC-treated animals. Overall, IPC had a significant renal protective effect of 1.12 
[0.89, 1.35]. Overall study heterogeneity was 63%. Subgroup analysis showed that the 
beneficial effect of IPC on histology was present in all subgroups. Between-subgroup 
analysis could only be performed for the variables window of protection, IPC protocol, 
gender and animal species, because of insufficient numbers of experiments in the other 
subgroups. No significant differences between subgroups were found (early vs. late, 
ΔSMD 1.8 [20.07, 3.67]; continuous vs. fractionated, ΔSMD 0.3 [20.50, 1.10]; males vs. 
mixed gender, ΔSMD 0.25 [20.58, 1.08]; rat vs. mice, ΔSMD 0.55 [20.14, 1.24]).
Subgroup interaction analysis 
In an attempt to further explain the expected study heterogeneity, subgroup interaction 
analysis was performed for all subgroup interactions which contained three or more 
experiments. Study heterogeneity was not notably reduced by combining subgroup 
variables and remained on average 80 ± 6% for serum creatinine, 62 ± 23% for BUN 
and 47 ± 30% for renal histology. The analyses revealed no significant differences in the 
interaction between subgroups, and did therefore not alter the results of the subgroups 
analysis. Interestingly, for serum creatinine, the subgroup interactions early-RIPC and 
continuous-RIPC did not show an overall effect of IPC, whereas early-LIPC and continuous- 
LIPC did show the protective effect. This may indicate that the positive effect of an early 
window of protection, or the benefits of a continuous IPC protocol are less pronounced 
for RIPC than for LIPC. However, because of the small number of experiments in these 
subgroups interactions (six and three experiments, respectively), these results must be 
interpreted with care.
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Publication bias 
The presence of publication bias was assessed for all outcome measures. Visual analysis 
of funnel plots revealed that small, negative studies appeared to be underrepresented 
(data not shown). This was especially true for serum creatinine and BUN, and to a lesser 
extent for renal histology data.
Sensitivity analysis
To assess the robustness of our findings, we undertook a sensitivity analysis by redefining 
the cut off-point for the early window of protection at a later time point (<48 hours) or 
an earlier time point (<6 hours). This did not significantly alter the outcome of any of 
the outcome measures (data not shown).
Figure 2.5. Effect of IPC on renal histology after renal IRI.
Left side favours control (renal IRI only), right side favours IPC. An overall beneficial effect of IPC on renal 
histology was observed (1.22 [0.89, 1.35]). Data presented as SMD and 95% CI.
Discussion
Here we report a unique systematic review and meta-analysis of
current literature reporting experimental animal models of IPC in
renal IRI. Three important outcome measures were assessed,
namely serum creatinine, BUN and histological renal damage
quantified by Jablonski score. For all three, protective effects of
IPC were observed, i.e. IPC reduced serum creatinine (1.54 [1.16,
1.93]), BUN (1.42 [0.97, 1.87]) and histological damage (1.12
[0.89, 1.35]) after IRI, when compared to control animals
undergoing renal IRI only. Importantly, in th clinical setting,
serum creatinine currently remains the gold standard to assess
renal function. In rodents however, questions have been raised
regarding the reliability of creatinine for measuring renal function,
since the impact of tubular creatinine excretion on creatinine
clearance is even larger in mice than in humans [31]. We therefore
put forward that other outcome measures, such as BUN and/or
renal histology may also be of great value when translating animal
study results to the human setting. Furthermore, other renal
damage markers such as Kidney Injury Molecule-1 (KIM-1) and
Neutrophil Gelatinase-Associated Lipocalin (NGAL) are gaining
ground in clinical prac ice [32]. Reporting these markers in both
animal and human studies may provide further information for the
translation of animal study data to the human setting.
We performed subgroup analysis to investigate several pre-
defined factors which we hypothesized to modify the efficacy of
IPC in renal IRI, namely: window of protection (early or late), IPC
protocol (continuous or fractionated), site of preconditioning
(RIPC, LIPC or both), species (mouse or rat) and gender (male,
female or mixed). The protective effects of IPC were persistent in
all subgroups, for all outcome measures, except for female (only 2
experiments). Based on the latter observation, we propose the need
for future studies should in females, since it has been shown that
there is a significant difference between males and females for
cardiac IPC efficacy (e.g. [33]).
For serum creatinine, the window of protection influenced the
efficacy of IPC: IPC was more effective when conducted .24 h
before index ischemia (late window of protection), as compared to
an early widow of protection (,24 h before index ischemia). We
observed the same trend towards higher efficacy in the late
window of protection for BUN and renal histology. The cut-off
point of,24 h for the early window could be redefined at,6 h or
,48 h without significantly influencing these results, since the vast
majority of experiments (93%) investigated a time window of
either ,40 minutes, or .4 days. The remaining 7% of the
experiments concerned a time window of 6–24 h between IPC
and IRI. Thus, there is a large gap in these data which makes it
difficult to assess the optimal window of protection for IPC.
Nevertheless, our data strongly indicate that the late window of
protection migh be more effective to reduce renal IRI as
compared to the early window. This finding is particularly
interesting since almost all clinical trials currently registered at
Clinicaltrials.gov investigating the effects of LIPC and RIPC use
only the early window of protection. To our knowledge data on
the efficacy of combined activation of the early and late window in
humans is lacking.
Figure 5. Effect of IPC on renal histology after renal IRI. Left side favours control (renal IRI only), right side favours IPC. An overall beneficial
effect of IPC on re al histology was observed (1.22 [0.89, 1.35]). Data presented as SMD and 95% CI.
doi:10.1371/journal.pone.0032296.g005
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DISCUSSION
Here we report a unique systematic review and meta-analysis of current literature 
reporting experimental animal models of IPC in renal IRI. Three important outcome 
measures were assessed, namely serum creatinine, BUN and histological renal damage 
quantified by Jablonski score. For all three, protective effects of IPC were observed, i.e. 
IPC reduced serum creatinine (1.54 [1.16, 1.93]), BUN (1.42 [0.97, 1.87]) and histological 
damage (1.12 [0.89, 1.35]) after IRI, when compared to control animals undergoing 
renal IRI only. Importantly, in the clinical setting, serum creatinine currently remains the 
gold standard to assess renal function. In rodents however, questions have been raised 
regarding the reliability of creatinine for measuring renal function, since the impact of 
tubular creatinine excretion on creatinine clearance is even larger in mice than in humans 
[31]. We therefore put forward that other outcome measures, such as BUN and/or renal 
histology may also be of great value when translating animal study results to the human 
setting. Furthermore, other renal damage markers such as Kidney Injury Molecule-1 
(KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) are gaining ground in 
clinical practice [32]. Reporting these markers in both animal and human studies may 
provide further information for the translation of animal study data to the human setting. 
We performed subgroup analysis to investigate several predefined factors which we 
hypothesized to modify the efficacy of IPC in renal IRI, namely: window of protection 
(early or late), IPC protocol (continuous or fractionated), site of preconditioning (RIPC, 
LIPC or both), species (mouse or rat) and gender (male, female or mixed). The protective 
effects of IPC were persistent in all subgroups, for all outcome measures, except for 
female (only two experiments). Based on the latter observation, we propose the need 
for future studies should in females, since it has been shown that there is a significant 
difference between males and females for cardiac IPC efficacy (e.g. [33]). 
For serum creatinine, the window of protection influenced the efficacy of IPC: IPC 
was more effective when conducted >24 hours before index ischemia (late window of 
protection), as compared to an early window of protection (<24 hours before index 
ischemia). We observed the same trend towards higher efficacy in the late window 
of protection for BUN and renal histology. The cut-off point of <24 hours for the early 
window could be redefined at <6 hours or <48 hours without significantly influencing 
these results, since the vast majority of experiments (93%) investigated a time window of 
either <40 minutes, or >4 days. The remaining 7% of the experiments concerned a time 
window of six to 24 hours between IPC and IRI. Thus, there is a large gap in these data 
which makes it difficult to assess the optimal window of protection for IPC. Nevertheless, 
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our data strongly indicate that the late window of protection might be more effective to 
reduce renal IRI as compared to the early window. This finding is particularly interesting 
since almost all clinical trials currently registered at Clinicaltrials.gov investigating the 
effects of LIPC and RIPC use only the early window of protection. To our knowledge data 
on the efficacy of combined activation of the early and late window in humans is lacking. 
The second variable which influenced IPC efficacy was animal species: for serum 
creatinine and BUN data, IPC was more effective when performed in mice vs. rats. This 
suggests that mouse models of renal IPC may be more sensitive when compared to rat, 
and are thus the preferable models for future animal studies. Furthermore, this finding 
implicates that IPC efficacy is species specific, and therefore the protective effect may be 
greater, or less pronounced in large animals and humans. This illustrates the difficulty in 
directly translating results from animal studies to the human setting, and further studies 
in large animals and humans are necessary to clarify this issue. 
No significant differences were observed for the variables IPC protocol (continuous 
vs. fractionated) or site of preconditioning (LIPC, RIPC or both). The latter finding is 
interesting, since the use of LIPC in clinical practice is limited because of the risk of damage 
to major vascular structures, and the fact that even brief ischemia may damage the target 
organ in vulnerable patients. RIPC therefore has more potential for clinical application, 
since the IPC stimulus can be applied to e.g. a limb, which is easy to handle and relatively 
resistant to IRI. Our finding that RIPC and LIPC are equally effective indicates that RIPC 
has an at least equal potential for translation to the clinic, although it must be noted 
that only two studies used the limb as remote organ. Subgroup analysis of the serum 
creatinine levels in animals undergoing simultaneous LIPC of one kidney and RIPC of 
the contralateral kidney show a trend towards higher efficacy (Table S2.2, filled circles), 
indicating that a combination of LIPC and RIPC may have an additive effect. However, this 
result must be interpreted with care, because of the low number of experiments included.
Methodological quality of studies 
Our assessment reveals that there is much to gain in terms of the methodological quality 
of animals studies in this field. Key characteristics of scientific practice, and measures 
to avoid bias, such as characteristics of the subject population, randomization, blinding 
and exclusion criteria, were infrequently reported. A number of recent systematic 
reviews show that this is the case in many fields of animal research. For scientific and 
ethical reasons, it is urgent that the standards routinely applied in human research 
become standard of practice in animal research as well. While it is possible that some 
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authors merely failed to report these details, there is reason for concern, since it is 
unclear whether there is a significant difference between the reported study quality and 
the actual study quality. For this reason, better reporting of animal studies is crucial. 
Regrettably, there appears to be an inverse correlation between the impact factor of 
the journal in which the study is published, and the required detail of the materials and 
methods description [24]. The high heterogeneity of the data presented in this systematic 
review may be explained in part by the differences in study quality, as well as the lack 
of consensus and general standards of practice in animal studies. It has proven difficult 
to obtain missing data by contacting authors directly, which further emphasizes the 
importance of adequately reporting animal studies. However, in spite of insufficient 
reporting, systematic review and meta-analysis of current publications aid in making 
possible bias transparent, and can provide us with valuable new insights, which will 
support the translation of animal data to the clinical setting.
Strengths and limitations
The major strength of our study is that, as far as we are aware, we are the first performing 
a systematic review and meta-analysis on renal protection by IPC in animal studies. We 
were able to include a large number of studies per outcome measure, which enabled 
us to investigate the effect of several subgroup variables. 
Some potential limitations should be discussed. Firstly, the extracted data are highly 
heterogeneous, which is most likely due to a large variety in experimental designs used 
and the variation in study quality. The fact that our subgroup interaction analysis did not 
notably reduce heterogeneity supports this notion. Although we have tried to account 
for this heterogeneity by using a random effects model and performing subgroup and 
sensitivity analysis, pooling of the results may not be appropriate for all subgroups. 
Therefore, differences between (small) subgroups should be interpreted with caution 
and be used to generate new hypotheses, rather than for drawing final conclusions. 
However, all studies provide information on the association between IPC and IRI in the 
animal kidney, and are thus valuable for this systematic review. 
Secondly, the included studies may be subject to publication bias. Visual analysis of funnel 
plots revealed that only small, negative studies appeared to be underrepresented in 
current literature on IPC in renal IRI. Asymmetry was most notable in serum creatinine 
and BUN data. This may indicate that publication bias is present, which could cause 
overestimation of the effect sizes. Importantly, funnel plot asymmetry can result from 
non-publication of negative results, but may also be caused by other factors, such as 
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true study heterogeneity, or differences in study quality [34]. Our finding that the study 
quality is rather heterogeneous may therefore explain part of the funnel plot asymmetry.
Clinical implications
Both LIPC and RIPC (and also the combination of the two), appear to have the potential 
to reduce IRI, and since RIPC by brief limb ischemia has the advantage of being safe and 
easy to perform, the latter has the greatest potential for clinical practice. In contrast 
to the variety of IPC protocols used in animal studies, current clinical trials on RIPC in 
renal IRI are using similar preconditioning protocols, namely fractionated IPC stimuli, 
and a short delay between IPC and index ischemia (early window of protection). The 
current review indicates that even though this approach might be effective, efficacy 
could be even higher in the late window of protection. Future studies should be designed 
to investigate the optimal window of protection in patients, taking into account the 
possible difference between acute and delayed ischemic preconditioning. Whether a 
combination of the two is additive or even synergistic requires further testing in animal 
and human models as well. 
It is important to realize that, to date, no studies (animal or human) have investigated 
the effect of co-medication and comorbidities such as diabetes, hypertension or obesity, 
on IPC in renal IRI. For the heart, it has been shown that medication and co-morbidities 
influence IPC efficacy (reviewed e.g. in [35]). Similarly, differences in IPC efficacy between 
genders may indicate that the optimal IPC stimulus is different in males vs. females. 
We propose that future clinical studies should be designed to optimize IPC efficacy for 
certain patient groups, and that animal studies in this area can inform the design of 
such clinical trials. Furthermore, a better mechanistic insight is needed in the cause of 
the observed interspecies difference. These data will give us a clue whether translation 
to humans is feasible.
CONClUSION
The currently applied approach of systematic review and metaanalysis indicates that, 
in animal studies, IPC has an overall protective effect on the kidney, since it reduces 
serum creatinine, blood urea nitrogen (BUN) and renal damage as assessed by histology 
after IRI. We found that IPC is more effective in reducing serum creatinine when the IPC 
stimulus is applied >24 hours before index ischemia (late window of protection), a trend 
which was also observed for BUN and renal histology data.
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Furthermore, serum creatinine and BUN data showed an effect of animal species on 
IPC efficacy: IPC was more effective when performed in mice vs. rats. No significant 
differences were observed for the variables site of preconditioning (local, remote or 
both) or IPC protocol (continuous vs. fractionated). Our review indicates that current 
clinical trials on RIPC may not be optimally designed, and further optimization may be 
necessary for successful translation to the clinical setting.
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Appendix S2.1. Full search strategy for PubMed and EMBASE
PubMed Kidney "kidney"[MeSH Terms] OR "acute kidney injury"[MeSH Terms] OR 
"kidney"[Tiab] OR "kidneys"[Tiab] OR "renal"[Tiab] OR "kidney 
transplantation"[MeSH Terms] OR "nephrology"[MeSH Terms] OR 
"nephrology"[Tiab]
Preconditioning "ischemic preconditioning"[MeSH Terms] OR "IPC"[tiab] OR 
"RIPC"[tiab] OR "brief ischemia"[tiab] OR "brief ischaemia"[tiab] 
OR "preconditioning"[tiab] OR "pre conditioning"[tiab] OR "pre-
conditioning"[tiab] OR "transient ischaemia"[tiab] OR "transient 
ischemia"[tiab] OR "intermittent ischaemia"[tiab]OR "intermittent 
ischemia"[tiab] OR "continuous ischemia"[tiab] OR "continuous 
ischaemia"[tiab]
Ischemia reperfusion 
injury
"warm ischemia"[Mesh Terms] OR "warm Ischemia"[Tiab] OR 
"warm Ischaemia"[Tiab] OR "cold ischemia"[Mesh Terms] OR 
"cold ischemia"[Tiab] OR"cold ischaemia"[Tiab] OR "primary graft 
dysfunction"[Mesh Terms] OR "primary graft dysfunction"[Tiab] 
OR "I/R"[Tiab] OR "IRI"[Tiab] OR "ischemic reperfusion"[Tiab] OR 
"ischaemic reperfusion"[Tiab] OR“ischemia reperfusion"[Tiab] 
OR“ischaemia reperfusion"[Tiab] OR “kidney ischemia"[Tiab] 
OR “kidney ischaemia"[Tiab] OR "renal ischaemia"[tiab] OR 
"renal ischemia"[tiab] OR "reperfusion injury"[Mesh Terms] OR 
"reperfusion injury"[tiab] OR "reperfusion injuries"[tiab] OR "ischemia 
reperfusion"[tiab] OR "ischaemia reperfusion"[tiab] OR "renal 
injury"[tiab] OR "renal injuries"[tiab]
Animals Laboratory animal search filter [94]
Embase Kidney exp kidney/ OR exp acute kidney failure/ OR exp kidney transplan-
tation/ OR exp kidney allograft rejection/ OR (renal OR kidney OR 
kidneys OR nephrology).ti,ab.
Preconditioning exp ischemic preconditioning/ OR (IPC OR RIPC OR brief ischemia 
OR brief ischaemia OR preconditioning OR pre conditioning OR 
pre-conditioning OR transient ischaemia OR transient ischemia OR 
intermittent ischaemia OR intermittent ischemia OR continuous 
ischemia OR continuous ischaemia).ti,ab.
Ischemia reperfusion 
injury
exp reperfusion injury/ OR exp cold ischemia/ OR exp primary graft 
dysfunction/ OR (warm ischemia OR warm ischaemia OR cold ischemia 
OR cold ischaemia OR reperfusion injury OR primary graft dysfunction 
OR I/R OR IRI OR ischemic reperfusion OR ischaemic reperfusion OR 
kidney ischemia OR kidney ischaemia OR renal ischaemia OR renal 
ischemia OR reperfusion injury OR reperfusion injuries OR ischemia 
reperfusion OR ischaemia reperfusion OR renal injury OR renal 
injuries).ti,ab. OR (cold ischemia OR cold ischemia time OR cold 
ischemia times OR cold ischemic time OR cold ischemic times OR cold 
ischaemia OR cold ischaemia time OR cold ischaemia times OR cold 
ischaemic time OR cold ischaemic times).ti,ab. OR (warm ischemia 
OR warm ischaemia).ti,ab.
Animals Laboratory animal search filter [95]
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ABSTRACT
Background
Renal ischemia-reperfusion injury (IRI) is a major cause of kidney damage after e.g. renal 
surgery and transplantation. Ischemic postconditioning (IPostC) is a promising treatment 
strategy for renal IRI, but early clinical trials have not yet replicated the promising results 
found in animal studies.
Method
We present a systematic review, quality assessment and meta-analysis of the preclinical 
evidence for renal IPostC, and identify factors which modify its efficacy.
Results
We identified 39 publications studying >250 control animals undergoing renal IRI only 
and >290 animals undergoing renal IRI and IPostC. Healthy, male rats undergoing warm 
ischemia were used in the vast majority of studies. Four studies applied remote IPostC, 
all others used local IPostC. Meta-analysis showed that both local and remote IPostC 
ameliorated renal damage after IRI for the outcome measures serum creatinine, blood 
urea nitrogen and renal histology. Subgroup analysis indicated that IPostC efficacy 
increased with the duration of index ischemia. Measures to reduce bias were insufficiently 
reported. 
Conclusion
High efficacy of IPostC is observed in animal models, but factors pertaining to the 
internal and external validity of these studies may hamper the translation of IPostC to 
the clinical setting. The external validity of future animal studies should be increased 
by including females, comorbid animals, and transplantation models, in order to better 
inform clinical trial design. The severity of renal damage should be taken into account 
in the design and analysis of future clinical trials.
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INTRODUCTION
Renal ischemia and reperfusion injury (IRI) is a major cause of acute kidney injury (AKI) 
after e.g. renal surgery, coronary artery bypass grafting and abdominal aortic aneurysm 
repair, which results in increased morbidity and mortality [1]. Renal IRI is also considered 
an important cause of delayed graft function after renal transplantation and is associated 
with prolonged hospital stay and acute rejection [2, 3]. 
Ischemic postconditioning (IPostC) is a protective strategy in which (repeated) brief, 
intermittent periods of ischemia and reperfusion are applied in the early phase of 
reperfusion after a prolonged ischemic episode. Since its discovery in 2003 in the dog 
heart [4], IPostC has been shown to attenuate IRI in various organs and a variety of animal 
species, and is effective when applied to either the target organ, or a remote organ or 
tissue [5, 6]. Thus, IPostC poses a promising treatment strategy for IRI in patients. 
Following the promising results obtained in animal studies, the feasibility and efficacy 
of renal IPostC in patients has been investigated in two clinical trials [7, 8]. Although 
application of local IPostC seemed feasible and safe in patients undergoing donation-
after-circulatory-death kidney transplantation, it had no effect on delayed graft function 
incidence or renal function in a paired kidney analysis [7]. Remote IPostC (RIPostC) 
appeared to hasten the early recovery of graft function in patients undergoing living 
donor kidney transplantation, but did not affect graft function >24 hours post-operatively 
[8]. In addition, clinical trials investigating the effect of IPostC on the myocardium have 
also yielded conflicting results (reviewed in [9, 10]). Thus, the question arises why the 
replication of the promising results found in animals has been limited in patients, and 
how the translation of IPostC from animal studies to patients may be improved. 
Previously, meta-analysis and systematic review of preclinical studies have proven useful 
in optimizing the design of both preclinical and clinical studies [11–13]. Although an 
overview of experimental studies in this field exists [14], a systematic review of the 
preclinical evidence for renal IPostC is lacking. It remains unclear if and how factors 
pertaining to the IPostC protocol (e.g. timing and duration) and the animals under 
investigation (e.g. sex, comorbidities) influence IPostC efficacy. As a result, the IPostC 
stimulus could have been suboptimal or incorrectly applied in clinical trials, or unsuitable 
for the patient population. We therefore conducted a systematic review and meta-
analysis of evidence on the protective effect of IPostC in animal models of renal IRI. This 
approach allowed us to analyze the influence of variables such as IPostC timing, IPostC 
duration, sex and comorbidity on treatment efficacy. We also assessed the extent to 
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which the preclinical data might be at risk of bias, either through publication bias, or 
through factors relating to experimental design.
MATeRIAlS AND MeThODS
For an extended version, see S3.1 Text. The review methodology was predefined and 
documented in a protocol [15], published online on February 12th 2015. The review 
question was: what is the effect of local or remote IPostC on renal function in animal 
models of renal IRI?
Amendments to the review protocol
After study selection, we found that the timing and duration of the IPostC protocol 
depended strongly on the site of postconditioning. We therefore decided to perform 
separate meta-analyses of studies using local, remote, and local+remote postconditioning, 
to avoid collinearity. 
For serum creatinine and blood urea nitrogen (BUN), all data could be expressed in 
the same unit of measurement, but differences in baseline measurements between 
studies were observed. We therefore performed meta-analysis of the normalised mean 
difference (NMD) instead of the standardized mean difference (SMD). For renal histology, 
we expressed all scores as a percentage on the grading scale used, and performed meta-
analysis of the mean difference (MD), instead of the SMD. This allowed us to include 
studies reporting the histology score as a percentage on the grading scale used.
Study identification
A systematic, computerized search in the databases Medline (via PubMed) and EMBASE 
(Table S3.1) was performed on February 4th 2015, using the search components ‘kidney’, 
‘ischemic postconditioning’ and an animal search filter for either PubMed [16] or EMBASE 
[17]. To identify additional relevant studies, the reference lists of included studies and 
relevant reviews were hand searched. No language restrictions were applied.
Selection of studies
After removal of duplicates, all references were screened for inclusion based on their title 
and abstract. The following inclusion criteria were applied: the study 1) is an original article 
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presenting unique data with a control group, 2) is performed in vivo in animals with or 
without comorbidities, but without genetic modifications, 3) reports on renal ischemia-
reperfusion injury and outcome measures related to kidney injury or function, and 4) 
examined the effect of remote and/or local ischemic postconditioning. Subsequently, the 
full-text manuscripts of eligible studies were reviewed for inclusion. Studies involving co-
medication other than anaesthetics or analgesics, or a co-intervention other than collateral 
nephrectomy were excluded. Studies performed in a renal transplantation model were 
excluded from the present dataset, but labelled for future reference. In both phases, 
references were independently assessed for inclusion by two reviewers (KW and SJ).
Study characteristics and data extraction
Study characteristics were extracted by one reviewer (SJ) and checked for inconsistencies 
by a second reviewer (TM). We selected the following outcome measures for analysis: 
serum creatinine, BUN and renal histology scores (Jablonski [18] or comparable). Data was 
collected as mean and standard deviation (SD). For serum creatinine and BUN, all data 
was recalculated to the same unit of measurement (respectively umol/L and mmol/L). 
For renal histology, scores were expressed as a percentage on the grading scale used. If 
an outcome was measured at several time-points, data was extracted for the time-point 
of greatest efficacy. If a study reported data from several experimental groups, it was 
extracted as separate comparisons and the number of animals in the control group was 
corrected (number of animals divided by number of comparisons).
Risk of bias and study quality
Two reviewers (SJ and TM) independently assessed the risk of bias and study quality 
of each included study. In case of discrepancies, consensus was reached by discussion 
with a third reviewer (KW). Risk of bias was assessed using SYRCLE’s Risk of Bias tool 
[19]. Reporting bias (item #9) was not assessed, since none of the studies reported the 
use of a study protocol predefining primary and secondary outcomes. When assessing 
selection bias, groups within a study were considered similar at baseline if sex and 
baseline serum creatinine did not significantlydiffer between groups (or, if baseline 
creatinine was unavailable, body weight). To assess whether studies were free of other 
risks of bias, addition of animals to groups during the experiment and a possible conflict 
of interest were taken into account. We also assessed reporting of the following study 
quality items: any randomization, any blinding, regulation of body temperature within 
3°C variation and sample size calculation.
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Data analysis
Data was analyzed using Stata/SE (StataCorp, Texas, USA). For the outcome measures 
serum creatinine and BUN, meta-analysis was performed on the NMD, which allows us to 
correct for baseline kidney injury by relating the magnitude of the effect of treatment to a 
baseline measured in untreated animals [20]. For histology, the MD was used. A random 
effects model was used to account for expected between-study heterogeneity. To assess 
heterogeneity, the I2 and adjusted R2 statistics were determined. To examine potential 
sources of heterogeneity, predefined subgroup analyses were performed on subgroups 
containing data from at least three studies. For the duration of IPostC ischemia, studies 
were categorized using increments of 0.7 log, which resulted in categories of 26–125, 
126–630 and 631–3162 seconds of ischemia. For the duration of index ischemia, studies 
were categorized using increments of 15 minutes, resulting in categories of 16–30, 
31–45, 46–60, 61–75 (no studies) and 76–90 minutes. Differences between subgroups 
were determined by calculating the difference in NMD and MD respectively and the 95% 
confidence intervals (CI) of the difference. Results are reported as a NMD or MD [95% CI], 
unless stated otherwise. For each outcome measure, the significance level for subgroup 
analyses was adjusted for the number of analyses using the Bonferroni-Holm method [21].
Publication bias was assessed for each outcome measure by visual evaluation of funnel 
plots, Duval and Tweedie’s trim and fill analysis and by performing Egger’s test for 
small study effects. Sensitivity analyses were carried out for creatinine and BUN using a 
fixed time point of outcome assessment (24 h). For histology, a sensitivity analysis was 
performed using only Jablonski histology scores.
ReSUlTS
Study identification and selection
A flow chart of the study selection process is shown in Figure 3.1. The computerized 
search retrieved 213 references from PubMed and 272 from EMBASE. Four additional 
references were added after hand searching reference lists of included studies and 
relevant reviews. After duplicate removal, 300 references were screened based on title 
and abstract and 51 studies continued to the eligibility phase. Two letters to the editor 
[22, 23] were included since they presented unique data and sufficient methodological 
detail. One study investigating IPostC in a canine model of renal transplantation with 
cold ischemia was excluded, because of the differences in pathophysiology compared to 
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warm ischemia. Finally, 35 studies were included in the risk of bias assessment, all but 
one of which reported on one or more of the selected outcome measures.
Study characteristics
The study characteristics are summarized in Table 3.1. Out of the 35 included studies, 31 
were performed in rats, one in dogs and three in mice. Male animals were used in all but 
three studies. There were only three studies investigating the effect of RIPostC, all of which 
used the hind limb as remote tissue. The most commonly used durations of index ischemia 
Figure 3.1. Flow chart of study selection.
The number of studies in each phase are shown between brackets.
min. The IPoC protocol varied between studies, however, local application of 6 cycles of 10/10
seconds of reperfusion/ischemia was most commonly used.
Risk of bias and study quality
The results of the study quality and risk of bias assessment are shown in Fig 2 and S2 Table.
Randomization and blinding are essential measures to reduce bias, but are infrequently
reported. Seventy-four percent of the included studies reported random allocation of the ani-
mals, oweve , only one study ad quately specified the method of ran omisation. Studies that
r ported bli ding (46%), only did so for the outcome assessment of hi tology. None of the
studies reported a sample size calculation. As a consequence of insufficient reporting, the risk
of bias was unclear for most items of the risk of bias tool.
Meta-analyses
Studies investigating local, remote, or local+remote IPoC were analyzed separately. Only the
local IPoC group contained enough studies to perform subgroup analysis for any of the out-
come measures. One study reporting creatinine clearance[24] was excluded from analysis
because serum creatinine data could not be obtained. Data from two studies[25,26] was
excluded because serum creatinine or BUN levels were the same in the experimental group and
Fig 1. Flow chart of study selection. The number of studies in each phase are shown between brackets.
doi:10.1371/journal.pone.0150863.g001
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were 45 and in. The IPostC protocol varied between studies, however, local application of 
six cycles of 10/10 seconds of reperfusion/ischemia was most commonly used.
Risk of bias and study quality
The results of the study quality and risk of bias assessment are shown in Figure 3.2 and 
Table S3.2. Randomization and blinding are essential measures to reduce bias, but are 
infrequently reported. Seventy-four percent of the included studies reported random 
allocation of the animals, however, only one study adequately specified the method 
of randomisation. Studies that reported blinding (46%), only did so for the outcome 
assessment of histology. None of the studies reported a sample size calculation. As a 
consequence of insufficient reporting, the risk of bias was unclear for most items of the 
risk of bias tool.
Figure 3.2. Risk of bias and study quality assessment.
Top: Reporting of five key study quality indicators was found to be poor in many cases. Bottom: Using SYRCLE’s 
risk of bias tool, the risk of selection, performance, detection, attrition and other biases was assessed. Lack of 
(adequate) reporting of measures to reduce bias resulted in a high percentage of unclear risk of bias for most items.
Subgroup analysis results for the LIPoC studies are shown in S4 Table. The effect of species
and sex on LIPoC efficacy could not be analyzed due to insufficient data. LIPoC had a benefi-
cial effect on BUN in all subgroups, except for mouse, female, 4 cycles of IPoC, 631–3162 sec-
onds of IPoC ischemia and 16–30 minutes of index ischemia. Overall heterogeneity was high
(I2 71.6%). A significant proportion of heterogeneity was explained by the duration of index
ischemia (adjusted R2 44.5%; p<0.007), indicating that the efficacy of postconditioning
increased with the duration of index ischemia. None of the other subgroup variables accounted
for a significant proportion of heterogeneity.
Fig 2. Risk of bias and study quality assessment. Top: Reporting of five key study quality indicators was found to be poor in many cases. Bottom: Using
SYRCLE's risk of bias tool, the risk of selection, performance, detection, attrition and other biases was assessed. Lack of (adequate) reporting of measures to
reduce bias resulted in a high percentage of unclear risk of bias for most items.
doi:10.1371/journal.pone.0150863.g002
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Subgroup analysis results for the LIPoC studies are shown in S4 Table. The effect of species
and sex on LIPoC efficacy could not be analyzed due to insufficient data. LIPoC had a benefi-
cial effect on BUN in all subgroups, except for mouse, female, 4 cycles of IPoC, 631–3162 sec-
onds of IPoC ischemia and 16–30 minutes of index ischemia. Overall heterogeneity was high
(I2 71.6%). A significant proportion of heterogeneity was explained by the duration of index
ischemia (adjusted R2 44.5%; p<0.007), indicating that the efficacy of postconditioning
increased with the duration of index ischemia. None of the other subgroup variables accounted
for a significant proportion of heterogeneity.
Fig 2. Risk of bias and study quality assessment. Top: Reporting of five key study quality indicators was found to be poor in many cases. Bottom: Using
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Meta-analyses
Studies investigating local, remote, or local+remote IPostC were analyzed separately. Only 
the local IPostC group contained enough studies to perform subgroup analysis for any 
of the outcome measures. One study reporting creatinine clearance [24] was excluded 
from analysis because serum creatinine data could not be obtained. Data from two 
studies [25, 26] was excluded because serum creatinine or BUN levels were the same 
in the experimental group and the sham group, indicating that the experimental group 
did not sustain a sufficient amount of renal IRI. For renal histology, two studies were 
excluded due to incomplete outcome data [26, 27].
Serum creatinine
Thirty-one studies reported serum creatinine data from 39 experiments, using 258 sham 
animals, 247 control animals undergoing renal IRI only and 298 experimental animals 
undergoing both IRI and IPostC. Both the control and experimental groups contained 
three to 12 animals (median n=8). The IRI-induced rise in serum creatinine was reduced 
by both LIPostC (34 experiments; NMD 45.0 [33.4, 56.6]) and RIPostC (four experiments; 
NMD 49.3 [22.8, 75.7]; Figure 3.3). One study investigating the combination of LIPostC 
and RIPostC showed no effect (NMD 57.84 [-12.0, 127.7]).
Subgroup analysis results for the LIPostC studies are shown in S3 Table. LIPostC had a 
beneficial effect on creatinine in all subgroups, except for mouse, female, four cycles 
of LIPostC and 16–30 minutes of index ischemia. Overall heterogeneity was high (I2 
74.7%), but none of the subgroupvariables accounted for a significant proportion of 
the observed heterogeneity.
BUN
Twenty-eight studies reported BUN data from 36 experiments, using 226 sham animals, 
222 control animals and 269 IPostC-treated animals. Both the control and experimental 
groups contained three to 12 animals (median n=8). The IRI-induced rise in BUN was 
reduced by both LIPostC (33 experiments; NMD 43.4 [30.8, 56.1]) and RIPostC (four 
experiments; NMD 41.0 [23.7, 58.3]; Figure 3.4). One study investigating the combination 
of LIPostC and RIPostC showed no effect (NMD 55.0 [-5.6, 115.6]).
Subgroup analysis results for the LIPostC studies are shown in S4 Table. The effect of 
species and sex on LIPostC efficacy could not be analyzed due to insufficient data. LIPostC 
had a beneficial effect on BUN in all subgroups, except for mouse, female, four cycles 
of IPostC, 631–3162 seconds of IPostC ischemia and 16–30 minutes of index ischemia. 
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Overall heterogeneity was high (I2 71.6%). A significant proportion of heterogeneity was 
explained by the duration of index ischemia (adjusted R2 44.5%; p<0.007), indicating that 
the efficacy of postconditioning increased with the duration of index ischemia. None of 
the other subgroup variables accounted for a significant proportion of heterogeneity.
Figure 3.3. Meta-analysis creatinine.
The summary effects show a decrease in serum creatinine after local or remote IPostC. One study investigating 
the combination of local and remote IPostC showed no effect. Data are presented as NMD and 95% CI. Within 
subgroup weights from random effects analysis are shown.
Fig 3. Meta-analysis creatinine. The summary effects show a decrease in serum creatinine after local or remote IPoC. One study investigating the
combination of local and remote IPoC showed no effect. Data are presented as NMD and 95%CI. Within subgroup weights from random effects analysis are
shown.
doi:10.1371/journal.pone.0150863.g003
Preclinical Evidence for Ischemic Postconditioning in Renal IRI
PLOS ONE | DOI:10.1371/journal.pone.0150863 March 10, 2016 9 / 19
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Renal histology
Nineteen studies reported data on renal histology from 26 experiments, using 149 sham, 
152 control and 191 IPostC-treated animals. Both the control and experimental groups 
contained four to ten animals (median n=8). Renal histology scores were reduced after 
renal IRI in animals treated with LIPostC (23 experiments; MD 27.8 [18.4, 37.2] or RIPostC 
(two experiments; MD 18.4 [6.4, 30.5]) or the combination of the two (one experiment; 
MD 1.0 [0.1, 1.93]; Figure 3.5). 
Figure 3.4. Meta-analysis blood urea nitrogen.
The summary effects show a decrease in blood urea nitrogen after local or remote IPostC. One study 
investigating the combination of local and remote IPostC showed no effect. Data are presented as NMD and 
95% CI. Within subgroup weights from random effects analysis are shown.
Fig 4. Meta-analysis blood urea nitrogen. The summary effects show a decrease in blood urea nitrogen after local or remote IPoC. One study investigating
the combination of local and remote IPoC showed no effect. Data are presented as NMD and 95%CI. Within subgroup weights from random effects analysis
are shown.
doi:10.1371/journal.pone.0150863.g004
Preclinical Evidence for Ischemic Postconditioning in Renal IRI
PLOS ONE | DOI:10.1371/journal.pone.0150863 March 10, 2016 10 / 19
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A positive effect of LIPostC on histology scores (Table S3.5) was observed in most 
subgroups, similar to the results obtained for serum creatinine. The effect of species, sex 
and site of postconditioning on IPostC efficacy could not be analyzed due to insufficient 
data. Overall heterogeneity was very high (I2 96.2%), but could not be attributed to any 
of the subgroup variables.
Publication bias
Publication bias could be assessed for LIPostC only, due to insufficient data for RIPostC. 
Possible publication bias was observed for all outcome measures when visually evaluating 
Figure 3.5. Meta-analysis renal histology.
The summary effects show a decrease renal damage score after local or remote IPostC, and the combination 
of the two. Data are presented as MD and 95% CI. Within subgroup weights from random effects analysis 
are shown.
Renal histology. Nineteen studies reported data on renal histology from 26 experiments,
using 149 sham, 152 control and 191 IPoC-treated animals. Both the control and experimental
groups contained 4 to 10 animals (median n = 8). Renal histology scores were reduced after
renal IRI in animals treated with LIPoC (23 experiments; MD 27.8 [18.4, 37.2] or RIPoC (2
experiments; MD 18.4 [6.4, 30.5]) or the combination of the two (1 experiment; MD 1.0 [0.1,
1.93]; Fig 5).
Fig 5. Meta-analysis renal histology. The summary effects show a decrease renal damage score after local or remote IPoC, and the combination of the
two. Data are presented as MD and 95%CI. Within subgroup weights from random effects analysis are shown.
doi:10.1371/journal.pone.0150863.g005
Preclinical Evidence for Ischemic Postconditioning in Renal IRI
PLOS ONE | DOI:10.1371/journal.pone.0150863 March 10, 2016 11 / 19
Chapter_3_Theo.indd   70 14-9-2017   08:20:34
71
Ischemic postconditioning in animal models: a systematic review and meta-analysis
3
funnel plots for asymmetry. Duval and Tweedie’s trim and fill analysis resulted in filled 
data points for all outcome measures (Figure 3.6A, 3.6C and 3.6E), indicating that small, 
negative studies were underrepresented. However, Egger’s test indicated that no small 
study effects were present (Figure 3.6B, 3.6D and 3.6F).
Figure 3.6. Publication bias.
Trim and fill analysis for studies on local IPostC indicates funnel plot asymmetry for respectively creatinine 
(A), BUN (C) and renal histology (E). The 95% confidence interval of Egger’s regression line (dashed lines) 
does not include the origin of the graph, indicating no small study effects for creatinine (B), BUN (D) and 
renal histology (F).
Fig 6. Publication bias. Trim and fill analysis for studies on local IPoC indicates funnel plot asymmetry for respectively creatinine (A), BUN (C) and renal
histology (E). The 95% confidence interval of Egger’s regression line (dashed lines) does not include the origin of the graph, indicating no small study effects
for creatinine (B), BUN (D) and renal histology (F).
doi:10.1371/journal.pone.0150863.g006
Preclinical Evidence for Ischemic Postconditioning in Renal IRI
PLOS ONE | DOI:10.1371/journal.pone.0150863 March 10, 2016 13 / 19
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Sensitivity analyses
Sensitivity analyses were performed to assess the robustness of our findings. For serum 
creatinine and BUN, a fixed time point of 24 hours for outcome assessment was chosen 
instead of the time point of the greatest efficacy. The analyses contained 24 studies for 
both creatinine and BUN. The summary effect found in the sensitivity analysis did not 
differ from the original analysis for either creatinine (NMD 43.3 [30.7, 55.9] vs. 45.0 [33.4, 
56.6]) or BUN (NMD 37.3 [24.7, 50.8] vs. 43.4 [30.8, 56.1]). The overall heterogeneity 
was slightly lower in the sensitivity analyses (I2 64.3% vs. 74.7% for creatinine and 69.3% 
vs. 71.6% for BUN). 
For renal histology, a sensitivity analysis was performed by excluding all studies which 
did not use the Jablonski grading scale. The summary effect found in the sensitivity 
analysis on the remaining 13 studies did not differ from the original analysis (MD 40.2 
[32.5, 47.8] vs. 27.8 [18.4, 37.2]). However, heterogeneity was considerably lower in 
the sensitivity analysis (I2 41.5% vs. 96.2%). This was surprising, since all scales roughly 
scored the same features of tubular damage (e.g. cellular vacuolization, loss of brush 
border, cast formation). However, since the overall effect of IPostC was robust, we feel 
that our decision to pool all scoring systems is justified. 
One study [28] measured serum creatinine and BUN twelve weeks after renal IRI. At 
this time-point, values were similar in all groups, which resulted in extremely large 
confidence intervals in our NMD meta-analysis. However, omitting this study had no 
effect on meta-analysis outcomes.
DISCUSSION
IPostC efficacy and sources of heterogeneity
This systematic review and meta-analysis provides a quantitative summary of all preclini-
cal in vivo evidence on IPostC against renal IRI. Our review shows a protective effect of 
both LIPostC and RIPostC on renal function and histology, based on a reduction in serum 
creatinine, BUN and renal histology scores. The high between-study heterogeneity was 
partially explained by the duration of index ischemia, i.e. LIPostC efficacy appeared to 
increase as the duration of index ischemia increased. The other study characteristics 
under investigation did not account for significant proportions of heterogeneity, or could 
not be analysed due to insufficient data (especially for RIPostC). For LIPostC, the remaining 
heterogeneity is high, especially for renal histology. Importantly, differences in the risk of 
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bias between studies may represent a significant source of unexplained heterogeneity, 
but insufficient reporting currently prevents us from testing this hypothesis (see below). 
Methodological quality
Adequate reporting of methodological details is crucial to determine the risk of bias in 
primary studies and to assess the quality of a body of evidence. Insufficient reporting of 
preclinical research methodology occurs in many fields and is often associated with an 
overestimation of treatment effects e.g. [29–31]. We show that details on key measures 
to reduce bias (such as randomisation and blinding) and other study quality indicators 
were missing from many studies included in our review. The risk of bias in most studies 
therefore remains unclear. Consequently, some studies may have overestimated the 
effect of IPostC, which may have influenced the outcome of our meta-analysis. 
The number of animals per group was very low in a number of studies. This is a matter 
of concern, since underpowered studies have an increased risk of finding false positive 
results. Systematic reviews have suggested that underpowering of in vivo studies is 
common, and that this greatly contributes to translational failure [31, 32]. Since none of 
the included studies reported a sample size calculation, we cannot exclude the possibility 
of an effect of underpowering on our meta-analysis.
Study characteristics
The present review points out several apparent differences between the experimental 
design of current clinical trials on renal IPostC, and the preceding animal studies. Firstly, 
we show that 99% of the preclinical evidence was obtained from animals undergoing 
warm renal ischemia. In contrast, the two published clinical trials on IPostC [7, 8], as well 
as a third trial in progress (ISRCTN66437627), all study the effect of IPostC after renal 
transplantation. To our knowledge, these trials were predominantly based on results 
obtained in animal models of warm IRI. Only one animal study investigating IPostC 
after renal transplantation [33] was retrieved by our search (which was not limited to a 
specific model of renal IRI). This study does show a protective effect of local IPostC after 
transplantation, however, there are substantial differences between these models (e.g. 
warm vs. cold ischemia and renal denervation), and animal models using warm ischemia 
may not optimally predict outcomes in the clinical transplantation setting. 
Secondly, we show that 90% of the animal studies investigated LIPostC, even though 
RIPostC is generally considered to be more applicable in clinical practice. Thus far, one 
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clinical trial investigated LIPostC [7], and two applied RIPostC ([8] and ISRCTN66437627). 
Regarding the LIPostC protocol, our meta-analysis did not identify any factors related to 
timing or duration which influence its efficacy. Since nearly all evidence was obtained in 
rats, it remains unclear whether the same timing and duration is effective in all species 
(including humans). Only two studies have used larger animals, whose metabolic rate 
is more comparable to humans. Of note, Van den Akker et al. [7] adjusted their clinical 
IPostC protocol to fit the metabolic rate in humans, but found no beneficial effect. 
Furthermore, there is not enough preclinical evidence to assess if timing and/or duration 
of the protocol influences the efficacy of RIPostC. We suggest that the optimal timing 
and duration of the postconditioning protocols should be determined separately for 
LIPostC and RIPostC. 
Concerning the population under investigation, nearly all preclinical studies used male 
animals, whereas the clinical trials included both men and women. This sex bias (which 
is widespread in preclinical studies) is reason for concern, considering the evidence that 
females react differently to both IRI [34] and IPostC [35]. Secondly, we found no studies 
using animals with relevant comorbidities such as hypertension or diabetes mellitus, 
which are often present in patients undergoing renal surgery or transplantation. The 
absence of comorbidities in experimental animals has previously been described as 
a possible explanation for the translational failure of conditioning strategies [36–38]. 
Publication bias 
Visual inspection of funnel plots, as well as trim and fill analysis, indicate a possible 
presence of publication bias in this field. The direction of effect did not change after 
trim and fill, but neutral and negative studies were underrepresented. On the other 
hand, Egger’s test did not indicate any small-study effects, and Funnel plot asymmetry 
may be explained by other factors such as true heterogeneity, study quality or chance 
[39]. Based on this analysis we assess the risk of publication bias to be mild (histology 
and creatinine) to moderate (BUN). This should be kept in mind when interpreting our 
results, since data from a range of animal studies strongly suggested that publication 
bias is associated with a substantial overestimation of treatment effects [40].
Clinical implications and future perspective
This review is the first systematic overview of preclinical evidence for the efficacy of IPostC 
in animal models of renal IRI. It provides useful insights in the variables influencing IPostC 
efficacy, within the limitations inherent to combining data from different experiments. 
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Sensitivity analyses showed that the observed overall efficacy is robust for all outcome 
measures. Our finding that IPostC efficacy may increase with the duration of renal 
ischemia suggests that IPostC is less effective when kidney injury is mild. The severity of 
renal IRI in patients varies with the type of surgery they receive, their co-morbidities and 
additional measures which can be taken to reduce IRI. Thus, IPostC may not be equally 
potent in all patients, and this should be taken into account when including patients in 
clinical trials and analyzing clinical and preclinical results. 
We also find that the body of evidence on which clinical trials are presently based is 
narrow, and its quality unclear. In particular, indirectness and risk of bias are reasons 
to interpret the preclinical findings with care. The present review points out a number 
of opportunities for improvement and future research, in order to increase clinical 
relevance of the preclinical studies and provide sufficient validity to guide clinical trial 
design. Preclinical studies should use both sexes, animals with relevant comorbidities, 
and it should be investigated whether the results obtained thus far can be replicated 
in transplantation models. Larger animal species may be used to better resemble 
the metabolic rate in humans. Importantly, to avoid effects of insufficient reporting, 
underpowering and publication bias in systematic reviews, it is of the utmost importance 
that the design, execution and reporting of animal studies is improved, for instance 
through the use of the GSPC and ARRIVE guidelines by authors and journals. Only then, 
preclinical evidence can be used to its full extent.
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SUppORTINg INfORMATION
S3.1 Text. Extended materials and methods
The review methodology was predefined and documented in a systematic review protocol 
[15], published online on February 12th 2015. The review question was: what is the effect 
of local or remote IPostC on renal function in animal models of renal IRI? 
2.1 Amendments to the review protocol
After study selection, we found that the timing and duration of the IPostC protocol 
depended strongly on the site of postconditioning. We therefore decided to perform 
separate meta-analyses of studies using local, remote, and local+remote postconditioning, 
to avoid collinearity. 
For serum creatinine and blood urea nitrogen (BUN), all data could be expressed in 
the same unit of measurement, but differences in baseline measurements between 
studies were observed. We therefore performed meta-analysis of the normalised mean 
difference (NMD) instead of the standardized mean difference (SMD). For renal histology, 
we expressed all scores as a percentage on the grading scale used, and performed meta-
analysis of the mean difference (MD), instead of the SMD. This allowed us to include 
studies reporting the histology score as a percentage on the grading scale used.
2.2 Study identification
A systematic, computerized search in the databases Medline (via PubMed) and EMBASE 
(Supplemental Table S3.1) was performed on February 4th 2015, using the search 
components ‘kidney’, ‘ischemic postconditioning’ and an animal search filter for either 
PubMed [16] or EMBASE [17]. To identify additional relevant studies, the reference lists 
of included studies and relevant reviews were hand searched. No language restrictions 
were applied. Studies in a language other than English were translated using Google 
Translate. In case of uncertainties, a native speaker of the language was consulted.
2.3 Selection of studies
After removal of duplicates, selection of studies was performed using Early Review 
Organizing Software (Institute of Clinical and Health Policy, Buenos Aires, Argentina). All 
references were first screened for inclusion based on their title and abstract. The following 
inclusion criteria were applied: the study 1) is an original article presenting unique data 
with a control group, 2) is performed in vivo in animals with or without comorbidities, 
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but without genetic modifications, 3) reports on renal ischemia-reperfusion injury and 
outcome measures related to kidney injury or function, and 4) examined the effect of 
remote and/or local ischemic postconditioning. Subsequently, the full-text manuscripts of 
eligible studies were reviewed for inclusion. Studies involving co-medication other than 
anaesthetics or analgesics, or a co-intervention other than collateral nephrectomy (e.g. 
renal transplantation) were excluded. In both phases, references were independently 
assessed for inclusion by two reviewers (KW and SJ). In case of discrepancies, consensus 
was reached through discussion. Authors of eligible conference abstracts were contacted 
through e-mail in order to retrieve the full manuscript if available. If there was no reply 
within three weeks after sending a reminder, the study was excluded from analysis.
2.4 Study characteristics and data extraction
The following study characteristics were extracted: bibliographical data (author, year, 
title, language), animal characteristics (species, strain, sex, age, weight), experimental 
groups, number of animals per group, duration of index ischemia, and details of the 
IPostC protocol (site of IPostC, number of cycles, duration of ischemia and reperfusion). 
One reviewer extracted the data (SJ) and a second reviewer (TM) checked the data for 
inconsistencies. Based on their clinical relevance, we selected the following outcome 
measures for analysis: serum creatinine, BUN and renal histology scores (Jablonski [18] 
or comparable). Data was collected as mean and standard deviation (SD). For serum 
creatinine and BUN, all data was recalculated to the two same unit of measurement 
(umol/L for creatinine and mmol/L for BUN). For renal histology, scores were expressed 
as a percentage on the grading scale used. If an outcome was measured at several time-
points, data was extracted for the time-point of greatest efficacy. If a study reported 
data from several experimental groups, it was extracted as separate comparisons and 
the number of animals in the control group was corrected (number of animals divided 
by number of comparisons). If data was only presented graphically, it was extracted 
using digital imaging software (ImageJ, National Institutes of Health, USA). Authors 
were contacted to provide additional information in case of unreported or unclear 
data. If there was no reply within three weeks after sending a reminder, a conservative 
estimate was made. 
2.5 Risk of bias and study quality
Two reviewers (SJ and TM) independently assessed the risk of bias and study quality 
of each included study. In case of discrepancies, consensus was reached by discussion 
with a third reviewer (KW). Risk of bias was assessed using SYRCLE’s Risk of Bias tool 
[19]. Reporting bias (item #9) was not assessed, since none of the studies reported the 
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use of a study protocol predefining primary and secondary outcomes. When assessing 
selection bias, groups within a study were considered similar at baseline if sex and 
baseline serum creatinine did not significantly differ between groups (or, if baseline 
creatinine was unavailable, body weight). To assess whether studies were free of other 
risks of bias, addition of animals to groups during the experiment and a possible conflict 
of interest were taken into account. We also assessed reporting of the following study 
quality items: any randomization, any blinding, regulation of body temperature within 
3°C variation, a sample size calculation and a conflict of interest statement.
2.6 Data analysis
Data was analyzed using Stata/SE (StataCorp, Texas, USA). For the outcome measures 
serum creatinine and BUN, meta-analysis was performed on the NMD, which allows us 
to correct for baseline kidney injury by relating the magnitude of the effect of treatment 
to a baseline measured in untreated animals [20]. For histology, the MD was used. A 
random effects model was used to account for expected between-study heterogeneity. 
To assess heterogeneity, the I2 and adjusted R2 statistics were determined. To examine 
potential sources of heterogeneity, predefined subgroup analyses were performed on 
subgroups containing data from at least three studies. For the duration of IPostC ischemia, 
studies were categorized using increments of 0.7 log, which resulted in categories of 
26–125, 126–630 and 631–3162 seconds of ischemia. For the duration of index ischemia, 
studies were categorized using increments of 15 minutes, resulting in categories of 16–30, 
31–45, 46–60, 61–75 (no studies) and 76–90 minutes. Differences between subgroups 
were determined by calculating the difference in NMD and MD respectively and the 
95% confidence intervals (CI) of the difference. Results are reported as a NMD or MD 
[95% CI], unless stated otherwise. For each outcome measure, the significance level for 
subgroup analyses was adjusted for the number of analyses using the Bonferroni-Holm 
method [21]. 
Publication bias was assessed for each outcome measure by visual evaluation of funnel 
plots, Duval and Tweedie’s trim and fill analysis and by performing Egger’s test for small 
study effects. Sensitivity analyses were carried out for creatinine and BUN using a fixed 
time point of outcome assessment (24 hours). For histology, a sensitivity analysis was 
performed using only Jablonski histology scores.
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Table S3.1. Complete search strategy for Medline (via PubMed) and EMBASE
Medline (via 
PubMed)
Kidney "kidney"[MeSH Terms] OR "acute kidney injury"[MeSH Terms] OR 
"kidney transplantation"[MeSH Terms] OR "nephrology"[MeSH 
Terms] OR "kidney"[Tiab] OR "kidneys"[Tiab] OR "renal"[Tiab] OR 
"nephrology"[Tiab]
Postconditioning "ischemic postconditioning"[MeSH Terms] OR 
"postconditioning"[tiab] OR "post conditioning"[tiab] OR 
"post-conditioning"[tiab] OR "IPostC"[tiab] OR "RIPostC"[tiab] 
OR “IPOC”[tiab] OR “RIPOC”[tiab] OR “IPC”[tiab] OR 
“RIPC”[tiab] OR “postcon”[tiab] OR "brief ischemia"[tiab] OR 
"brief ischaemia"[tiab] OR "transient ischaemia"[tiab] OR 
"transient ischemia"[tiab] OR "intermittent ischaemia"[tiab]OR 
"intermittent ischemia"[tiab] OR “continuous ischemia"[tiab] OR 
"continuous ischaemia"[tiab] OR “IPost” [tiab] OR “RIPost” [tiab] 
OR “rPostC” [tiab] OR “PostC” [tiab]
Animals Laboratory animal search filter 16
February 4th 2015: 213 hits
NB: adding additional abbreviations of ischemic postconditioning “POC”[tiab] OR “IPO”[tiab] did not 
generate additional relevant hits
EMBASE Kidney exp kidney/ or exp acute kidney failure/ or exp kidney 
transplantation/ or exp kidney allograft rejection/ or (renal or 
kidney or kidneys or nephrology).ti,ab.
Postconditioning ischemic postconditioning/ or (brief ischemia or brief ischaemia 
or postconditioning or post conditioning or post-conditioning 
or transient ischaemia or transient ischemia or intermittent 
ischaemia or intermittent ischemia or continuous ischemia or 
continuous ischaemia or IPost or RIPost or IPOC or RIPOC or 
IPostC or RIPostC or IPC or RIPC or postcon or rPostC or PostC).
ti,ab.
Animals Laboratory animal search filter 17
February 4th 2015: 272 hits
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Table S3.2. Study quality and risk of bias assessment, individual scores
Reporting Risk of bias
Any random
ization
Any blinding
Sam
ple size calculation
Conflict of interest statem
ent
Tem
perature regulation
Overall (tim
es Y out of 5)
Random
 group allocation (selection)
Groups sim
ilar at baseline (selection)
Blinded group allocation (selection)
Random
 housing (perform
ance)
Blinded interventions (perform
ance)
Random
 outcom
e ass. (detection)
Blinded outcom
e ass. (detection)
Reporting of drop-outs (attrition)
Other biases
Chen 2008 41 Y Y† N N Y 3 ? ? # ? ? ? ? ? ? ?
Chen 2011 42 Y N N N N 1 ? ? # ? ? ? ? ? ? ?
Chen 2014 43 Y Y† N N Y 3 ? ? # ? ? ? ? ? ? ?
Chen 2015 44 Y Y† N Y Y 4 ? ? # ? ? ? ? ? H L
Eldaif 2010 45 N Y† N N Y 2 ? ? # ? ? ? ? ? H ?
fan 2009 46 Y N N N N 1 ? ? # ? ? ? ? ? L ?
guo 2014 47 N N N N N 0 ? ? # ? ? ? ? ? ? ?
Ji 2012 48 Y N N N Y 2 ? ? # ? ? ? ? ? L ?
Jiang 2010 49 Y Y† N N Y 3 ? ? # ? ? ? ? ? L ?
Jiang 2014 50 Y N N Y N 2 ? ? # ? ? ? ? ? L L
Kadkhodaee 2011 22 Y N N Y N 2 ? ? # ? ? ? ? ? ? L
Kadkhodaee 2014 51 Y N N Y Y 3 ? ? # ? ? ? ? ? ? L
lemoine 2015 52 N Y† N Y Y 3 ? ? # ? ? ? ? ? ? L
li 2010 53 Y N N N Y 2 ? ? # ? ? ? ? ? ? ?
li 2012 54 Y N N N N 1 ? ? # ? ? ? ? ? L ?
liu 2007 55 N Y† N N Y 2 ? ? # ? ? ? ? ? ? ?
Mahfoudh-Boussaid 2012 24 Y Y† N Y Y 4 ? ? # ? ? ? ? ? L L
Mahmoudi 2014 35 Y N N N N 1 ? ? # ? ? ? ? ? ? ?
Miklós 2012 26 N Y† N N N 1 ? L ? ? ? ? ? ? ?
Serviddio 2008 27 N Y† N Y N 2 ? L ? ? ? ? ? ? L
Shokeir 2012 56 Y N N Y N 2 ? L ? ? ? ? ? ? L
Shokeir 2014 57 Y N N Y N 2 ? L ? ? ? ? ? L L
Szwarc 2007 58 N N N N Y 1 ? L ? ? ? ? ? L ?
Tan 2013 59 N N N Y Y 2 ? ? # ? ? ? ? ? ? L
Tang 2008 60 Y N N N N 1 ? ? # ? ? ? ? ? L ?
Tao 2012 61 Y N N Y N 2 L L ? ? ? ? ? L L
Wang 2010 62 Y Y† N N Y 3 ? ? # ? ? ? ? ? ? ?
Weng 2012 28 Y Y† N Y Y 4 ? ? # ? ? ? ? ? L L
Wever 2012 23 Y Y† N Y N 3 ? ? # ? ? ? ? ? L L
Xia 2014 25 Y N N Y N 2 ? ? # ? ? ? ? ? L L
Yun 2009 A 63 Y Y† N N Y 3 ? ? # ? ? ? ? ? L ?
Yun 2009 B 64 Y Y† N N Y 3 ? ? # ? ? ? ? ? ? ?
Zhang 2011 65 Y N N N N 1 ? ? # ? ? ? ? ? L ?
Zhu 2008 66 Y N N N N 1 ? ? # ? ? ? ? ? L ?
Zhuang 2009 67 N Y† N N N 1 ? ? # ? ? ? ? ? ? ?
Total Y/l 26 16 0 14 17 1 6 0 0 0 0 0 16 14
Y = yes, N = no, ? = unclear risk of bias, H = high risk of bias, L = low risk of bias; †Only blinded for histology; 
#groups were similar only for sex
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Table S3.3. Subgroup analysis serum creatinine local IPoC
# pub # comp NMD [95% CI]
All (T2 539, I2 74.7%) 29 34 45.0 [33.4, 56.6]
Species
p=0.14, adj. R2 12.8%
Dog 1 3 79.3 [29.0, 129.6]
Mouse 3 4 19.5 [-13.1, 52.0]
Rat 25 27 47.2 [33.8, 60.5]
Sex 
p=0.21, adj. R2 10.4%
Female 3 3 20.9 [-18.3, 60.2]
Male 27 31 47.8 [35.1, 60.6]
# cycles
p=0.26, adj. R2 8.8%
3 cycles 10 11 39.6 [21.3, 58.0]
4 cycles 4 5 28.3 [-5.8, 62.4]
6 cycles 14 16 51.3 [31.4, 71.3]
10 cycles 2 2 86.2 [36.4, 136.0]
IPoC ischemia
p=0.12, adj. R2 8.7%
26–125 sec 23 26 41.8 [27.5, 56.1]
126–630 sec 4 5 82.0 [45.4, 118.5]
631–3162 sec 3 3 35.9 [5.6, 66.3]
Index ischemia 
p=0.15, adj. R2 7.7%
16–30 min 4 5 20.2 [-10.7, 51.1]
31–45 min 20 22 43.7 [28.2, 59.1]
46–60 min 4 6 72.3 [41.5, 103.1]
76–90 min 1 1 58.3 [7.5, 109.1]
Delay (linear)
p=0.20, adj. R2 6.4% 30 34
Total # comparisons = 6, corrected p<0.009; IPoC = ischemic postconditioning, pub = publications, comp = 
comparisons, NMD = normalized mean difference, adj. = adjusted. Protocol ischemia; amount of total ischemia 
time within IPoC protocol, delay; amount of delay between index ischemia and start IPoC protocol.
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Table S3.4. Subgroup analysis blood urea nitrogen local IPoC
# pub # comp NMD [95% CI]
All (T2 703, I2 71.6%) 28 33 43.4 [30.8, 56.1]
Species
Not analyzed
Dog 1 3 74.4 [9.6, 139.3]
Mouse 2 3 4.2 [-22.7, 31.0]
Rat 25 27 48.3 [36.5, 60.0]
Sex 
Not analyzed
Female 2 2 30.6 [-15.3, 76.6]
Male 27 31 44.0 [31.5, 56.5]
Cycles
p=0.05, adj. R2 31.9%
3 cycles 8 9 28.1 [12.0, 44.2]
4 cycles 4 5 29.5 [-2.4, 61.5]
6 cycles 15 17 56.2 [39.1, 73.4]
10 cycles 2 2 81.9 [35.4, 128.3]
Protocol ischemia
p=0.12, adj. R2 8.5%
26–125 sec 22 25 42.6 [29.0, 56.2]
126–630 sec 4 5 78.2 [39.1, 117.2]
631–3162 sec 3 3 25.2 [-3.2, 53.7]
Index ischemia 
p=0.007, adj. R2 44.5%
16–30 min 3 4 6.2 [-17.4, 29.9]
31–45 min 19 21 43.1 [29.8, 56.4]
46–60 min 5 7 73.2 [48.5, 97.9]
76–90 min 1 1 47.1 [8.8, 85.5]
Delay (linear)
p=0.05, adj. R2 14.4% 28 33
Total # comparisons = 4, corrected p<0.012; IPoC = ischemic postconditioning, pub = publications, comp = 
comparisons, NMD = normalized mean difference, adj. = adjusted. Protocol ischemia; amount of total ischemia 
time within IPoC protocol, delay; amount of delay between index ischemia and start IPoC protocol.
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Table S3.5. Subgroup analysis renal histology local IPoC
# pub # comp MD [95% CI]
All (T2 369, I2 96.2%) 18 23 27.8 [18.4, 37.2]
Species
Not analyzed
Dog 1 3 59.7 [31.7, 87.6]
Mouse 2 3 17.3 [-1.5, 36.1]
Rat 15 17 26.2 [17.3, 35.1]
Sex 
Not analyzed
Female 1 1 3.6 [-29.1, 36.3]
Male 18 22 28.8 [20.6, 37.0]
Cycles
p=0.84, adj. R2 -17.0%
3 cycles 4 5 23.4 [5.5, 41.3]
4 cycles 2 3 22.2 [-1.0, 45.3]
6 cycles 12 14 29.5 [18.1, 40.9]
10 cycles 1 1 37.5 [2.7, 72.3]
Protocol ischemia 
p=0.63, adj. R2 -5.7%
26–125 sec 15 18 25.5 [16.2, 34.7]
126–630 sec 3 4 36.1 [14.7, 57.4]
631–3162 sec 1 1 35.0 [-5.6, 75.5]
index ischemia
p=0.13, adj. R2 3.3%
16–30 min 3 4 15.5 [-1.6, 32.6]
31–45 min 11 13 25.9 [14.6, 37.1]
46–60 min 4 6 39.9 [24.4, 55.3]
Delay (linear) 
p=0.22, adj. R2 2.45% 18 23
Total # comparisons = 4, corrected p<0.012; IPoC = ischemic postconditioning, pub = publications, comp = 
comparisons, MD = mean difference, adj. = adjusted. Protocol ischemia; amount of total ischemia time within 
IPoC protocol, delay; amount of delay between index ischemia and start IPoC protocol.
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have synergistic protective effects on renal 
ischemia-reperfusion injury
KE Wever, TP Menting, R Masereeuw, JA van der Vliet, 
GA Rongen, MC Warlé
Transplantation. 2012 Jul 15;94(1), letter
4
Chapter_4_Theo.indd   89 6-9-2017   10:29:45
Chapter 4
90
In the current era of meticulous surgical technique and modern immunosuppressive 
therapy, ischemia-reperfusion injury (IRI) is one of the major determinants of early and 
longterm allograft function after kidney transplantation [1, 2]. In an experimental model 
of renal IRI, we showed that remote ischemic preconditioning using the hind limb as 
the remote organ is effective in reducing IRI [3]. Kadkhodaee et al. [4] recently reported 
that remote ischemic perconditioning and remote ischemic postconditioning (RIPostC) 
also significantly reduce renal IRI in a comparable model. 
Here, we report the first data on the combined effect of local IPostC (LIPostC) and RIPostC 
on renal IRI. Male Sprague-Dawley rats weighing approximately 300 g were randomized 
into five groups before surgery. All animals underwent nephrectomy of the left kidney. 
Five sham-operated animals served as a baseline control (sham). All other animals 
were subjected to 25 minutes of renal ischemia (by clamping the renal artery and vein 
of the right kidney) with 48 hr of reperfusion. Eight animals underwent renal IRI only 
(no IPostC). In nine animals, three cycles of RIPostC by brief hind limb ischemia were 
induced directly after clamp release, by inflating small blood pressure cuffs around both 
proximal thighs for five min, followed by five minutes of reperfusion (RIPostC). Successful 
hind limb occlusion (loss of pulse and strong decrease of saturation) was confirmed 
by means of a pulse oximeter clip placed on the foot. In another nine animals, LIPostC 
was induced by six cycles of eight sec of ischemia, followed by eight sec of reperfusion 
(LIPostC). Seven animals underwent both postconditioning procedures (RIPostC plus 
LIPostC). After 48 hr, blood, urine, and renal tissue samples were analyzed to assess 
renal function and damage. 
Renal IRI caused a decline in renal function, as reflected by an increase in plasma 
creatinine level, plasma urea level, and fractional excretion of sodium. These detrimental 
effects were only partially reduced by RIPostC or LIPostC alone. However, the combined 
application of RIPostC and LIPostC significantly reduced the IRI-induced decrease in 
renal function (Figure 4.1A-C). Furthermore, a similar synergistic effect of RIPostC plus 
LIPostC was observed for renal histologic damage, as assessed by scoring periodic 
acidYSchiffYstained sections of renal cortex on a 0 to 5 scale by an investigator blinded 
to treatment allocation (Figure 4.1D) [3].
In contrast with a previous report [3], RIPostC did not significantly reduce plasma 
creatinine and urea levels in our model. This may be explained by the use of a shorter 
sustained ischemic stimulus (25 vs. 45 min) and hind limb occlusion by blood pressure 
cuff, rather than clamping of the iliac vessels. Nevertheless, we demonstrate that RIPostC 
effectively prevents an IRI-induced increase in fractional excretion of sodium. More 
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importantly, we show that RIPostC and LIPostC have synergistic protective effects on IRI 
of the kidney. Although both strategies have been shown to influence the status of the 
mitochondrial permeability transition pore, it has been postulated that LIPostC does so by 
delaying the normalization of the intracellular pH [5], whereas RIPostC is believed to cause 
the release of various signalling molecules, such as adenosine, opioids, and cytokines, 
which act on the mitochondrial permeability transition pore through the activation of 
the cyclic guanosine monophosphate, Protein Kinase G (cGMP/PKG), Reperfusion Injury 
Salvage (RISK), or Survivor Activating Factor Enhancement (SAFE) pathway [6].
Figure 4.1. Remote ischemic postconditioning (RIPostC) and local ischemic postconditioning (LIPostC) reduce 
renal damage after ischemia-reperfusion injury.
When compared with sham-operated animals, rats subjected to 25 minutes of renal ischemia and 48 hours of 
reperfusion (no IPostC) experienced a decline in renal function, as reflected by an increase in plasma creatinine 
level (A), plasma urea level (B), and fractional excretion of sodium (FENa) (C). These detrimental effects were 
only partially reduced by RIPostC (three cycles of 5-min hind limb occlusion) or LIPostC (six cycles of 8-sec 
renal reocclusion) alone. Combined application of RIPostC and LIPostC significantly reduced the ischemia-
reperfusion injury induced decrease in renal function (A–C). A similar synergistic effect of RIPostC plus LIPostC 
was observed for the degree of renal histologic damage (D). # PG0.01 vs. sham. * PG0.05, ** PG0.01 vs. no 
IPostC by one-way analysis of variance followed by Tukey multiple comparison posttest. n=5 for sham, n=8 
for no IPostC, n=9 for RIPostC, n=9 for IPostC, and n=7 for RIPostC plus IPostC.
Local and Remote Ischemic Postconditionings Have Synergistic Protective
Effects on Renal Ischemia-Reperfusion Injury
I n the current era of meticuloussurgical technique and modern im-
munosuppressive therapy, ischemia-
reperfusion injury (IRI) is one of the
major determinants of early and long-
term allograft functi n after kidney
transplantation (1, 2). In an experimen-
tal model of renal IRI, we showed that
remote ischemic preconditioning using
the hind limb as the remote organ is
effective in reducing IRI (3). Kadkhodaee
et al. (4) recently reported that remote
ischemic percondition ng nd remote is-
chemic postconditioning (RIPostC) also
significantly reduce renal IRI in a compa-
rable model. Here, we report the first data
on the combined effect of local IPostC
(LIPostC) and RIPostC on renal IRI.
Male Sprague-Dawley rats weigh-
ing approximately 300 g w re random-
ized into five groups before surgery. All
animals underwent nephrectomy of the
left kidney. Five sham-operated ani-
mals served as a baseline control (sham).
All other animals were subjected to
25 min of renal ischemia (by clamping
the renal a tery and vei of the right
kidney) with 48 hr of reperfusion. Eight
animals underwent renal IRI only (no
IPostC). In ine a imals, three cycles
of RIPostC by brief hind limb ischemia
were induced directly after clamp release,
by inflating small blood pressure cuffs
around both pr ximal thighs for 5 min,
followedby5minof reperfusion (RIPostC).
Successful hind limb occlusion (loss of
pulse and strong decrease of saturation)
was confirmed by means of a pulse oxi-
meter clip placed on the foot. In another
nine animals, LIPostC was induced by
six cycles of 8 sec of ischemia, followed
by 8 sec of reperfusion (LIPostC). Seven
FIGURE 1. Remote ischemic postconditioning (RIPostC) and local ischemic postconditioning (LIPostC) reduce renal
damage after ischemia-reperfusion injury. When compared with sham-operated animals, rats subjected to 25 min of renal
ischemia and 48 hr of reperfusion (no IPostC) experienced a decline in renal function, as reflected by an increase in plasma
creatinine level (A), plasma urea level (B), and fractional excretion of sodium (FENa) (C). These detrimental effects were
only partially reduced by RIPostC (three cycles of 5-min hind limb occlusion) or LIPostC (six cycles of 8-sec renal reoc-
clusion) alone. Combined application of RIPostC and LIPostC significantly reduced the ischemia-reperfusion injuryY
induced decrease in renal function (AYC). A similar synergistic effect of RIPostC plus LIPostC was observed for the degree
of renal histologic damage (D). # PG0.01 vs. sham. * PG0.05, ** PG0.01 vs. no IPostC by one-way analysis of variance followed
by Tukey multiple comparison posttest. n=5 for sham, n=8 for no IPostC, n=9 for RIPostC, n=9 for IPostC, and n=7 for
RIPostC plus IPostC.
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 Our present finding supports the theory that the mechanisms of action could be different 
for LIPostC vs. RIPostC. For the implementation of IPostC into the clinical practice of 
kidney transplantation, we believe that its efficacy should be tested further in animal 
models of renal transplantation. Our data suggest that the combination of LIPostC and 
RIPostC is a highly interesting approach for further preclinical studies.
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ABSTRACT
Background
In animal studies, remote ischemic preconditioning (RIPC) and anesthetic preconditioning 
are successful in reducing renal ischemia reperfusion injury (IRI), however the protective 
effect of RIPC may be improved by repeating the RIPC stimulus.
Methods
Sprague-Dawley rats underwent unilateral nephrectomy followed by 30 minutes of renal 
pedicle clamping. Animals were allocated into six groups: sham, control (IRI), RepISO (daily 
isoflurane anesthesia), RIPC (single dose isoflurane anesthesia and single dose RIPC), 
RepISO+RIPC (7-day isoflurane anesthesia and single dose RIPC) and RepISO+RepRIPC 
(7-day isoflurane anesthesia with 7-day RIPC). RIPC was applied by 3x 5 minutes of cuff 
inflation on both thighs. Serum creatinine and urea levels were measured and histology 
was obtained at day two.
Results
RepISO diminished renal IRI, as reflected by a significant reduction in serum creatinine 
levels as compared to the control group, 170 ± 74 resp. 107 ± 29 µmol/L. The other 
preconditioning protocols showed similar reduction in serum creatinine levels as 
compared to the control group. No significant differences were observed between 
the different preconditioning protocols. For urea levels, only RepISO+RIPC resulted in 
significantly lower levels as compared to the control group, 14 ± 4 resp. 22 ± 7 mmol/L 
(p=0.010). In the preconditioning groups only RepISO showed less histological damage 
as compared to controls 1.73 ± 1.19 resp. 2.91 ± 1.22 (p=0.032). 
Conclusions
In this study no additional protective effect of repeated ischemic preconditioning was 
observed as compared to single dose RIPC. Repeated administration of isoflurane 
provided stronger protection against renal IRI as compared to single dose isoflurane.
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INTRODUCTION
Ischemia reperfusion injury (IRI) is tissue damage caused by the restoration of blood 
flow after a period of deprived circulation of that tissue [1]. The deficit of oxygen and 
nutrients during the ischemic phase creates a condition in which the return of blood flow 
induces oxidative stress, inflammation and results in apoptosis of the cell [2]. This may 
lead to tissue damage and loss of organ function [3]. The kidney is an organ especially 
vulnerable to IRI, due to its high-energy demand and delicate microcirculation. IRI of 
the kidney is a significant clinical problem in shock, renal transplantation and major 
cardiac or vascular surgery [4]. A promising method to diminish IRI was first described 
in 1986 by Murry [5], he discovered that short harmless periods of ischemia can protect 
the heart against a prolonged ischemic period; this phenomenon is called ischemic 
preconditioning (IPC). It was later described that the interruption of blood flow to an 
organ different than the target organ could also have a protective effect on IRI. This 
phenomenon is known as remote ischemic preconditioning (RIPC) [6]. Although the exact 
mechanism of RIPC is unknown, prevention of apoptosis by closure of the mitochondrial 
permeability transition pores (mPTP), seems to play a pivotal role [3]. A limb is often 
used as the remote organ for the application of the RIPC stimulus as the blood flow can 
safely and easily be obstructed by insufflation of a blood pressure cuff around an arm 
or leg. Experimental studies have shown that RIPC does not only protect against IRI in 
the heart, but also in other organs, including the kidney [7].
Not only a distant ischemic impulse can cause renal protection from IRI, some anesthetics 
also protect the kidney against IRI. In myocardial and renal animal studies [8], anesthetics 
have shown to reduce IRI in a similar signaling cascade as RIPC, known as anesthetic 
preconditioning (APC). Volatile anesthetics have extensively been tested for their APC 
effectiveness in cardiac studies: isoflurane, sevoflurane, desflurane [9, 10], halothane [11] 
and ether derived anesthetics [12] have proven clinical and preclinical cardioprotective 
effects. Experiments with intravenous anesthetics, propofol, barbitarates and ketamine 
[13–15] show no protective effect and have been demonstrated to inhibit mKATP channels 
which is an indication these anesthetics might diminish the protective effect of APC or 
RIPC [16]. The effects of multiple periods of anesthetics on IRI are unknown.
In general, animal studies show that RIPC is effective in reducing renal IRI [17]; however, 
human studies show disappointing results, with a small or non-significant protective 
effect [18, 19]. Cumulating evidence exists that in cardiac IRI models, repeating the 
RIPC stimulus over a period of multiple days, repeated RIPC (RepRIPC), could be more 
effective as compared to single dose RIPC [13, 20, 21]. It is unclear if this holds true for 
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renal IRI. In this study we test whether the null-hypothesis could be rejected that single 
dose and repeated RIPC are equally effective in an experimental model of renal IRI.
MATeRIAlS AND MeThODS
The Committee for Animal Experiments of the Radboud Medical Center, Nijmegen 
approved all procedures (registration number 20149), and the experiment was 
conducted according to the ARRIVE criteria. Fifty- nine male Sprague–Dawley rats (Harlan 
Laboratories, Eystrup, Germany) were brought into the facility two weeks before the 
start of the experiment to acclimatize. Rats from different groups were housed randomly 
in the same room and under standard specific pathogen-free housing conditions. The 
environmental temperature was regulated at 22°C, with a relative humidity of 45% and 
a 12/12h day/night cycle. At the start of the experiment the animals weight was 311 ± 
21g, at the age of ten weeks.
Blinding
Group assignment of each rat was done by computer-generated randomization. The 
surgeon, caregivers and the analysts performing creatinine, urea and histology measure-
ments were blinded for group assignment of the animals. 
Study design
All animals were anesthetized using isoflurane for the same period of time and all animals 
underwent right nephrectomy. Animals were randomly divided in six groups (Figure 5.1): 
Group 1 and 2 underwent no preconditioning. The sham group (n=4, group 1) underwent 
a laparotomy, including the resection of the right kidney. The control group (n=11, 
group 2) underwent 30 minutes of left renal ischemia (IRI stimulus) during right kidney 
resection. Groups 3–6 were the experimental, preconditioning groups, all undergoing 
30 minutes of left renal ischemia at the day of surgery and a specific preconditioning 
stimulus: In group 3; repeated isoflurane (RepISO, n=11), the animals underwent seven 
days of isoflurane anesthesia for 25 minutes prior to the day of the operation. In group 
4; single RIPC (RIPC, n=11); the animals underwent 3x 5 minutes of cuff inflation and five 
minutes of reperfusion prior to the operation. Cuff inflation was initiated by using human 
toe pressure cuffs, inflating them simultaneously to 200mmHg on both thighs. RIPC 
required 25 minutes of anesthesia as the last five minutes of reperfusion did not require 
anesthesia. In group 5; repeated isoflurane and a single RIPC stimulus (RepISO+RIPC, 
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n=11), the animals underwent seven days of anesthesia for 25 minutes prior to the day 
of the operation. On the day of surgery, during isoflurane anesthesia, 3x 5 minutes of 
cuff inflation on both thighs and five minutes of reperfusion was performed. In group 6; 
repeated isoflurane and repeated RIPC (RepISO+RepRIPC, n=11), the animals underwent 
seven days of anesthesia for 25 minutes together with seven days of 3x 5 minutes of 
cuff inflation on both thighs and five minutes of reperfusion.
Surgical procedures
All experiments were randomly performed between 8.00 and 16.00h on Mondays 
and Tuesdays. Preoperative analgesic [Carprofen, 5 mg/kg body weight (b.w.)] was 
administered subcutaneously 30 minutes prior to surgery. Surgical procedures were 
conducted using standard aseptic surgical techniques and all microsurgical instruments 
were sterilized using a dry bead sterilizer (Inothech, Dottikon, Switzerland). Animals were 
placed on a sterile drape overlying a heating pad to maintain body temperature at 36–38°C, 
monitored continuously using a rectal thermometer. Body weights were recorded prior to 
surgery, prior to blood collection and at the end of the experiment. Anesthesia was induced 
with 5% isoflurane in pressurized air and maintained at 2.5–3%. Depth of anesthesia was 
assessed by toe and tail pinch. Preconditioning was done by TM. All operations were done 
Figure 5.1. Schematic protocol of the animal groups were the line is a non linear timeframe of seven days.
The open boxes indicate a period of anesthesia alone, gray boxes a period or RIPC and black boxes a period of 
renal ischemia. Animals were randomly allocated into six groups: sham, control (IRI), RepISO (daily isoflurane 
anesthesia), RIPC (single dose isoflurane anesthesia and single dose RIPC), RepISO+RIPC (7-day isoflurane 
anesthesia and single dose RIPC) and RepISO+RepRIPC (7-day isoflurane anesthesia with 7-day RIPC). RIPC 
was applied by 3x 5 minutes of cuff inflation on both thighs.
1. Sham (n=4)
2. Control (n=11)
3. RepISO (n=11)
4. RIPC (n=11)
5. RepISO+RIPC (n=11)
6. RepISO+RepRIPC (n=11)
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by an experienced microsurgeon (RL), renal ischemia was initiated by blunt dissection of 
the left renal hilus, and an atraumatic vascular clamp was used to obstruct the venous and 
arterial blood flow of the kidney. Complete obstruction was confirmed by visualization of 
the kidney gaining the typical ischemic dark purple color; complete revascularization after 
removal of the clamp was also visualized before closure of the abdomen. Closure of the 
abdomen was done by a running suture, securing both ends with a metal clip to prevent 
opening of the wound by the animal. One day post-operatively, an analgesic (Carprofen, 
5 mg/kg b.w.) in 5 mL saline was administered subcutaneously.
Renal function analysis and histology
At baseline, day one and day two blood samples were collected and stored. Blood samples 
were collected in EDTA tubes and centrifuged for 15 minutes at 3000g to obtain plasma. 
Plasma was snap frozen in liquid nitrogen and stored at -80°C until further use. For the 
histology, tissue from the remaining kidney was taken two days after surgery and was fixed 
in 4% paraformaldehyde for at least 48 hours. For light microscopy of the renal cortex, 
kidneys were dehydrated and embedded in paraffin. To score renal damage, sections 
of 4 µm were stained with periodic acid-Schiff. Of each kidney, four sections were taken 
at different latitudes and scored for damage of the renal cortex and averaged. Damage 
scoring was performed by a blinded investigator, on a scale from 0 to 4 according to the 
Jablonski scale [22], with 0: no proximal tubule damaged, and 4: all tubules damaged. 
Statistical and power analysis
Serum creatinine levels were used as the primary outcome measure. Previous experi-
ments have shown that in our model of 30 minutes renal injury, serum creatinine levels 
in control animals 48 hours post-operative are on average 290 µmol/L, with an average 
standard deviation of 103 µmol/L [23, 24]. We aim to detect a difference in serum creati-
nine between the RepISO+RepRIPC and all the other experimental groups including the 
control group of 100 µmol/L. Since there are five comparisons we have adjusted our level 
of significance for five comparisons, using Bonferonni correction: 0.05/5=0.01. In order 
to achieve a statistical power of at least 80%, we require 11 animals per group. Previous 
experiments have shown that the standard deviation in sham-operated animals is low 
(average serum creatinine 48 hours post-operative = 46 ± 8). Therefore four animals in 
the sham group were required. Although the animals were obtained from a different 
supplier, we estimated that the susceptibility to renal IRI would be similar because the 
strain, age, sex and weight were identical as in the previously mentioned experiments. 
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All data are presented as mean ± SD unless otherwise specified. The means of the differ-
ent groups were compared using the Student-t test. The level of statistical significance 
was set at p<0.05. Data were assessed and SPSS 22 and GraphPath 5.03 plotted graphs.
ReSUlTS
Peri-operative complications
Fifty-nine rats were randomly assigned to six different groups. Two rats died during 
anesthesia. A third animal was excluded at day two of the experiment due to intestinal 
rotation with obstruction. A fourth rat was excluded because the remaining kidney 
contained a large tumor, which filled one third of the kidney’s volume. The excluded rats 
belonged to different groups: control, RepISO, RIPC and RepISO+RepRIPC. The weight of 
the animals at baseline and the average weight loss at day two in the different groups 
were not significantly different between the groups.
Renal function analysis
Serum creatinine (Figure 5.2) and serum urea concentrations (Figure 5.3) were measured 
at baseline (ten days before surgery) and on postoperative day one and two. All baseline 
outcome measures were not significantly different.
In comparison with the control group, all groups showed a significantly lower level 
of creatinine; control 170 ± 74 µmol/L vs. sham and experimental group 1 and 
3–6 respectively; 71 ± 16 µmol/L (p=0.023), 107 ± 29 µmol/L (p=0.022), 107 ± 45 
µmol/L (p=0.032), 96 ± 22 µmol/L (p=0.007) and 102 ± 37 µmol/L (p=0.023). For the 
experimental groups only serum creatinine levels of RepISO on day 1 were significantly 
higher than sham creatinine levels; 107 ± 29 µmol/L resp. 71 ± 16 µmol/L (p=0.039). 
On day two the creatinine concentrations were reduced compared with day one and 
on day two there was no significant difference between sham and the experimental 
groups. The control animals showed significantly higher creatinine concentrations 
compared with the experimental groups, RepISO, RepISO+RIPC and RepISO+RepRIPC 
respectively: 102 ± 29 µmol/L vs. 63 ± 21 µmol/L (p=0.036), 49 ± 8 µmol/L (p=0.006) 
and 57 ± 21 µmol/L (p=0.028).
For urea levels, all groups showed significantly higher levels on day one as compared 
to sham: 9 ± 1 mmol/L vs. control 22 ± 7 mmol/L (p=0.000), vs. RepISO 18 ± 5 mmol/L 
(p=0.000), vs. RIPC 17 ± 8 mmol/L (p=0.010), vs. RepISO+RIPC 14 ± 4 mmol/L (p=0.002) 
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and vs. RepISO+RepRIPC 17 ± 7 mmol/L (p=0.047). Compared to control operated 
animals, only serum urea levels in RepISO+RIPC were significantly lower, 14 ± 4 vs. 22 
± 7 mmol/L (p=0.010). 
Figure 5.2. Serum creatinine.
Day -10 (baseline), 1 and 2 postoperative (* significantly different from sham, # significantly different from 
control group).
Figure 5.3. Serum urea.
Day -10 (baseline), 1 and 2 postoperative (* significantly different from sham, # significantly different from 
control group).
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histology
Histology, according to the Jablonski score, showed significantly more renal damage 
in the control group 2.91 ± 1.22 as compared to sham 0.75 ± 0.96 (p=0.007). In the 
preconditioning groups only RepISO, 1.73 ± 1.19 (p=0.032), showed significantly less 
damage as compared to control (Figure 5.4).
Figure 5.4. Histology.
Day 2 postoperative (* significantly different from sham, # significantly different from control group).  
 
 
 
 
 
   
DISCUSSION
To our knowledge this is the first experiment of RepRIPC compared to single dose RIPC 
in an experimental renal IRI model. With regard to the primary hypothesis, we were not 
able to demonstrate an additive protective effect of a repeated ischemic preconditioning 
stimulus in this experiment. However the question whether an additive protective 
effect of RepRIPC does not exist or the unanticipated large reduction in renal IRI by 
repeated isoflurane blurred the additional protective effects of repeated RIPC, remains 
unanswered. 
Results show that all different preconditioning protocols, including RepRIPC, showed a 
significant reduction in serum creatinine at day one, which was the primary outcome 
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measure. However it is important to note that the observed differences in serum 
creatinine levels at day one between the different preconditioning protocols and the 
control group (single dose APC) were smaller than the difference used for the power 
calculation (100 µmol/L). This indicates that a smaller difference in serum creatinine 
levels would have been more appropriate to reduce the risk of a type I error. With regard 
to serum urea levels, only RepISO+RepRIPC showed a significant reduction as compared 
to the control group, receiving a single period of isoflurane. Probably the number of 
animals per group was too small to detect differences in serum urea levels between 
RepISO and controls. With regard to the histology data, only animals in the RepISO group 
had lower scores for renal injury as compared to controls. This finding supports the 
main observation of this study, repeated administration of isolfurane provides stronger 
protection against renal IRI as compared to single dose isolfurane.
In this study isoflurane was chosen as an anesthetic because it is safe, has little side effects 
and is widely used in animal studies and in patients. The downside of using isoflurane 
in this experiment is the protective effect of isoflurane on renal IRI. One previous study 
[8] showed that single dose isoflurane preconditioning ameliorated IRI of the kidney. 
In our study we showed that a 7-day repeated isoflurane preconditioning provided 
significantly more protection against renal IRI as compared to single dose isoflurane in 
the control group. The smallest number of daily repeated isoflurane preconditioning 
cycles providing maximum protection remains unknown. To our knowledge, the strong 
protective effects of repeated isoflurane administrations over multiple days has not 
been described previously.
Another remarkable observation is that 30 minutes of pedicle clamping induced less 
renal injury as compared to our previous experiments [23, 24]. As the amount of renal 
injury varied between this experiment and previous observations, it would have been 
better to include more animals to control for this variation in our experimental model. 
The most likely explanation for the difference with the previous experiments is that 
our animals were obtained from a different supplier. Despite the fact that we used the 
same strain, there may have been differences in the genetic makeup leading to a lower 
susceptibility to renal IRI. This phenomenon is supported by studies showing that different 
strains of mice have a different susceptibility to cardiac IRI [25, 26]. In this experiment 
30 minutes of IRI was chosen, despite the fact that 45 minutes is more commonly used 
in similar experiments [17]. The reason to shorten the IRI period is that the amount of 
IRI in most animal studies is relatively large as compared to clinical trials [17–19, 21, 
27]. In our view the induction of a lower amount of IRI results in a more realistic animal 
model for the translation into clinical practice. 
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CONClUSION
IPC has been a promising phenomenon since its discovery in 1986 [5]; however, the 
vast amount of IRI protection by IPC, shown in animal studies, cannot be translated into 
clinical trials [17, 19]. Accumulating evidence indicate that RepRIPC is a promising tool 
to provide a more effective and robust RIPC stimulus. RepRIPC was successfully studied 
in animal heart models [28, 29], endothelial dysfunction models in healthy humans 
[21], coronary artery bypass grafting [30] and after stroke [20]. Nevertheless our results 
show that it is difficult to establish additional protection of a repeated RIPC stimulus as 
compared to single dose RIPC in animal studies reducing renal IRI. 
In future animal studies investigating the mechanisms and/or efficacy of repeated 
RIPC and APC, the strong protective effects of the repeated administration of (volatile) 
anesthetics, i.e. isoflurane, should be taken into account.
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ABSTRACT
Background
Ischaemia reperfusion injury can lead to kidney dysfunction or failure. Ischaemic pre-
conditioning is a short period of deprivation of blood igurupply to particular organs or 
tissue, followed by a period of reperfusion. It has the potential to protect kidneys from 
ischaemia reperfusion injury.
Objectives
This review aimed to look at the benefits and harms of local and remote ischaemic 
preconditioning to reduce ischaemia and reperfusion injury among people with renal 
ischaemia reperfusion injury.
Search methods
We searched Cochrane Kidney and Transplant’s Specialised Register to the eighth of 
August 2016 through contact with the Information Specialist using search terms relevant 
to this review. 
Selection criteria
We included all randomised controlled trials measuring kidney function and the role of 
ischaemic preconditioning in patients undergoing a surgical intervention that induces 
kidney injury. Kidney transplantation studies were excluded.
Data collection and analysis
Studies were assessed for eligibility and quality; data were extracted by two independ-
ent authors. We collected basic study characteristics: type of surgery, remote ischaemic 
preconditioning protocol, type of anaesthesia. We collected primary outcome measure-
ments: serum creatinine and adverse effects to remote ischaemic preconditioning and 
secondary outcome measurements: acute kidney injury, need for dialysis, neutrophil 
gelatinase-associated lipocalin, hospital stay and mortality. Summary estimates of effect 
were obtained using a random-effects model, and results were expressed as risk ratios 
(RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean 
difference (MD) and 95% CI for continuous outcomes.
Main results
We included 28 studies which randomised a total of 6,851 patients. Risk of bias assessment 
indicated unclear to low risk of bias for most studies. For consistency regarding the 
direction of effects, continuous outcomes with negative values, and dichotomous 
outcomes with values less than one favour remote ischaemic preconditioning. Based 
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on high quality evidence, remote ischaemic preconditioning made little or no difference 
to the reduction of serum creatinine levels at postoperative days one (14 studies, 
1,022 participants: MD -0.02 mg/dL, 95% CI -0.05 to 0.02; I2=21%), two (9 studies, 770 
participants: MD -0.04 mg/dL, 95% CI -0.09 to 0.02; I2=31%), and three (6 studies, 417 
participants: MD -0.05 mg/dL, 95% CI -0.19 to 0.10; I2=68%) compared to control.
Serious adverse events occurred in four patients receiving remote ischaemic precon-
ditioning by iliac clamping. It is uncertain whether remote ischaemic preconditioning 
by cuff inflation leads to increased adverse effects compared to control because the 
certainty of the evidence is low (15 studies, 3,993 participants: RR 3.47, 95% CI 0.55 to 
21.76; I2=0%); only two of 15 studies reported any adverse effects (6/1,999 in the remote 
ischaemic preconditioning group and 1/1,994 in the control group), the remaining 13 
studies stated no adverse effects were observed in either group.
Compared to control, remote ischaemic preconditioning made little or no difference to 
the need for dialysis (13 studies, 2,417 participants: RR 0.85, 95% CI 0.37 to 1.94; I2=60%; 
moderate quality evidence), length of hospital stay (8 studies, 920 participants: MD 0.17 
days, 95% CI -0.46 to 0.80; I2=49%, high quality evidence), or all-cause mortality (24 
studies, 4,931 participants: RR 0.86, 95% CI 0.54 to 1.37; I2=0%, high quality evidence).
Remote ischaemic preconditioning may have slightly improved the incidence of acute 
kidney injury using either the AKIN (eight studies, 2,364 participants: RR 0.76, 95% CI 0.57 
to 1.00; I2=61%, high quality evidence) or RIFLE criteria (three studies, 1,586 participants).
Authors’ conclusions
Remote ischaemic preconditioning by cuff inflation appears to be a safe method, and 
probably leads to little or no difference in serum creatinine, adverse effects, need for 
dialysis, length of hospital stay, death and in the incidence of acute kidney injury. Overall 
we had moderate-high certainty evidence; however the available data does not confirm 
the efficacy of remote ischaemic preconditioning in reducing renal ischaemia reperfusion 
injury in patients undergoing major cardiac and vascular surgery in which renal ischaemia 
reperfusion injury may occur.
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PlAin lAnguAge SuMMARy
Short periods of limb blood flow obstruction to reduce kidney injury
What is the issue?
The kidney is highly sensitive to shortage in blood flow and thus oxygen supply. This may 
cause irreversible kidney injury leading to haemodialysis or death. Kidney injury does not 
only relate to the temporary lack of oxygen supply, but is also due to the re-saturation of 
blood flow. At this stage, toxic products are released and initiate a reaction of the body 
causing further cellular damage within the kidney, the so called ‘ischaemia-reperfusion 
injury’. A lack of oxygen supply to the kidney injury may have many different causes, for 
example blood pressure changes that may occur during major surgery.
What did we do?
Our hypothesis is that short harmless periods (five minutes) of blood flow obstruction to 
an organ can reduce injury in this particular organ (local ischaemic preconditioning), but 
can also reduce injury in other organs at a distance (remote ischaemic preconditioning). 
A blood flow obstruction can easily and safely be achieved in a limb by inflating blood 
pressure cuff around the upper arm or leg. The mechanism of this remote ischaemic 
preconditioning is not precisely known, it is assumed that a protective signal from the 
remote organ to the kidney is transferred through the blood stream or nervous system.
In this analysis our primary goal is to investigate whether remote ischaemic precondi-
tioning is safe and effective in reducing kidney injury in patients undergoing a (surgical) 
procedure in which kidney injury may occur. Kidney injury after kidney transplantation 
may have a different underlying pathophysiology and therefore these studies are not 
taken into account. The impact of remote ischaemic preconditioning on the need for 
dialysis, hospital stay and mortality will be assessed.
What did we find?
We performed a search off all available literature on the eighth of August 2016 to find 
all randomised controlled studies. 28 studies including 6,851 patients were included in 
this analysis. Five studies included children undergoing cardiac surgery. Adult studies 
included patients undergoing major vascular surgery (three studies), cardiac surgery 
(nine studies), coronary bypass surgery (ten studies) and partial kidney resection (one 
study). The overall quality of the studies was acceptable.
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Twenty studies were funded without economical interest. One study was funded from 
a source with commercial interest. The other seven studies did not report funding.
Remote ischaemic preconditioning performed with a blood pressure cuff appears to be 
safe as no side effects were reported. However remote ischaemic preconditioning by 
vascular clamping may cause vascular complications. Kidney injury in patients undergoing 
(surgical) procedures in which kidney injury may occur, was not reduced by remote 
Ischaemic preconditioning measured at day one, two or three after surgery. The need for 
dialysis, hospital stay and death were not reduced by remote ischaemic preconditioning.
Conclusion
Although remote ischaemic preconditioning by cuff inflation is safe, available data do 
not confirm the efficacy of remote ischaemic preconditioning in reducing kidney injury.
Chapter_6_Theo.indd   113 6-9-2017   10:30:13
Chapter 6
114
BACkgROunD
Description of the condition 
Ischaemia reperfusion injury is defined as damage to an organ that occurs after a critical 
period of ischaemia, followed by restoration of blood supply. This can happen sponta-
neously, such as in stroke or myocardial infarction, or during transplantation and other 
types of surgery. Cells become deprived of oxygen in the ischaemic phase, and as a 
result, metabolism switches from aerobic to anaerobic glycolysis, leading to cell swelling, 
acidosis, ATP depletion, intracellular sodium (Na+) and calcium ion (Ca2+) overload and 
inhibition of the mitochondrial respiration chain. This leads to cell death in minutes to 
hours, depending on the cell type. Restoration of blood flow after ischaemia is therefore 
essential for cell survival. However, reperfusion of ischaemic tissue invokes paradoxical 
effects that are detrimental, rather than beneficial, to cells. This particularly holds true 
for sudden restoration of oxygen (which leads to oxidative stress), pH (which can induce 
cell death), and evoked inflammatory response. Inflammatory response induces adhesion 
of cytokine-releasing leukocytes, which attracts neutrophils, macrophages, lymphocytes 
and dendritic cells to the site. This may cause further release of reactive oxygen species 
and microvascular dysfunction [30, 44, 60].
Ischaemia reperfusion injury can lead to organ dysfunction or failure and is a significant 
clinical problem in transplantation, shock and major surgery. The high metabolism and 
vascular anatomy of the kidney is particularly sensitive to ischaemia reperfusion injury. 
The critical ischaemic period is organ-dependent: 15 to 20 minutes of ischaemia has 
been shown to cause irreversible damage to the kidney [40, 48, 50].
Description of the intervention 
Ischaemic preconditioning is a short and harmless period of deprivation of blood supply 
to particular organs or tissue, followed by a period of reperfusion [31, 37, 61]. Precon-
ditioning stimulus is applied before onset of ischaemia reperfusion injury to a target 
organ. In 1986 it was shown that ischaemic preconditioning on the heart can reduce 
ischaemia reperfusion injury, (local ischaemic preconditioning) [43], and has since been 
reproduced in many other target organs. Later on, studies have shown that ischaemic 
preconditioning of remote organs and tissues at a distance can protect the target organ 
from ischaemia reperfusion injury as well (remote ischaemic preconditioning) [45]. 
Use of the limbs as remote tissue offers many advantages, since skeletal muscle is less 
susceptible to ischaemia reperfusion injury compared to visceral tissues.
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A typical schedule of five minute periods of ischaemic preconditioning, separated by 
five minutes of reperfusion, applied directly before the ischaemia reperfusion injury 
period of the target organ, is used in most clinical studies. Numerous variations to this 
schedule have been studied in animals and the efficacy of the ischaemic preconditioning 
has been shown to vary, depending on the animal sex, animal species, preconditioned 
tissue volume, length of ischaemic preconditioning, reperfusion and time between 
ischaemic preconditioning and ischaemia reperfusion injury. The optimal schedule is 
still unclear and is probably different for different target organs and species [29, 32, 58].
How the intervention might work 
Several endogenous molecules have been implicated in local and remote ischaemic 
preconditioning signalling, most of which are known to have cytoprotective effects. 
Downstream, the ultimate protective step in ischaemic preconditioning signalling appears 
to be inhibition of mitochondrial permeability transition pore opening, which prevents 
cell death. Remote and local ischaemic preconditioning appear to be similar in terms 
of invoking mitochondrial permeability transition pore inhibition, and many signalling 
molecules seem to be similar to those implicated in local ischaemic preconditioning 
signalling. The theoretical difference is that remote ischaemic preconditioning requires 
transduction of the protective signal from the remote organ or tissue to the target 
organ. The protective effects of ischaemic preconditioning are found both directly 
after application of the stimulus (early window of protection), and in the days or weeks 
following (second window of protection). In animal models, both windows of protection 
have been shown to reduce renal ischaemia reperfusion injury [58]. Although there are 
similarities in the mechanisms underlying early and second windows of protection, the 
second window of protection has been found to require de novo protein synthesis of 
distal mediators such as iNOS and COX-2. However, remote ischaemic preconditioning 
signalling has been most extensively studied in the early window of protection, where 
three major pathways have been indicated in this process (Figure 6.1): the humoral route, 
the neurogenic pathway and alteration of immune cells. Signalling via the humoral route 
(upper route, Figure 6.1) requires release of signalling molecules such as adenosine or 
endorphins from the remote organ into the bloodstream, which are then carried to the 
target organ to exert their protective effects via their respective receptors. The nervous 
system also appears to play a role in some models of remote ischaemic preconditioning: 
denervation or ganglion blockade inhibit the protective effect of remote ischaemic 
preconditioning (middle route, Figure 6.1). Activation of the neurogenic pathway by 
peptides released from the remote organ may cause systemic factor release (combined 
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humoral-neurogenic route), lead to local factor release or activation of central reflexes. 
Both the humoral and the neurogenic pathways are thought to induce various kinase 
cascades and eventually prevent opening of the mitochondrial permeability transition 
pore in the target organ cells, thereby reducing cell death. Thirdly, remote ischaemic 
preconditioning has been shown to modulate gene and receptor expression on immune 
cells, which therefore pose a third signalling pathway that presumably reduces damage 
by altering the inflammatory response (lower route, Figure 6.1) [54]. 
Figure 6.1. Remote ischaemic preconditioning signalling pathways.
Source: KE Wever. Novel protective approaches in ischemia-reperfusion injury in vivo studies in animals and 
humans. PhD thesis, p. 16.
Why it is important to do this review 
Despite that the efficacy of ischaemic preconditioning has been acknowledged since 
described by [43], the technique was introduced into clinical studies only relatively 
recently; however, results to date have not been consistently positive [1, 3, 25, 28, 
57]. Although experimental data show promise, the mechanism underlying ischaemic 
preconditioning signalling remains unclear and the optimal preconditioning protocol 
remains unknown [58].
The kidney is very sensitive to ischaemia reperfusion injury, and therefore, is an organ 
system that can benefit from ischaemic preconditioning. Furthermore, kidney function 
and damage are very well documented and can be tested using robust endpoints. The 
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kidney is therefore an ideal target organ to investigate the protective effects of ischaemic 
preconditioning on renal ischaemia reperfusion injury.
OBjeCTiveS 
This review aimed to look at the benefits and harms of local and remote ischaemic 
preconditioning to reduce ischaemia and reperfusion injury among people with renal 
ischaemia reperfusion injury.
MeTHODS
Criteria for considering studies for this review 
Types of studies 
All randomised controlled trials (RCTs) looking at the role of ischaemic preconditioning 
vs. no ischaemic preconditioning among patients undergoing interventions that result 
in ischaemic kidney damage were eligible for inclusion. There was no restriction on 
publication status, language, or sample size. Quasi-RCTs (RCTs in which allocation to 
treatment was obtained by alternation, use of alternate medical records, date of birth 
or other predictable methods) were excluded.
Types of participants 
We included all patients who underwent any intervention for any indication that resulted 
in ischaemic kidney damage (e.g. extracorporeal membrane oxygenation, open aneurysm 
repair, coronary artery bypass grafting, aortic surgery and any other type kidney surgery). 
Liver, lung and peripheral bypass surgeries in which kidney injury was highly unlikely 
were excluded. Studies investigating ischaemic preconditioning in kidney transplantation 
or patients at risk for contrast-induced nephropathy, including endovascular aneurysm 
repair, were excluded.
Types of interventions 
The ischaemic preconditioning protocol could include remote and/or local ischaemic 
preconditioning stimulus applied before the intervention and the remote stimulus could 
be applied to any organ. Preconditioning stimuli could be continuous (one continuous 
ischaemic pulse followed by reperfusion) or fractioned (two or more cycles of brief 
ischaemia and reperfusion). The ischaemic preconditioning stimulus could be applied 
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directly before index ischaemia or some time, even days, before. The control condition of 
no ischaemic preconditioning could be no intervention or mock ischaemic precondition-
ing, that is, application of a tourniquet, blood pressure cuff or other means of occlusion 
without actually interrupting blood flow.
Types of outcome measures 
Primary outcomes 
•	 Serum creatinine on days one, two or three postoperative
•	 Complications and adverse effects related to ischaemic preconditioning
Secondary outcomes 
•	 Need for dialysis following kidney-related ischaemia
•	 Acute kidney injury (AKI) as defined by KDIGO, AKIN and RIFLE criteria [41, 42, 47]
•	 Blood urea nitrogen (BUN)
•	 Serum/urine neutrophil gelatinase-associated lipocalin (NGAL)
•	 Serum/urine kidney injury molecule-1 (KIM-1)
•	 Mortality
•	 Quality of life
•	 Length of hospital stay
Search methods for identification of studies 
Electronic searches 
 
We searched the Cochrane Kidney and Transplant Specialised Register up to the eighth 
of August 2016 through contact with the Information Specialist using search terms 
relevant to this review. The Specialised Register contains studies identified from the 
following sources.
1. Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the proceedings of major kidney 
conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register (ICTRP) Search Portal and 
ClinicalTrials.gov
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Studies contained in the Specialised Register are identified through search strategies for 
CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. 
Details of these strategies, as well as a list of handsearched journals, conference pro-
ceedings and current awareness alerts, are available in the Specialised Register section 
of information about Cochrane Kidney and Transplant.
See Appendix 6.1 for search terms used in strategies for this review.
Searching other resources 
1. Reference lists of review articles, relevant studies, and clinical practice guidelines.
2. Letters seeking information about unpublished or incomplete studies to investigators 
known to be involved in previous studies.
Data collection and analysis 
Selection of studies 
The search strategy described was used to obtain titles and abstracts of studies that 
may be relevant to the review. Titles and abstracts were screened independently by two 
authors, who discarded studies that were not applicable; however studies and reviews 
thought to include relevant data or information on studies were retained initially. Two 
authors independently assessed retrieved abstracts and if required assessed the full text 
of these studies to determine which satisfied the inclusion criteria.
Data extraction and management 
Data extraction was carried out independently by two authors using standard data 
extraction forms. Studies reported in non-English language journals were to be translated 
before assessment. Where more than one publication of one study existed, reports 
were grouped together and the publication with the most complete data was used in 
the analyses. Where relevant outcomes were only published in earlier versions these 
data were used. Any discrepancy between published versions was to be highlighted.
Assessment of risk of bias in included studies 
•	 The following items were independently assessed by two authors using the risk of 
bias assessment tool [39] (see Appendix 6.2).
•	 Was there adequate sequence generation (selection bias)?
•	 Was allocation adequately concealed (selection bias)?
•	 Was knowledge of the allocated interventions adequately prevented during the study?
 - Participants and personnel (performance bias)
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 - Outcome assessors (detection bias)
•	 Were incomplete outcome data adequately addressed (attrition bias)?
•	 Are reports of the study free of suggestion of selective outcome reporting (reporting 
bias)?
•	 Was the study apparently free of other problems that could put it at a risk of bias?
Measures of treatment effect 
For dichotomous outcomes (e.g. need for dialysis and death) results were expressed 
as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of 
measurement had been used to assess the effects of treatment (e.g. serum creatinine), 
the mean difference (MD) was used, or the standardised mean difference (SMD) if 
different scales were used.
Dealing with missing data 
Any further information required from the original author was requested by written 
correspondence (e.g. e-mailing or writing to corresponding authors) and any relevant 
information obtained in this manner was included in the review. Evaluation of important 
numerical data such as screened, randomised patients as well as intention-to-treat, 
as-treated and per-protocol population was carefully performed. Attrition rates, for 
example dropouts, losses to follow-up and withdrawals were investigated. Issues of 
missing data and imputation methods (for example, last-observation-carried-forward) 
were critically appraised [39].
Assessment of heterogeneity 
Heterogeneity was analysed using a Chi2 test on N-1 degrees of freedom, with an alpha 
of 0.05 used for statistical significance and with the I2 test [38]. I2 values of 25%, 50% 
and 75% correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases 
If possible, funnel plots were to be used to assess for the potential existence of small 
study bias [39].
Data synthesis 
Data were pooled using the random-effects model but the fixed-effect model was also 
to be used to ensure robustness of the model chosen and susceptibility to outliers.
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Subgroup analysis and investigation of heterogeneity 
Subgroup analysis was used to explore possible sources of heterogeneity (e.g. precon-
ditioning site, number of ischaemic preconditioning stimuli, early vs. late windows of 
protection). Heterogeneity among participants related to age and gender. Heterogeneity 
in treatments related to the type of intervention such as major aorta surgery or coronary 
artery bypass surgery. Adverse effects were to be tabulated and assessed using descrip-
tive techniques. Where possible, the risk difference with 95% CI was to be calculated for 
each adverse effect, either compared with no treatment or another agent.
Sensitivity analysis 
We performed sensitivity analyses to explore the influence of the following factors on 
effect size.
•	 Repeating the analysis excluding unpublished studies
•	 Repeating the analysis taking account of risk of bias, as specified
•	 Repeating the analysis excluding any very long or large studies to establish how much 
they dominate the results
•	 Repeating the analysis excluding studies using the following filters: diagnostic criteria, 
language of publication, source of funding (industry vs. other), and country.
SuMMARy Of finDingS TABleS
We presented the main results of the review in ‘Summary of findings’ tables. These 
tables present key information concerning the quality of the evidence, the magnitude 
of the effects of the interventions examined, and the sum of the available data for the 
main outcomes [51]. The ‘Summary of findings’ tables also include an overall grading 
of the evidence related to each of the main outcomes using the GRADE (Grades of 
Recommendation, Assessment, Development and Evaluation) approach [36]. The GRADE 
approach defines the quality of a body of evidence as the extent to which one can be 
confident that an estimate of effect or association is close to the true quantity of specific 
interest. The quality of a body of evidence involves consideration of within-trial risk of 
bias (methodological quality), directness of evidence, heterogeneity, precision of effect 
estimates and risk of publication bias [52]. We presented the following outcomes in the 
‘Summary of findings’ tables.
•	 Serum creatinine on days one, two and three
•	 Adverse events of remote ischaemic preconditioning
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•	 Need for dialysis
•	 AKI defined by the AKIN score
•	 Mortality
ReSulTS
Descripti on of studies 
A detailed description of all studies can be found in Characteristics of included studies 
and Characteristics of excluded studies.
Results of the search 
The search identified 1,381 unique records (Appendix 6.1). Two independent review 
authors screened each reference for inclusion on the basis of title and abstract, and 
subsequently assessed full-text copies of all publications eligible for inclusion. For five 
studies presented only as abstract, full text publications were obtained by contacting 
authors by e-mail. We identified 55 studies (70 records). Of these, 28 studies (38 records) 
were included and 27 excluded (32 records) (Figure 6.2).
Figure 6.2. The flow diagram of references.
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included studies
We included 28 studies ([1–4, 4a, 5–28]) reporting data from a total of 6,851 patients 
undergoing a surgical procedure associated with renal ischaemia and reperfusion (I/R). 
[4] and [4a] are the same study, however we have analysed this as two separate studies 
because the outcomes for two different patient populations (stable and unstable angina) 
were reported separately.
Patients were randomised to undergo remote ischaemic preconditioning (remote 
ischaemic preconditioning; n=3,441) or a control intervention consisting of sham remote 
ischaemic preconditioning or no treatment (n=3,441). All 28 studies reported at least one 
kidney outcome measure. See Characteristics of included studies (for details on sample 
size, procedure, patient characteristics, inclusion and exclusion criteria, intervention 
and reported outcomes.
Participants
Five studies included only children, all aged <17 years old, scheduled for heart surgery 
([10, 14–17]). Other studies included adult cardiovascular patients scheduled for a 
coronary artery bypass graft (11 studies), cardiac surgery (nine studies) or aortic aneurysm 
repair (three studies). One study included kidney cancer patients undergoing partial 
nephrectomy [8].
Methods of remote ischaemic preconditioning induction: site, timing and 
protocols
The intervention of interest in all studies was remote ischaemic preconditioning, which 
was compared to a control intervention. All studies applied preconditioning only, except 
for [6], [7] and [9], in which the conditioning protocol was applied both before and after 
surgery, thereby inducing a combination of remote ischaemic preconditioning and remote 
ischaemic postconditioning.
Cuff inflation was the preferred method of remote ischaemic preconditioning induction: 
25 studies used a blood pressure cuff to induce ischaemia in an upper arm (15 studies), 
lower limb (nine studies) or both [2]. [25] applied their remote ischaemic preconditioning 
protocol to each lower limb, one after the other. [1] and [25] induced remote ischaemic 
preconditioning by clamping of the common iliac artery. In one study, ([4]; [4a]) the 
(suprarenal) ascending aorta was clamped, thereby inducing both remote ischaemic 
preconditioning and local ischaemic preconditioning.
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The remote ischaemic preconditioning stimulus was applied directly after anaesthetic 
induction in all studies, except for [15], in which remote ischaemic preconditioning was 
induced 24 hours before surgery, making this the only study investigating the so-called 
second window of protection by ischaemic preconditioning.
Seven different remote ischaemic preconditioning protocols were used among the 28 
studies. The most frequently used protocol consisted of three cycles of five minutes of 
occlusion of the remote organ, interspersed with five minutes of reperfusion (3 x 5’/5’ 
I/R), ([8, 11, 12, 18, 19, 21–24, 27, 28]). Other protocols were 4 x 5’/5’ I/R ([5–7, 10, 
13–17, 20, 26]), 3 x 10’/10’ I/R ([3, 9]), 2 x 10’/10’ I/R ([1]), 2x 5 minutes ([2]), 2 x 2’/3’ I/R 
([4, 4a]) and cross-clamping the right common iliac artery ten min, thereafter clamping 
the left common iliac artery ([25]).
Outcome measures
The included studies reported a variety of outcome measures. Kidney impairment (e.g. 
postoperative creatinine, NGAL, AKIN score and RIFLE score) was the primary outcome 
in seven studies (25%) ([3, 8, 16, 25–28]). [20] reported a composite primary end 
point of death, myocardial infarction, stroke and AKI. Cardiac outcome measures were 
the primary endpoint in ten studies ([1, 2, 5, 6, 7, 10, 18, 19, 22, 23]), and pulmonary 
outcome measures were the primary endpoint in three studies ([9, 11, 13]). [14] reported 
hospital stay, [15] reported IL4, and [21] reported myocardial microRNA expression 
as primary outcome measures. In the remaining four studies there were no specified 
primary or secondary outcome measures ([4, 4a, 12, 17, 24]). Mortality was reported 
in 24 studies, duration of hospital stay in eight studies, and incidence of adverse effects 
of remote ischaemic preconditioning in 13 studies. Other reported outcome measures 
were myocardial injury, pulmonary injury, stroke, ICU stay, inotropic support, and a wide 
variety of non-kidney molecular markers (e.g. IL-8, CK-MB and NF-kB).
Kidney outcome measures differed substantially among studies. Serum creatinine was 
published in 15 studies at 13 different time points postoperatively. Serum NGAL was 
reported in two studies ([3, 16]) at day one, two and three after surgery. Incidence of AKI 
was reported in ten studies, of which [16], [20] and [26] assessed AKI incidence according 
to the RIFLE criteria, and [2], [3], [5], [18], [24], [27], and [28] used the AKIN criteria.
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excluded studies 
Studies on surgical procedures unlikely to cause kidney ischaemia reperfusion injury 
[62–69], studies without remote ischaemic preconditioning applied [70–74], studies 
relating to transplantation [75], and studies investigating iodine contrast [76–84] were 
excluded. Studies in patients undergoing kidney transplantation or intravenous contrast 
administration were excluded because of the differences in pathophysiology of the 
inflicted kidney injury.
Studies with a different primary outcome measure than kidney injury and with an inter-
vention causing kidney injury were included if they published kidney outcome measures. 
However, not all studies reported kidney outcome measures, we emailed the authors 
of those studies for kidney data and if no reply was received, we attempted to contact 
them again after three weeks. Studies without published kidney outcome measures 
were excluded after this second email attempt [85–88]. 
Risk of bias in included studies 
Risk of bias assessment was performed by two independent review authors and 
summarised in Figure 6.3 and Figure 6.4.
Figure 6.3. Risk of bias graph.
Review authors’ judgements about each risk of bias item presented as percentages across all included studies.
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Figure 6.4. Risk of bias summary.
Review authors’ judgements about each risk of 
bias item for each included study.
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Allocation (selection bias) 
Most included studies reported adequate methods of random sequence generation for 
patient allocation, which was assessed at low risk of selection bias. A computer generated 
random number sequence was used in 22 studies; [28] used manually shuffled blocks 
which we also reported as low risk of bias. In one study ([4, 4a]) randomisation was 
not reported, leading to a high risk of selection bias. [10], [12], [17] and [22] reported 
randomisation, but did not report the method used, and were therefore assessed to be 
at unclear risk of selection bias.
There were 16 studies reporting blinding of allocation using numbered, sealed, opaque 
envelopes, which was assessed to introduce a low risk of selection bias. The remaining 12 
studies did not mention whether the patient allocation was blinded. For these studies ([3, 
4, 4a, 5, 8, 10, 12, 15, 17, 18, 22, 24]), the risk of selection bias was assessed as unclear.
Blinding (performance bias and detection bias) 
Many studies did not adequately report measures to reduce performance and detection 
bias. Only 16 studies reported adequate blinding of investigators and involved personnel, 
such as by hiding the blood pressure cuff and using an independent investigator to 
perform the remote ischaemic preconditioning protocol. The risk of performance bias 
in these studies was therefore assessed to be low. [18] reported their study as single 
blinded and therefore was assessed as high risk of bias. The remaining 11 studies had 
unclear risk of bias as blinding was not described. Patients were anaesthetised during 
remote ischaemic preconditioning in all studies except for [15]; however, anaesthesia 
does not ensure that patients are fully blinded for the allocated intervention. All studies 
therefore were assessed at unclear risk of bias.
Ten studies ([2, 5, 13, 14, 15, 18–21, 26]) reported adequate blinding of outcome assessors 
and were therefore rated as being at low risk of detection bias. Fifteen studies did not 
adequately report blinding of outcome assessors and were assessed at unclear risk of 
detection bias. Three studies did not mention blinding of outcome assessors and were 
assessed at high risk of bias ([4, 4a, 11, 28]).
Incomplete outcome data (attrition bias) 
Risk of attrition bias was unclear in 15 studies ([1, 4, 4a, 6, 7, 10, 12–15, 17, 18, 20, 22, 
25, 26]) and high in two studies ([21, 23]). Eleven studies ([2, 3, 5, 8, 9, 11, 16, 19, 24, 
27, 28]) reported missing data and prespecified outcome measures, indicating a low 
risk of attrition bias.
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Selective reporting (reporting bias) 
The risk of reporting bias due to selective outcome reporting was assessed to be low in 
most studies. This was based on the fact that, in most studies, the outcome measures 
specified in the introduction matched those presented in the results of the article (19 
studies). In six studies ([18, 20, 21, 23, 24, 27]) the risk of reporting bias was assessed 
to be high, due to the incoherency between reported outcome measures in the method 
section of the articles and the results.
Performing funnel plots for the primary outcome measures, there is a high suspicion 
of underreporting negative small studies as can be seen in the funnel plots of serum 
creatinine on days one and two (Figure 6.5; Figure 6.6).
Other potential sources of bias
Five studies were classified as high risk of bias for the following reasons.
•	 [15] failed to adequately report the patient inclusion and exclusion criteria
•	 [23] and [24] studies reported changes in the anaesthesia protocol during the study
•	 [20] recalculated the sample size during the inclusion period and reduced the total 
number of patients to include
•	 The authors of [14] were shareholders in a company producing a remote ischaemic 
preconditioning device.
[4], [4a], [11], [13], [22], [25], and [28] did not report their funding source and were 
classified as unclear risk of bias. All remaining 21 studies adequately reported their 
funding sources and there were no other concerns.
Effects of interventions 
See: Summary of findings for the main comparison Summary of findings table. For 
consistency regarding the direction of effects, continuous outcomes with negative 
values, and dichotomous outcomes with values less than one favour remote ischaemic 
preconditioning.
Primary outcome measures
Serum creatinine
Serum creatinine levels were reported in 15 studies ([1, 3, 4, 4a, 8–10, 13–17, 21, 22, 
24, 25]), measured at 13 different time points postoperatively. In total, serum creatinine 
was measured in 707 patients undergoing remote ischaemic preconditioning and in 704 
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Figure 6.5. (Analysis 1.6). Funnel plot of comparison.
Serum creatinine, outcome: 1.6 Creatinine day 1 [mg/dL].
Figure 6.6. (Analysis 1.8). Funnel plot of comparison.
1 Serum creatinine, outcome: 1.8 Creatinine day 2 [mg/dL].
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patients undergoing a control intervention. Our meta-analysis shows no difference in 
serum creatinine between patients undergoing remote ischaemic preconditioning vs. 
controls on postoperative days one (Analysis 1.6 (14 studies, 1,022 participants): MD 
-0.02 mg/dL, 95% CI -0.05 to 0.02; I2=21%), two (Analysis 1.8 (9 studies, 770 participants): 
MD -0.04 mg/dL, 95% CI -0.09 to 0.02; I2=31%), and three (Analysis 1.10 (6 studies, 770 
participants): MD -0.05 mg/dL, 95% CI -0.19 to 0.10; I2=68%).
We found a reduction in peak postoperative creatinine during the first three days in 
patients undergoing remote ischaemic preconditioning (Analysis 1.16 (3 studies, 365 
participants): MD -0.10 mg/dL, 95% CI -0.20 to -0.01; I2=0%).
Complications and adverse effects related to ischaemic preconditioning
Data on adverse effects of the preconditioning stimulus were reported in 15 studies 
([1–4, 4a, 5–9, 12, 15, 17, 23, 25]), including a total of 1,999 patients receiving remote 
ischaemic preconditioning and 1,994 patients undergoing a control intervention. 
Overall there was no significant difference between the two groups (Analysis 2.1 (15 
studies, 3,993 participants): RR 3.47; 95% CI 0.55 to 21.76; I2=0%). No serious adverse 
effects were reported in studies using a blood pressure cuff for remote ischaemic 
preconditioning induction. [5] reported skin petechiae at the time of the intervention 
(35/801 participants; 4.4%), which is considered to be a minor side effect and is 
therefore not included in this review. Severe adverse effects occurred only in patients 
in the experimental arm of the study by [25], in which four patients receiving remote 
ischaemic preconditioning developed lower limb ischaemia due to the traumatic effects 
of vascular clamping of the iliac artery.
Secondary outcome measures
Need for dialysis
The need for dialysis was reported in 13 studies ([1, 3, 6, 7, 11–13,  16, 18, 19, 24, 27, 
28]), including 1,211 remote ischaemic preconditioning-treated patients and 1,206 
patients undergoing a control intervention. Forty-four patients in the remote ischaemic 
preconditioning group required dialysis vs. 46 patients in the control group. There was 
no difference between the two groups (Analysis 3.1 (13 studies, 2,417 participants): RR 
0.85; 95% CI 0.37 to 1.94; I2=60%).
Acute kidney injury (KDIGO, AKIN, RIFLE criteria)
There were no studies reporting AKI according to the KDIGO criteria.
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Eight studies ([2, 3, 5, 9, 18, 24, 27, 28]) used the AKIN criteria to assess the incidence 
of AKI, including 1,170 remote ischaemic preconditioning-treated patients and 1,194 
patients undergoing a control intervention. The incidence of AKI did not differ overall 
(Analysis 4.1 (8 studies, 2,364 participants): RR 0.76, 95% CI 0.57 to 1.00; I2=61%), or 
when stratified for AKIN grade 1 (Analysis 4.2 (5 studies, 2,135 participants): RR 0.72, 
95% CI 0.47 to 1.11; I2=67%) grade 2 (Analysis 4.3 (5 studies, 2,135 participants): RR 0.71, 
95% CI 0.41 to 1.24; I2=26%) and grade 3 (Analysis 4.4 (5 studies, 2,135 participants): RR 
0.63, 95% CI 0.37 to 1.07; I2=11%).
Three studies ([16, 20, 26]) reported data on the incidence of AKI according to the RIFLE 
criteria for 794 remote ischaemic preconditioning-treated patients and 792 patients 
undergoing a control intervention. The incidence of AKI did not differ overall (Analysis 
5.1 (3 studies, 1,586 participants): RR 0.91, 95% CI 0.75 to 1.12; I2=0%) or when stratified 
for Risk (Analysis 5.2 (3 studies, 1,586 participants): RR 0.77, 95% CI 0.58 to 1.03; I2=0%) 
Injury (Analysis 5.3 ((RR 1.09, 95% CI 0.59 to 2.02)) or Failure (Analysis 5.4 (3 studies, 
1,586 participants): RR 1.09; 95% Cl 0.59 to 2.02; I2=0%). There were no events in either 
group for RIFLE criteria Loss and End-stage kidney failure.
Blood urea nitrogen (BUN)
Blood urea nitrogen was not reported as an outcome measure by any of the included 
studies.
Neutrophil gelatinase associated lipocalin (NGAL)
Two studies ([3, 16]) reported serum NGAL levels measured post-operatively on day one 
for 92 preconditioned and 89 control patients. Our meta-analysis showed no difference 
in serum NGAL between the groups (Analysis 6.1 (2 studies, 181 participants): MD 0.57 
ng/mL, 95% CI -2.65 to 3.79; I2=0%).
[16] also measured serum NGAL post-operatively at six and 12 hours, and on day two 
and three, and reported no difference between the groups for any of these time points.
[27], reported urine NGAL was reduced in patients undergoing remote ischaemic 
preconditioning, when measured four, 12 and 24 hours after surgery (Analysis 7.1; 
Analysis 7.2; Analysis 7.3).
Kidney injury molecule-1 (KIM-1)
KIM-1 was not reported as an outcome measure by any of the included studies.
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Mortality
Twenty-four studies ([1, 2, 4, 4a, 5–7, 9, 11–17, 19, 21–28]) reporting mortality in 2,467 
patients receiving remote ischaemic preconditioning and 2,464 control patients. We 
included data on all-cause mortality to 30 days and all-cause in-hospital mortality in 
our analysis. When both in-hospital mortality and 30-day mortality were reported, [27] 
in-hospital mortality was used in the analysis. Mortality after a longer postoperative 
period and mortality due to a specific condition or disease were excluded. Our analysis 
showed no difference in mortality between the groups (Analysis 8.1 (24 studies, 4,931 
participants): RR 0.86, 95% CI 0.54 to 1.37; I2=0%).
Quality of life
Quality of life was not reported as an outcome measure by any of the included studies.
Length of hospital stay
Eight studies ([1, 2, 3, 6, 9, 22–24]) report data on the length of hospital stay, including 
a total of 457 remote ischaemic preconditioning-treated patients and 463 patients 
undergoing a control intervention. The length of hospital stay did not differ between 
the groups (Analysis 9.1 (8 studies, 920 participants): MD 0.17 days, 95% CI -0.46 to 
0.80; I2=49%).
Subgroup analyses
We aimed to perform subgroup analyses for our primary outcome measures, for all 
subgroups containing two or more studies. Adverse effects occurred only in six patients 
in two studies ([5, 25]), and as a consequence, RR could only be calculated for these two 
studies. Therefore, no subgroup analysis was performed for this outcome measure. The 
following subgroup analyses therefore only concern serum creatinine on postoperative 
day one, two and three. All subgroup analysis results are shown in Table 6.1.
Age
We stratified the included studies according to participants’ age (child or adult). There 
was no effect of remote ischaemic preconditioning on serum creatinine on day one, 
two or three postoperatively in any of the subgroups, and no difference in treatment 
effect between subgroups. Compared to the overall analysis of serum creatinine on 
postoperative day two, heterogeneity was reduced in the subgroup of studies performed 
in adults, while heterogeneity in the subgroup of children increased to high. No change 
in heterogeneity was observed on for serum creatinine on day one and three.
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Sex
Subgroup analysis could not be performed, since none of the studies reported separate 
outcomes for men and women and no individual patient data were retrieved.
Remote ischaemic preconditioning protocol
There were seven different remote ischaemic preconditioning protocols used in the 
studies, but only three different remote ischaemic preconditioning protocols were used 
in more than one study. We stratified the protocols according to the total duration of 
ischaemia and the number of remote ischaemic preconditioning cycles (see Table 6.1).
For total duration of ischaemia, the subgroups of 15, 20 and 30 minutes contained 
two or more studies and were included in the analysis. The subgroup of four minutes 
total ischaemia was not analysed since it contained two comparisons from the same 
study ([4, 4a]). There was no effect of treatment on serum creatinine on day one, two 
or three postoperatively in any of the subgroups, and no difference in treatment effect 
between subgroups.
Compared to the overall analysis, heterogeneity was reduced in the 15 minutes subgroup, 
but increased in the other subgroups, on all three postoperative days.
For the number of preconditioning cycles, the subgroups of two, three, and four cycles 
contained two or more studies and were included in the analysis. In the subgroup of 
two preconditioning cycles, serum creatinine was reduced on postoperative day one, 
while there was no effect of treatment on this day in the subgroups of three and four 
cycles. However, the confidence intervals overlapped between all subgroups. No effect 
of treatment and no differences between subgroups were observed for serum creatinine 
on postoperative days two and three.
Heterogeneity in the subgroups was similar to the overall analysis on day one, was 
increased in the four cycles subgroup on day two, and was reduced in all subgroups on 
day three.
Method of remote ischaemic preconditioning induction
The type and amount of tissue used to induce the remote ischaemic preconditioning 
stimulus may influence its efficacy in reducing kidney damage. Often, the preconditioning 
stimulus is applied to an extremity, by inflating a blood pressure cuff around an upper 
or lower limb. Alternatively, atraumatic vascular clamping of the aorta or iliac artery 
may be used. We therefore stratified the studies according to the method of remote 
ischaemic preconditioning induction, creating three subgroups: blood pressure cuff on 
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the upper arm, blood pressure cuff on the lower limb or clamping of the aorta or iliac 
artery (see Table 6.1).
On postoperative day one, there was no effect of treatment in the subgroups using blood 
pressure cuff occlusion, but serum creatinine was reduced in the subgroup of studies 
using vascular clamping. On postoperative day two, serum creatinine was reduced in 
the subgroup using blood pressure cuff occlusion of the upper arm, but not in the lower 
limb subgroup. On postoperative day three, there was no effect of treatment in any of 
the groups. Importantly, the confidence intervals of all subgroups overlapped on each 
postoperative day.
Heterogeneity in the subgroups was similar to the overall analysis for postoperative day 
one and two, and reduced in both subgroups on day three.
Type of surgical procedure
The type of surgery is a major determinant of the risk and severity of perioperative 
kidney injury, which may influence remote ischaemic preconditioning efficacy. The type 
of surgery may also correlate to a type of patient with a specific susceptibility to kidney 
injury. Studies were stratified according to the type of surgery performed, including 
abdominal aortic aneurysm repair, coronary artery bypass grafting, and other types of 
cardiac surgery (see Table 6.1). Only [8] reported partial nephrectomy and was excluded 
from this subgroup analysis.
There was no effect of treatment on serum creatinine on day one, two or three 
postoperatively in any of the subgroups, and no difference in treatment effect between 
subgroups.
Compared to the overall analysis, heterogeneity in the subgroup of cardiac surgery was 
increased on day one and day two, but decreased on day three. Heterogeneity in the 
other subgroups and days was similar or decreased compared to the overall analysis.
Sensitivity analysis
Excluding studies of lower quality with regard to the primary outcome measures had no 
significant effect on the results of this meta-analysis. Excluding studies of less than 30 
patients in each group showed no significant difference in primary outcome measures.
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Publication bias
We aimed to construct funnel plots to assess publication bias for the primary outcome 
measures.	For	adverse	events	and	creatinine	on	postoperative	day	three,	there	were	≤	six	
data points, which were considered insufficient to reliably assess funnel plot asymmetry. 
Our assessment of the funnel plot of serum creatinine data on postoperative day one 
and two (Figure 6.5; Figure 6.6) showed signs of publication bias, with small studies 
predominantly showing positive results.
SuMMARy Of finDingS TABle
The summary of findings table can be found at: Summary of findings table S6.1.
DiSCuSSiOn
Summary of main results 
Our search identified 28 studies investigating the effect of remote ischaemic precon-
ditioning on kidney outcomes in patients undergoing surgery associated with kidney 
ischaemia reperfusion injury. Our primary endpoints showed no protective effect for 
remote ischaemic preconditioning application. Adverse effects were found in one 
study after vascular clamping to induce remote ischaemic preconditioning. The general 
method using cuff inflation on the upper arm or thigh showed no serious adverse effects. 
Furthermore, the secondary outcomes – need for dialysis, AKI indicated by RIFLE or 
AKIN criteria, serum NGAL, mortality and length of hospital stay – were unchanged in 
patients undergoing remote ischaemic preconditioning when compared with controls. 
One study reported urinary NGAL was significantly reduced in the remote ischaemic 
preconditioning group [27].
We found that a significant effect was seen regarding the method of remote ischaemic 
preconditioning induction. The subgroup of Invasive clamping of arteries to induce remote 
ischaemic preconditioning is more effective compared to non-invasive cuff inflation. 
However, this observation should be interpreted with care, since invasive remote ischaemic 
preconditioning induction included only three studies, one of which [1] introduced high 
heterogeneity in the data-set. Subgroup analysis indicated that age, type of surgery, site of 
preconditioning, number of cycles and duration of the remote ischaemic preconditioning 
protocol did not influence remote ischaemic preconditioning efficacy.
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Overall we conclude that after major surgery associated with kidney ischaemia reper-
fusion injury, remote ischaemic preconditioning does not significantly reduce kidney 
injury. Based on these data, routine use of remote ischaemic preconditioning in major 
surgery cannot be justified.
Overall completeness and applicability of evidence 
The heterogeneity of the outcome measurements and surgical procedures makes them 
difficult to compare. Of note, local ischaemic preconditioning, which has been shown 
to be highly effective in animal models ([58]), has not been studied in patients and its 
feasibility therefore remains unclear.
Because of expected differences in the underlying mechanism of kidney injury, studies 
including patients undergoing kidney transplantation or interventions using nephrotoxic 
contrast media were excluded from this review. Despite inclusion of 28 studies, the 
primary outcome measures were heterogeneous and this severely hampered our 
meta-analysis. Therefore, we advocate a more standardised primary outcome measure 
in future studies.
Many studies, as well as our meta-analysis, focused on serum creatinine as the primary 
outcome. However, the use of this outcome measure as a gold standard for kidney 
injury is under debate [56] and its relationship with the long-term quality of life is not 
straightforward. Only a few studies assessed the effect of remote ischaemic precondi-
tioning on long-term outcome measures such as quality of life and long term mortality.
Quality of the evidence 
Overall, the quality of the evidence provided by the included studies was acceptable. 
Including data from studies of lower quality may lead to an overestimation of treatment 
effects, since low-quality studies generally overstate efficacy. Excluding studies of lower 
quality did not affect the primary outcomes. Therefore, after performing the risk of bias 
assessment we included all available data in our analysis.
One important aspect in the quality of the evidence and potential bias is the funding 
of the studies which might influence the outcome. Influential funding was reported by 
one study and seven studies did not report their funding sources, which is a source of 
potential bias.
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Potential biases in the review process 
We attempted to identify all relevant studies through comprehensive, systematic 
searching of the literature in multiple databases, as well as contacting authors to obtain 
additional publications and data. Still we could not exclude the presence of publication 
bias in our data-set.
Data extraction was completed independently by two authors without conflicts of interest 
regarding the outcome, thereby avoiding potential bias. We performed several subgroup 
analyses. However, since our approach is observational rather than experimental, their 
results should be regarded as hypothesis generating. This meta-analysis was slightly 
hampered by missing data, resulting from studies reporting outcome data as medians 
and interquartile ranges. We were unable to obtain raw data for a number of these 
studies, and this may have biased our analysis.
In summary, we consider this review to be influenced by missing data and an unclear 
risk of publication bias.
Agreements and disagreements with other studies or reviews 
The results of this review are comparable with other meta-analyses in the literature 
([33, 34, 59]) despite differences in inclusion criteria (i.e. others included contrast 
studies and did not include studies in children). The negative result from this review 
contradicts the overall beneficial effect of remote ischaemic preconditioning in animal 
models of kidney ischaemia reperfusion injury. A meta-analysis of animal studies by 
[58] showed that remote ischaemic preconditioning was successful in reducing kidney 
ischaemia reperfusion injury. Possible explanations for the discrepancy between human 
and animal studies are:
The lower amount of kidney injury in human studies compared with experimental models 
of kidney ischaemia reperfusion injury. This review (Analysis 1.6; Analysis 1.8; Analysis 
1.10) showed that postoperative serum creatinine levels among control groups were 
comparable with normal values serum creatinine. When there is limited kidney damage, 
very large numbers of patients are required to show a significant reduction by remote 
ischaemic preconditioning. The ischaemia reperfusion injury applied to the kidney in the 
animal models is much more severe compared to the amount of kidney injury in human 
studies. Most animal studies have a single kidney model where the pedicle is clamped for 
45 minutes [58]. For such an amount of kidney damage there is no comparable human 
patient group. Although kidney transplant recipients were not addressed in this review, 
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kidneys from deceased donors are exposed to prolonged periods of (cold) ischaemia. 
Therefore, it may be interesting to pursue remote ischaemic preconditioning efficacy 
in those patients.
Animal studies generally use healthy young animals ([58]); studies included in this review 
mostly recruited aged patients with significant comorbidity. Aging and comorbidity 
significantly reduce the effectiveness of remote ischaemic preconditioning in human 
models of ischaemia reperfusion injury ([35, 53, 55]). Experimental studies using 
animals with diabetes and hypertension confirm a decreased effectiveness of remote 
ischaemic preconditioning compared with healthy animals [46]. Furthermore, studies in 
the present review may have included patients suffering from pathologies which induce 
temporary (mild) ischaemia of remote tissues, e.g. unstable angina or claudication. Such 
episodes could induce a protective remote preconditioning effect on kidney’s ischaemia 
reperfusion injury, which may have abolished the protective effect of the experimental 
preconditioning stimulus.
AuTHORS’ COnCluSiOnS 
Implications for practice 
Although remote ischaemic preconditioning by cuff inflation is safe, available data do not 
confirm the efficacy of remote ischaemic preconditioning in reducing kidney ischaemia 
reperfusion injury. Remote ischaemic preconditioning applied by currently used protocols 
should not be used routinely in clinical practice to reduce kidney ischaemia reperfusion 
injury in patients undergoing major surgery in which kidney injury may occur.
Implications for research 
Future RCTs should focus on patients undergoing a procedure that is associated with 
significant kidney ischaemia reperfusion injury, such as open abdominal aortic or kidney 
transplant surgery. Furthermore, fundamental research is required to be able to predict 
the protective effect of remote ischaemic preconditioning and to increase the efficacy 
of the preconditioning protocol in humans.
Future studies should be adequately powered and designed with undisputed endpoints 
such as need for dialysis, mortality and/or quality of life, rather than short-term kidney 
function. Markers of (subtle) ischaemic kidney injury are useful for research purposes, 
but should be secondary to long-term clinically pertinent outcome measures.
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Studies need to report methods of allocation, blinding and outcome data in detail and 
should publish a predefined study protocol. Doing so will increase study quality and 
make the conclusions more applicable to clinical practice.
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DiffeRenCeS BeTween PROTOCOl AnD Review 
Where outcome measure data were presented graphically, data were extracted using 
digital image analysis software ([49], ImageJ; imagej.nih.gov). When data distributions 
were presented as median and interquartile range, or both, we attempted to obtain data 
as mean ± SD or SEM by contacting authors by email. In case of no response after two 
attempts or data not available the study was excluded from the analysis.
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Appendix 6.1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor Ischemic Preconditioning explode all trees
2. MeSH descriptor Reperfusion Injury explode all trees
3. (ischemi*):ti,ab,kw in Trials
4. (reperfusion):ti,ab,kw in Trials
5. (renal or kidney*):ti,ab,kw in Trials
6. (#2 OR #3 OR #4 OR #5)
7. (#1 AND #6)
MEDLINE (OVID SP) 1. exp Ischemic Preconditioning/
2. exp Reperfusion Injury/
3. ischemi$.tw.
4. reperfusion$.tw.
5. (renal or kidney).tw.
6. or/2-5
7. and/1,6
EMBASE (OVID SP) 1. ischemic preconditioning/
2. reperfusion injury/
3. (renal or kidney).tw.
4. or/1-2
5. and/1,4
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ABSTRACT
Background
Despite the increasing use of pre- and posthydration protocols and low-osmolar instead 
of high-osmolar iodine-containing contrast media, the incidence of contrast-induced 
nephropathy (CIN) is still significant. There is evidence that contrast media cause 
ischemia-reperfusion injury of the medulla. Remote ischemic preconditioning (RIPC) is 
a non-invasive, safe, and low-cost method to reduce ischemia-reperfusion injury.
Methods
The RIPCIN study is a multicenter, single-blinded, randomized controlled trial in which 76 
patients at risk of CIN will receive standard hydration combined with RIPC or hydration 
with sham preconditioning. RIPC will be applied by four cycles of five minutes ischemia 
and five minutes reperfusion of the forearm by inflating a blood pressure cuff at 50 
mmHg above the actual systolic pressure. The primary outcome measure will be the 
change in serum creatinine from baseline to 48 to 72 hours after contrast administration.
Discussion
A recent pilot study reported that RIPC reduced the incidence of CIN after coronary 
angioplasty. The unusual high incidence of CIN in this study is of concern and limits its 
generalizability. Therefore, we propose a randomized controlled trial to study whether 
RIPC reduces contrast-induced kidney injury in patients at risk for CIN according to the 
Dutch guidelines.
Trial registration
Current Controlled Trials ISRCTN76496973.
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Iodine-containing contrast media are often used for diagnostic and therapeutic procedures 
and their use is the leading cause of hospital-acquired acute kidney injury [1]. Prospective 
studies demonstrate that contrast media are responsible for approximately 15% of 
acute kidney injury cases [2, 3]. Despite the increasing use of pre- and posthydration 
protocols and low-osmolar instead of high-osmolar iodine-containing contrast media, 
the incidence of contrast-induced acute kidney injury is still significant [4, 5]. This so 
called contrast-induced nephropathy (CIN) is defined as an absolute rise of ≥0.5 mg/dL 
and/or a relative increase of ≥25% in serum creatinine compared to baseline within 48 
to 72hoursafter contrast administration without an alternative cause of kidney injury [6]. 
CIN is strongly associated with morbidity and mortality [7, 8]. In patients with CIN, 8% 
need dialysis treatment and between 22% and 34% die during the index hospitalization 
[3, 9–11]. In accordance with international guidelines, all patients who receive iodine-
containing contrast are screened for risk factors of CIN, including measures of renal 
function (estimated glomerular filtration rate, based upon the MDRD formula) [12–15]. 
High-risk patients receive pre- and posthydration by saline solution infusion for four 
to 12 h. Furthermore, 48 to 72 hours after contrast administration, serum creatinine 
should be measured [16]. Despite the identification of high-risk patients and the use 
of hydration protocols, the incidence of CIN still varies between 2% and 13% [17–20]. 
The exact mechanism underlying CIN remains to be elucidated. There is evidence to 
suggest that contrast media have direct toxic effects on the tubular cells resulting in 
altered mitochondrial function and apoptosis [21]. Moreover, ischemia-reperfusion 
injury of the medulla has been shown to play an important role [22]. The outer part of 
the medulla has an area with a high oxygen demand and is located at a distance from 
the vasa recta which supplies the medulla of blood. Contrast-induced vasoconstriction 
of the vasa recta induces ischemia-reperfusion injury of the medulla which contributes 
significantly to the pathophysiology of CIN. Remote ischemic preconditioning (RIPC) 
is a short and harmless discontinuation of blood supply to particular organs or tissue, 
followed by reperfusion [23, 24]. A preconditioning stimulus is applied before the 
onset of prolonged ischemia. In animal models it has been found to reduce ischemia-
reperfusion injury of the kidney [25]. Although the precise mechanism of RIPC remains 
unknown, two major pathways may play a pivotal role: the humoral and neurogenic 
pathways. Both are thought to induce various kinase cascades and eventually prevent 
opening of the mitochondrial permeability transition pore in the target organ, thereby 
reducing cell death [26]. A retrospective cohort study by Whittaker et al. indicated that 
multiple balloon inflations during coronary angioplasty (as a remote stimulus) might 
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reduce CIN [27]. Furthermore, a recent pilot study by Er et al. showed that RIPC reduced 
CIN in high-risk patients undergoing elective coronary angiography [28]. However, there 
was an unusually high incidence of CIN (40%) in the control group. The question arises 
whether protection by RIPC, as an adjunct to standard preventive measures (that is, 
hydration and discontinuation of nephrotoxic drugs), also holds for patients with a lower 
risk of CIN. As generalizability of the results by Er et al. is confined to a selected group 
of patients with an unusual high risk of CIN, we propose a randomized controlled trial 
to study whether RIPC reduces contrast-induced kidney injury in patients at risk of CIN 
according to the Dutch guideline [14].
MeThoDS/DeSign
A multicenter, single-blinded, randomized controlled trial will be performed at the 
Radboud University Nijmegen Medical Centre and Slingeland Hospital Doetinchem. 
Inclusion will be performed by the physician researcher after written informed consent.
Study population
A total of 76 patients will be randomized. Sealed envelopes are used to randomly assign 
consecutive patients in a 1:1 ratio to receive either sham preconditioning or RIPC (Figure 
7.1). The study population consists of patients at risk of CIN according to criteria adopted 
from the Dutch guidelines: (1) eGFR <45 mL/min/1.73 m2; (2) eGFR <60 mL/min/1.73 
m2; (3) eGFR <60 mL/min/1.73 m2 and two additional risk factors (that is, peripheral 
vascular disease, heart failure, >75 years of age, anemia, dehydration, use of diuretics 
and/or NSAIDs). Patients undergoing contrast procedures for diagnostic and/or treatment 
purposes are eligible. As patients receiving less than 100 mL of iodinated contrast media 
may not have an increased risk of contrast-induced kidney injury, an expected use of at 
least 100 mL was used as inclusion criterion [3, 29]. Inclusion criteria 
1. Patients undergoing an interventional or diagnostic radiological procedure in which 
they receive an expected >100 mL intravascular contrast including:
• Thoracic and/or abdominal endovascular aortic repair
• Endovascular aortic repair
• Digital subtraction angiography
• Percutaneous transluminal angioplasty
• Percutaneous intentional extraluminal revascularization
• Carotic artery stenting
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• Percutaneous coiling/embolization procedures
• Computed tomography
2. Patients who comply with the risk criteria for CIN according to the Dutch guidelines 
[14] 
• Peripheral vascular disease, heart failure, >75 years, anemia (Ht <0.39 men and 
<0.36 women, dehydration, diuretics and/or NSAID use)
3. Written informed consent.
exclusion criteria
• Age <18 years
• Hemodialysis or peritoneal dialysis
• Simultaneous participation in another interventional study
• Percutaneous coiling/embolization procedures of the kidney
• Impossibility to perform RIPC, due to pathology of both arms (for example, dystrophy, 
recent trauma, chronic wounds)
Figure 7.1. Study flow chart.
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Study protocol
All participating patients will receive the standard hydration schedule consisting of an 
infusion with saline 0.9% solution 3 to 4 mL/kg/h for four hours prior to and four hours 
after contrast administration. In patients with congestive heart failure or MDRD <30 
mL/min/1.73 m2 a long schedule is used with an infusion of saline 0.9% solution 1 mL/
kg/h for 12 hours prior to and 12 hours after the contrast administration. Nephrotoxic 
drugs (for example, metformin and diuretics) are discontinued at least 24 hours before 
and after contrast administration [14]. Patients in the experimental group of the study 
will receive RIPC by four cycles of ischemia and reperfusion of the forearm by inflating a 
blood pressure cuff around the upper arm at 50 mmHg above the actual systolic pressure 
during five minutes followed by five minutes of reperfusion. In the control group, patients 
receive sham preconditioning by inflating the blood pressure cuff to ten mmHg below 
the actual diastolic pressure during five minutes followed by five minutes of reperfusion 
(four cycles). The time between the last inflation cycle and the start of the intervention 
isplanned within 45 min. In the interest of blinding, the investigator ensures that the 
inflation pressure is not visible for both the patient and the (interventional) radiologist. All 
patients receive Xenetrix 300 (0.6 to 0.85 Osmol/kg H2O), a low osmolar, non-ionic, and 
hydrophilic contrast medium [30, 31]. Patients will complete a questionnaire to obtain 
all relevant baseline characteristics such as age, weight, previous contrast procedures, 
diabetes, vascular-related diseases, and (discontinuation of) medication. Chart review 
will be performed to complement and double check this information. Blood and urine 
samples are taken at baseline and four to six hours after contrast administration. A 
final blood sample is taken 48 to 72 hours after contrast administration. According to 
the Dutch guidelines, monitoring of renal function in highrisk patients is recommended 
within 48 to 72 hours after contrast administration. All samples will be number coded 
before analysis to ensure blinding of the independent investigator performing the 
analyses.
Primary endpoint
The primary endpoint is change in serum creatinine form baseline to serum creatinine 
within 48 to 72 hours after contrast administration. 
Secondary endpoint
The secondary endpoints are the incidence of CIN (defined as an absolute rise of ≥0.5 
mg/dL or a relative increase of ≥25% in serum creatinine over baseline within 48 to 72 
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hours after contrast administration), rehospitalization, hemodialysis, and mortality within 
six weeks after contrast administration.
Ethics, informed consent 
An independent ethics committee, the Central Committee on Research involving Human 
Subjects, Arnhem-Nijmegen, approved the protocol. Oral and written informed consent 
from the patient will be obtained prior to inclusion.
Adverse events
Although RIPC by repeated insufflations of a blood pressure cuff around the upper arm 
is considered safe, serious adverse events possibly related to the application of RIPC 
will be reported to the ethical committee. Mild adverse events are: transient discomfort 
due to compression and/or ischemia and the formation of ecchymosis (upper arm) or 
petechia (lower arm). 
Power analysis
In this randomized study, the change of serum creatinine from baseline to 48 to 72 hours 
after contrast administration will be compared between the experimental and control 
group. Using serum creatinine change as continuous response variable increases the power 
of the study. In a previous retrospective cohort study at our center including 2,169 patients 
at risk for contrast-induced nephropathy, serum creatinine values decreased from 120 
μmol/L at baseline to 118 μmol/L at 48 to 72 hours after contrast administration due to 
adequate hydration protocols [17]. This mean change in serum creatinine (-2 μmol/L) was 
normally distributed with a standard deviation of 23 μmol/L. Based on existing evidence we 
assume that RIPC with hydration may provide a further decrease in mean serum creatinine 
from baseline to 48 to 72 hours of approximately 14 μmol/L as compared to hydration only. 
This corresponds with approximately 60% of the effect that was found by Er et al. [28]. 
If the true difference in the experimental and control means is 14 μmol/L, we will need 
to study 34 experimental and 34 controls to be able to reject the null hypothesis with a 
power of 0.80 and an alpha of 0.05 calculated with a one-sided independent t-test. Based 
on existing animal [25] and human studies [32, 33] investigating the influence of RIPC on 
renal ischemiareperfusion injury, we assume that RIPC does not negatively affect renal 
function. Therefore, one-sided testing would be appropriate for this study. Expected lost to 
follow-up (for example, blood sampling not realized between 48 to 72 h) is approximately 
5%. For this reason 38 patients will be included in both the experimental and control arm.
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Statistical analysis
The analysis will be performed on the basis of intentionto-treat principles. Student’s t-test 
will be used to compare normally distributed variables, and Mann-Whitney U test will be 
used to compare not-normally distributed continuous data. Categorical variables will be 
compared with the chi-square test. If univariable analysis reveals a significant difference 
in baseline characteristics, then a multivariable linear regression analysis will be used to 
assess its impact on the primary outcome measure (that is, change in serum creatinine 
between baseline and 48 to 72 hours after contrast administration). A subgroup analysis 
will be performed to assess whether the impact of RIPC on the primary outcome measure 
is affected by the Mehran risk score. For this analysis patients will be divided into three 
equal groups (that is, tertiles) according to their Mehran risk score. Statistical analyses 
will be performed with SPSS 20.0. A probability value of <0.05 is considered to indicate 
statistical significance and 95% confidence intervals will be calculated. The RIPCIN study 
is registered at: http://www.controlled-trials.com/ISRCTN76496973.
DiSCuSSion
In this study, we hypothesize that RIPC reduces the occurrence of CIN in patients at 
risk of acute kidney injury due to the use of contrast media. A recent randomized pilot 
study suggested that RIPC reduced contrastinduced kidney injury, however this study 
was performed in patients with an unusual high risk of CIN. A comment on this study by 
Mehta Oza et al. clarified that based on the reported Mehran risk score the incidence of 
CIN should lie between 26% and 30% instead of 40% as reported by Er et al. [34]. The 
authors stated that this high incidence of CIN could be attributed to a high prevalence 
of heart failure and diabetes mellitus in their cohort. However, if standard measures 
to prevent CIN, that is, hydration with saline and discontinuation of nephrotoxic drugs, 
were not carried out appropriately, then the incidence of CIN would also be increased. 
As compliance to standard preventive measures against CIN was not described by Er et 
al. their results do not fully justify the conclusion that RIPC, as an adjunct to standard 
preventive measures, effectively reduces CIN. Another important issue to address is 
the fact that the incidence of CIN varies with the criteria used [35]. Er et al. defined 
CIN as an absolute or relative increase in serum creatinine, whereas some evidence 
exists that both an absolute and a relative increase in serum creatinine more accurately 
predicts adverse events after coronary angioplasty. To overcome the flaws related to 
the use of different definitions of CIN, we will use the change in serum creatinine from 
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baseline to 48 to 72 hours after contrast administration as that primary endpoint in 
the proposed trial. As serum creatinine levels generally peak between 48 and 72 hours 
after contrast administration, it would be ideal to measure serum creatinine at both 48 
and 72 h. However, this would not be in line with Dutch and international guidelines 
which recommend checking renal function once between 48 and 72 hours after contrast 
administration. In practice most patients are discharged within 24 hours after contrast 
administration and for many it is already difficult to realize one blood sample between 
48and 72 hours after contrast administration. In our view, it is appropriate for proof-of-
concept studies investigating new strategies to reduce contrast-induced kidney injury 
to use the change in serum creatinine from baseline to 48 to 72 hours as the primary 
endpoint. Once the efficacy of a new strategy against contrast-induced kidney injury has 
been confirmed, much larger clinical trials should be conducted with adverse effects after 
the use of contrast-media (for example, dialysis and/or death) as the primary endpoint.
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ABSTRACT
Background
Despite the increasing use of pre- and post-hydration protocols and low osmolar instead 
of high osmolar iodine containing contrast media, the incidence of contrast induced 
nephropathy (CIN) is still significant. There is evidence that contrast media cause ischemia 
reperfusion injury of the renal medulla. Remote ischemic preconditioning (RIPC) is a non-
invasive, safe, and low cost method to reduce ischemia reperfusion injury. The aim of 
this study is to investigate whether RIPC, as an adjunct to standard preventive measures, 
reduces contrast induced acute kidney injury in patients at risk of CIN.
Methods
The RIPCIN study is a multicenter, single blinded, randomized controlled trial in which 
76 patients at risk of CIN received standard hydration combined with RIPC or hydration 
with sham preconditioning. RIPC was applied by four cycles of five minutes ischemia 
and five minutes reperfusion of the forearm. The primary outcome measure was the 
change in serum creatinine from baseline to 48 to 72 hours after contrast administration.
Results
With regard to the primary endpoint, no significant effect of RIPC was found. CIN occurred 
in four patients (two sham and two RIPC). A pre-defined subgroup analysis of patients 
with a Mehran risk score ≥11, showed a significantly reduced change in serum creatinine 
from baseline to 48 to 72 hours in patients allocated to the RIPC group (Δ creatinine 
-3.3 ± 9.8 mmol/L) compared with the sham group (Δ creatinine +17.8 ± 20.1 mmol/L). 
Conclusion
RIPC, as an adjunct to standard preventive measures, does not improve serum creatinine 
levels after contrast administration in patients at risk of CIN according to the Dutch 
guideline. However, the present data indicate that RIPC might have beneficial effects 
in patients at a high or very high risk of CIN (Mehran score ≥11). The RIPCIN study is 
registered at: http://www.controlled-trials.com/ISRCTN76496973.
What this paper adds
Remote ischemic preconditioning, as an adjunct to standard preventive measures, does 
not improve serum creatinine levels after contrast administration in patients at risk of 
contrast induced nephropathy according to the Dutch guideline.
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INTRODUCTION
The use of iodine containing contrast media for diagnostic and therapeutic procedures is 
the leading cause of hospital acquired acute kidney injury [1]. Despite the increasing use 
of low osmolar instead of high osmolar iodine containing contrast media and hydration 
protocols, the incidence of contrast induced acute kidney injury (CI-AKI) is still significant 
(2–13%) [2–7]. This so called contrast induced nephropathy (CIN) is defined as an absolute 
rise of ≥0.5 mg/ dL and/or a relative increase of ≥25% in serum creatinine compared with 
baseline within 48–72 hours after contrast administration without an alternative cause 
of kidney injury [8]. In patients with CIN, 8% require dialysis treatment and between 22% 
and 34% die during the index hospitalization [2, 9–11] In accordance with international 
guidelines, all patients who receive iodine containing contrast media are screened for 
risk factors of CIN, including measures of renal function (estimated glomerular filtration 
rate [eGFR], based on the MDRD formula) [12, 13]. Patients with an eGFR <45 mL/ 
min/1.73 m2, an eGFR ≤60 mL/min/1.73 m2 with diabetes mellitus, or an eGFR ≤60 mL/
min/1.73 m2 with two or more additional risk factors are at high risk of CIN according 
to the Dutch guideline [14]. For high risk patients, the Dutch guideline recommends the 
use of pre- and post-hydration by saline infusion and the discontinuation of nephrotoxic 
medication. Furthermore, 48–72 hours after contrast administration serum creatinine 
should be measured. Despite the identification of high risk patients and the use of 
hydration protocols, the incidence of CIN still varies between 2% and 13% [2–7]. 
Although the precise mechanism underlying CIN remains unknown, evidence exists 
that contrast media have direct toxic effects on the tubular cells resulting in altered 
mitochondrial function and apoptosis. Moreover, solid evidence exists from experimental 
models that renal ischemia, resulting from contrast induced vasoconstriction, plays a 
key role in the pathogenesis of contrast induced kidney injury [15, 16]. The outer part 
of the medulla has an area with high oxygen demand and is therefore vulnerable to 
contrast induced vasoconstriction of the vasa recta. When vasoconstriction resolves 
and the oxygen supply is restored, post-ischemic cells produce free oxygen radicals. 
The formation of free radicals contributes at least in part to the renal tubular cell injury 
[17]. Upon reperfusion, ischemic cells may become apoptotic because of the opening 
of mitochondrial permeability transition pores [18]. Remote ischemic preconditioning 
(RIPC) is a short and harmless discontinuation of blood supply to an organ or tissue, 
followed by reperfusion, which is applied before the onset of prolonged ischemia 
to a distant organ or tissue [19, 20]. It has been shown that RIPC induces various 
kinase cascades that eventually prevent the opening of mitochondrial permeability 
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transition pores in the target organ cells, thereby reducing cell death [18]. Moreover, 
evidence exists that RIPC reduces oxidative stress by improving antioxidative defence 
mechanisms (e.g. increased superoxide dismutase activity and glutathione peroxidase) 
and/or decreasing the generation of free radicals (e.g. decreased xanthine oxidase 
activity) [21].
In animal models and in some clinical trials, RIPC reduces ischemia reperfusion injury of 
the kidney [22, 23]. A pilot study by Er et al. indicated that RIPC reduced the incidence 
of CIN in high risk patients undergoing elective coronary angiography [24]. However, 
there was an unusually high incidence of CIN (40%) in the control group in that study 
[25]. Another recent study showed that RIPC reduced urinary liver type fatty acid 
binding protein (L-FABP), a biomarker for tubulointerstitial damage, 24 hours after 
contrast administration in patients at low-moderate risk of CIN [26]. However, RIPC 
did not show beneficial effects on eGFR or the incidence of CIN in this study. Although, 
patients enrolled in the study by Er et al. had a lower mean baseline eGFR (41 vs. 48 mL/
min/1.73 m2), there was considerable overlap in the integer CI-AKI risk score between 
the studies. Therefore, the difference in baseline integer CI-AKI risk score may not fully 
explain the discrepancies between the studies. Given the inconclusive data in literature, 
a randomized controlled trial was performed to study whether RIPC, as an adjunct to 
standard preventive measures, reduces CI-AKI in patients at risk of CIN.
METHODS
A multicenter, single blinded, randomized controlled trial was performed at the Radboud 
University Medical Center Nijmegen and the Slingeland Hospital Doetinchem. The RIPCIN 
study is registered at: http://www.controlled-trials.com/ISRCTN76496973 and the study 
protocol has been published previously [27].
Study population
A total of 76 patients were enrolled after written informed consent was obtained. Sealed 
envelopes were used to randomly assign consecutive patients using a 1:1 ratio to receive 
either sham preconditioning or RIPC. The study population consisted of patients at risk 
of CIN according to criteria adopted from the Dutch guidelines. Inclusion criteria were: 
1. patients undergoing an interventional or diagnostic radiological procedure in which 
they receive an expected >100 mL intravascular contrast; and 
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2. patients who comply with the risk criteria for CIN according to the Dutch guidelines 
[14]: (a) eGFR <45 mL/min/1.73 m2; (b) eGFR <60 mL/min/1.73 m2 with diabetes 
mellitus; (c) eGFR <60 mL/min/1.73 m2; and two additional risk factors from peripheral 
vascular disease, heart failure, age >75 years, anemia, dehydration, diuretics, and 
non-steroidal anti-inflammatory drug use. Exclusion criteria were: (1) age <18 years; 
(2) hemodialysis or peritoneal dialysis; 
3. simultaneous participation in another interventional study; 
4. percutaneous coiling/embolization procedures of the kidney; 
5. impossibility to perform RIPC, caused by pathology in both arms (e.g. dystrophy, 
recent trauma, chronic wounds); and 
6. no written informed consent. 
An independent regional ethics committee, the central committee on research involving 
human subjects, Arnhem-Nijmegen, approved the protocol (number: 41890.091.12; 
date: October 16, 2012). 
Study protocol
All participating patients received the standard hydration schedule consisting of intra-
venous infusion with saline 0.9% solution 3–4 mL/kg/h for four hours prior to and four 
hours after contrast administration. In patients with congestive heart failure or eGFR <30 
mL/min/1.73 m2, a long schedule was used with an infusion of saline 0.9% solution 1 mL/
kg/h for 12 hours prior to and 12 hours after the contrast administration. Nephrotoxic 
drugs (e.g. diuretics) and metformin were discontinued 24 hours before and after contrast 
administration. Patients in the experimental group of the study received RIPC by four 
cycles of ischemia and reperfusion of the forearm by inflating a blood pressure cuff 
around the upper arm at 50 mmHg above the actual systolic pressure for five minutes, 
followed by five minutes of reperfusion. In the control group, patients received sham 
preconditioning by inflating the blood pressure cuff to ten mmHg below the actual 
diastolic pressure during five minutes, followed by five minutes of reperfusion (four 
cycles). The time between the last inflation cycle and the start of the intervention was 
planned to be within 45 minutes; this time window allowed performance of the sham 
or RIPC procedure under calm conditions on the ward. In the interest of blinding, the 
investigator ensured that the inflation pressure was not visible to either the patient or 
the (interventional) radiologist. All patients received Xenetrix 300 (0.6–0.85 Osmol/kg 
H2O), a low osmolar, non-ionic, and hydrophilic contrast medium. Patients completed a 
questionnaire to obtain all relevant baseline characteristics including (discontinuation 
of) medication. Chart review was performed to complement and double check this 
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information. Blood samples were taken at baseline and four to six hours after contrast 
administration. A final blood sample was taken 48–72 hours after contrast administration. 
Endpoints
The primary endpoint was change in serum creatinine from baseline to serum creatinine 
48–72 hours after contrast administration. The secondary endpoints were the incidence 
of CIN (defined as an absolute rise of ≥0.5 mg/dL or a relative increase of ≥25% in serum 
creatinine over baseline within 48–72 hours of contrast administration), rehospitalization, 
hemodialysis, and mortality within six weeks of contrast administration.
Power analysis
In this randomized study, the change of serum creatinine from baseline to 48–72 hours 
after contrast administration was compared between the experimental and control groups. 
Using serum creatinine change as the continuous response variable increased the power 
of the study. In a previous retrospective cohort study at the authors’ center including 2,169 
patients at risk of contrast induced nephropathy, serum creatinine values decreased from 
120 μmol/L at baseline to 118 μmol/L at 48–72 hours after contrast administration as 
a result of adequate hydration protocols [1, 28]. This mean change in serum creatinine 
(-2 μmol/L) was normally distributed with a standard deviation of 23 μmol/L. Based on 
existing evidence, it was assumed that RIPC with hydration may provide a further decrease 
in mean serum creatinine from baseline to 48–72 hours of approximately 14 μmol/L 
compared with hydration only. This corresponds with approximately 60% of the effect 
found by Er et al. [24]. If the true difference between the experimental and control means 
is 14 mmol/L, then 36 experimental participants and 36 control participants would be 
required for the study to be able to reject the null hypothesis with a power of 0.80 and an 
α of 0.05 calculated using a one-sided independent t test. In addition, the expected loss 
to follow up (e.g. blood sampling not done between 48 and 72 hours) was approximately 
5%. Therefore, a total of 76 patients was required for inclusion in the study.
Statistical analysis
The analysis was performed on the basis of intention to treat principles. Student t test 
was used to compare normally distributed variables, and Mann-Whitney U test was used 
to compare non-normally distributed continuous data. In a previously published trial 
protocol [23], a subgroup analysis was defined to assess whether the impact of RIPC on 
the primary endpoint is affected by the Mehran risk score [29]. For this analysis patients 
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were divided into three groups according to their Mehran risk score (i.e. (1) risk score 
≤5; (2) risk score 6–10; (3) risk score ≥11). Statistical analyses were performed with 
SPSS 20.0. A probability value of <.05 was considered to indicate statistical significance.
RESULTS
A total of 102 patients was assessed for eligibility, but 26 patients did not fulfill the 
inclusion criteria (Figure 8.1). Seventy-six patients were randomly allocated to receive 
sham preconditioning or RIPC in a 1:1 ratio. Four patients, two in the sham group and 
two in the RIPC group, were excluded after randomization because blood sampling 48–72 
hours after contrast administration was not performed. A total of 72 patients completed 
follow up of the study. There were no significant differences in baseline characteristics 
or cardiovascular medication between the experimental and control groups (Tables 8.1 
and 8.2).
Trial outcomes
With regard to the primary study endpoint (i.e. change in serum creatinine from baseline 
to 48–72 hours after contrast administration), no significant effect of RIPC was found 
Figure 8.1. Study flow chart.
by inﬂating the blood pressure cuff to 10 mmHg below the
actual diastolic pressure during 5 minutes, followed by 5
minutes of reperfusion (four cycles). The time between the
last inﬂation cycle and the start of the intervention was
planned to be within 45 minutes; this time window allowed
performance of the sham or RIPC procedure under calm
conditions on the ward. In the interest of blinding, the
investigator ensured that the inﬂation pressure was not
visible to either the patient or the (interventional) radiolo-
gist. All patients received Xenetrix 300 (0.6e0.85 Osmol/kg
H2O), a low osmolar, non-ionic, and hydrophilic contrast
medium. Patients completed a questionnaire to obtain all
relevant baseline characteristics including (discontinuation
of) medication. Chart review was performed to complement
and double check this information. Blood samples were
taken at baseline and 4e6 hours after contrast administra-
tion. A ﬁnal blood sample was taken 48e72 hours after
contrast administration.
Endpoints
The primary endpoint was change in serum creatinine from
baseline to serum creatinine 48e72 hou s after contrast
administration. The secondary endpoints were the inci-
dence of CIN (deﬁned as an absolute rise of 0.5 mg/dL or
a relative increase of 25% in serum creatinine over
baseline within 48e72 h ur of contrast admi istration), re-
hospitalization, hemodialysis, and mortality within 6 weeks
of contrast administration.
Power analysis
In this randomized study, the change of serum creatinine
from baseline to 48e72 hours aft r contrast administratio
was compared between the experimental and control
groups. Using serum creatinine change as the continuous
response variable increased the power of the study. In a
previous retrospective cohort study at the authors’ center
including 2169 patients at risk of contrast induced ne-
phropathy, serum creatinine values decreased from
120 mmol/L at baseline to 118 mmol/L at 48e72 hours after
contrast administration as a result of adequate hydration
protocols.28,1 This mean change in serum creatinine
(2 mmol/L) was normally distributed with a standard de-
viation of 23 mmol/L. Based on existing evidence, it was
assumed that RIPC ith hydration may provide a further
decrease in mean serum creatinine from baseline to 48e72
hours of approximately 14 mmol/L compared with hydration
only. This corresponds with approximately 60% of the effect
found by Er et al.24 If the true difference between the
experimental and control means is 14 mmol/L, then 36
experimental participants and 36 control participants would
be required for the study to be able to reject the null hy-
pothesis with a power of 0.80 and an a of 0.05 calculated
using a one-sided independent t test. In addition, the ex-
pected loss to follow up (e.g. blood sampling not done
between 48 and 72 hours) was approximately 5%. There-
fore, a total of 76 patients was required for inclusion in the
study.
Statistical analysis
The analysis was performed on the basis of intention to
treat principles. Student t test was used to compare nor-
mally distributed variables, and ManneWhitney U test was
used to compare non-normally distributed continuous data.
In a previously published trial protocol,23 a subgroup anal-
ysis was deﬁned to assess whether th impact of RIPC on
the primary endpoint is affected by the Mehran risk score.29
102 patients assessed for
eligibility
76 patients randomly assigned to
treatment in a 1:1 ratio
38 patients received
Sham preconditioning
38 patients received
RIPC
- 2 patients had arm pathology
- 24 patients gave no informed consent
2 patients lost in
follow-up. No
creatinine at day 2-3
36 patients completed follow-up
2 patients lost in
follow-up. No
creatinine at day 2-3
36 patients completed follow-up
Figure 1. Study ﬂow chart.
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Table 8.1. Baseline characteristics
Sham group 
(n=36)
RIPC group 
(n=36) p-value
Age, years 73 ± 8.5 71 ± 11 0.37
Male sex, n (%) 21 (58) 14 (39) 0.16
BMI kg/m² 27 ± 4.7 29 ± 5.6 0.22
Contrast administration
Diagnostic 18 (50) 21 (58)
Treatment 18 (50) 15 (42) 0.64
Underlying disease
Diabetes 10 (28) 8 (22) 0.58
Peripheral vascular disease 21 (58) 20 (56) 0.64
Myocardial infarction 16 (44) 13 (36) 0.46
Heart failure 8 (22) 7 (19) 0.78
Brain infarction 5 (14) 4 (11) 0.73
TIA 7 (19) 6 (17) 0.76
Anemia 5 (14) 3 (8) 0.47
Hypertension 24 (67) 28 (78) 0.59
Malignancy 8 (22) 7 (19) 0.77
Vital signs
Systolic (mmHg) 137 ± 17 144 ± 20 0.12
Diastolic (mmHg) 75 ± 10 76 ± 11 0.82
Heart rate (beats/min) 68 ± 13 69 ± 12 0.75
Hydration protocol
Short 31 (86) 31 (84)
Long 5 (14) 5 (14) 0.60
Baseline serum creatinine, µmol/L 119 ± 32 115 ± 27 0.50
Baseline eGFR ml/min/1.73m² 52 ± 13 51 ± 11 0.87
Volume of contrast used (mL) 98 ± 29 99 ± 29 0.85
Time between last inflation and contrast administration, 
minutes
44 ± 36 46 ± 23 0.83
Integer CI-AKI risk score
Mean (Q1–Q3) 6 (2–9) 6 (2–9) 1.00
Integer CI-AKI risk score
<5 15 (42) 17 (47)
6–10 16 (44) 13 (36)
>11 5 (14) 6 (17) 0.91
Data given as mean ± SD, n (%) or as specified. BMI = body mass index; CI-AKI, contrast-induced acute kidney 
injury; eGFR = estimated glomerular filtration rate; TIA = transient ischemic attack; y = years.
Chapter_8_Theo.indd   174 6-9-2017   10:30:37
175
Contrast-induced nephropathy: a randomized controlled trial
8
(Table 8.3). CIN occurred in four patients (two sham and two RIPC) and their respective 
Mehran risk scores were 1, 2, 6, and 14. None of the patients required dialysis or 
rehospitalization. Two patients (one with CIN) died within six weeks of the intervention. 
No adverse events occurred because of the preconditioning protocols. A subgroup 
analysis, in which all patients were classified according to their Mehran risk score, 
showed a significantly reduced change in serum creatinine in patients with a Mehran 
risk score ≥11 allocated to the RIPC group compared with the sham group (Table 8.4).
Table 8.2. Baseline cardiovascular medication
Sham group 
(n=36)
RIPC group 
(n=36) p-value
Platelet aggregation inhibitors 20 (56) 14 (39) 0.24
Coumarin 9 (25) 8 (22) 1.00
NSAID 0 (0) 2 (3) 0.49
Beta-blocker 23 (64) 24 (67) 1.00
Isosorbide dinitrate 8 (22) 3 (8) 0.19
Calcium channel blocker 8 (22) 12 (33) 0.43
Angiotensin-converting enzyme inhibitor 13 (36) 9 (25) 0.44
Angiotensin II receptor blocker 11 (31) 8 (22) 0.59
Loop/thiazide diuretics 24 (67) 15 (42) 0.10
Spironolactone 3 (8) 3 (8) 1.00
Data given as n (%).
RIPC = remote ischaemic preconditioning; NSAID = Non-Steroidal AntiInflammatory Drug.
Table 8.3. Trial outcomes
Sham group 
(n=36)
RIPC group 
(n=36) p-value
Primary endpoint
Change in serum creatinine from baseline to 48–72 
hours (µmol/L) 
-0.3 ± 14.7 0.25 ± 14.6 0.87
Secondary endpoints
Change in serum creatinine from baseline to 4–6 hours 
(µmol/L)
-14.5 ± 11.8 -11.4 ± 11.0 0.26
Contrast-induced nephropathy n (%) 2 (6) 2 (6) 1.00
Rehospitalization within 6 wk 0 (0) 0 (0) n.a.
Dialysis within 6 wk 0 (0) 0 (0) n.a.
Mortality within 6 wk 2 (6) 0 (0) 0.49
Data given in mean ± SD, n (%). RIPC = remote ischaemic preconditinong; wk = weeks.
Chapter_8_Theo.indd   175 6-9-2017   10:30:37
Chapter 8
176
DISCUSSION
The present study demonstrates that RIPC, induced by intermittent upper arm ischemia 
before diagnostic and therapeutic intravascular contrast procedures, does not reduce 
contrast induced kidney injury in patients who are at risk of developing CIN according 
to the Dutch guideline [14]. However, the data indicate that a subgroup of patients 
who are at high to very high risk of developing CI-AKI, may benefit from RIPC as an 
adjunctive preventive measure. Therefore, the findings do not necessarily contradict 
results from previous studies in which RIPC was found to alleviate CI-AKI [24, 26]. Er 
et al. investigated the effects of RIPC in patients with a (very) high risk of developing 
CIN according to the risk classification system developed by Mehran et al. This best 
validated risk score includes both clinical and procedural variables and is divided into 
four risk classes of developing CI-AKI: low (risk score ≤5), moderate (risk score 6–10), 
high (risk score 11–15), and very high (risk score ≥16). In the study by Er et al., 60% of 
the participants were at high or very high risk of developing CI-AKI, whereas Igarashi 
et al. included only 6% of these (very) high risk patients [24, 26]. In the present study, 
15% were at high or very high risk of developing CI-AKI. In line with these findings, 
Igarashi et al. did not find a reduction in creatinine based CI-AKI. Although their finding, 
that RIPC reduced the incidence of L-FABP based CI-AKI, provides interesting proof of 
concept evidence, its clinical relevance remains to be established. With regard to the 
study by Er et al., it should be noted that based on the reported Mehran risk score, the 
incidence of CIN should lie between 26% and 30% rather than 40% in the control group 
[25]. Although the authors attributed this discrepancy to the high prevalence of heart 
failure and diabetes in their cohort, the question arises whether the standard preventive 
measures (i.e. hydration and discontinuation of nephrotoxic drugs) were carried out 
appropriately. Nevertheless, the results of the present subgroup analysis support the 
Table 8.4. Change in serum creatinine per group divided by Mehran risk score
Mehran risk score Group
Change in serum creatining 
(mean ± SD) p
<5  n=32 Sham (n=15) - 0.2 ± 14.2
RIPC (n=17) 0.9 ± 13.1 0.83
6–10 n=29 Sham (n=16) -6.1 ± 8.2
RIPC (n=13) 1.1 ± 18.6 0.18
≥11 n=11 Sham (n=5) 17.8 ± 20.1
RIPC (n=6) -3.3 ± 9.8 0.048
RIPC = remote ischaemic preconditioning.
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hypothesis that RIPC reduces the incidence of creatinine based CI-AKI in patients who 
are at high or very high risk of developing CI-AKI. 
With regard to the preconditioning protocol, the present study used a similar protocol 
to that of the studies by Er et al. [24] and Igarashi et al. [26], consisting of four cycles of 
five minutes inflation of a blood pressure cuff around the upper arm and five minutes 
deflation. This protocol is relatively “standard” and has been used in many clinical 
trials. A recently performed meta-analysis investigating the effect of RIPC on ischemia 
reperfusion injury on animal kidneys, did not reveal a significant difference in efficacy 
between RIPC protocols using repeated short cycles of ischemia (fractionated stimulus) 
and those using one (usually) longer continuous ischemic stimulus [22]. To date, human 
data comparing the efficacy of different RIPC protocols are very scarce and there is no 
convincing evidence that justifies the use of an alternative RIPC protocol for clinical trials. 
The major strengths of this study are related to its design as a blinded, sham controlled 
study with a registered and previously published study protocol. All physicians, nursing 
staff, and radiology personnel were blinded to the allocation of treatment. This minimized 
the risk of bias because of altered adherence to other preventive measures including 
saline infusion, and discontinuation of diuretics and metformin, as both patients and 
nursing staff were unaware of the allocation of treatment. Physicians and radiology 
personnel, responsible for the amount of contrast used, were also blinded. As inclusion 
criteria were not confined to patients with low to moderate or high to very high risk 
of developing CIN, the present study cohort reflects routine clinical practice very well. 
There are several limitations to this study. First, as serum creatinine levels generally 
peak between 48 and 72 hours after contrast administration, it would have been ideal to 
measure serum creatinine at both 48 and 72 hours. However, in practice most patients 
were discharged within 24 hours of the contrast procedure. Those patients were asked 
to visit the outpatient clinic or their general practitioner for blood sampling at 48 or 72 
hours after contrast administration. Sampling at both time points would severely increase 
the burden for the participants. It is also important to note that blood samples taken by 
the general practitioner were analyzed outside the authors’ institution. Although slight 
variability between the different laboratories cannot be ruled out, it is not expected 
that this influenced results significantly. Second, this was a relatively small study 
with small numbers available for subgroup analysis. Although this subgroup analysis 
has been described in a previously published study protocol, its outcome should be 
interpreted with care. Third, a certain influence of the sham RIPC treatment, by inflating 
a cuff ten mmHg below the actual diastolic pressure, cannot be ruled out. As the sham 
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inflation around the upper arm only restricts blood flow to a very limited extent, this 
theoretical disadvantage does not outweigh the risk of bias related to a study design 
without adequate blinding. Finally the incidence of CIN was not used as the primary 
endpoint. Given the low incidence of CIN in patients who are at risk according to the 
Dutch guidelines (approximately 2%), use of this as the endpoint would require a trial 
with a very large number of participants. Therefore, the change in serum creatinine 
from baseline to 48–72 hours was used as the primary endpoint. However, the clinical 
relevance of improved serum creatinine levels in those patients remains to be elucidated. 
In conclusion, the results from this randomized controlled trial show that RIPC, as an 
adjunct to standard preventive measures, does not reduce CI-AKI in patients at risk of CIN 
according to the Dutch guideline. However, it is proposed that RIPC might have clinical 
benefits in patients with a high or very high risk of CIN, and this should be pursued in 
new clinical trials.
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In this thesis we identified and discussed the translation of ischemic preconditioning 
(IPC) from animal models to clinical trials. We started by analysing all renal IPC studies 
reported in literature. These analyses revealed unanswered questions which were 
addressed in subsequent animal and human studies. We hypothesized that a combination 
of conditioning protocols could increase the efficacy of IPC and used a previously 
successful renal IPC rat model available in our group to test this hypothesis. This specific 
rat model was meant to be converted into a transplantation model in future studies. It 
was decided to diminish the amount of renal ischemia-reperfusion injury (IRI) to better 
represent the clinical situation. A systematic review and meta-analysis of human studies 
was performed to select the proper patient population and the proper outcomes before 
designing a clinical trial. Results of this analysis were disappointing, not providing clear 
guidance for a future successful clinical trial. We subsequently selected reduction of 
contrast induced nephropathy (CIN) as a model to clinically study IPC, although to date 
the mechanism of IRI in CIN is not fully understood. Patients prone to CIN are ideal to 
study clinical benefit of IPC. It comprises a single intervention related to renal IRI, and the 
magnitude (the amount of iodine contrast) and timing of IRI can be determined rather 
precisely. We expanded the indication from high risk patients, as previous studies did, 
to all patients requiring renal protection from CIN according to our national guidelines. 
Results revealed no significant protective effect. Subgroup analysis, however, indicated 
that patients at very high risk of CIN allocated to the remote ischemic preconditioning 
(RIPC) group had significantly lower serum creatinine levels after contrast administration. 
There are two main explanations for the lack of translation in the studies presented in 
this thesis: the differences between animals and patients and methodological issues. 
There are many differences between animals and patients included in experimental 
and human studies respectively. For instance, animal studies usually include young 
adolescent, healthy animals, whereas patients are typically elderly with medication 
and comorbidities. In the literature there is evidence that ageing, medication use and 
comorbid conditions can result in a smaller protective effect of IPC [1]. To compensate 
for the differences between patients and animal models, a limited number of animal 
studies have included aged animals [2–4], animals with comorbidities [5, 6] or medication 
[7] and these studies confirm that IPC does indeed have a smaller protective effect in 
these animals. Within translational medicine [8], another explanation for the problem 
of translation of IPC from animal models to clinical trials is related to sex differences. 
Specifically, male animals, used in the majority of studies, are better protected from renal 
IRI by RIPC when compared to female animals (Chapter 2). In theory, female patients 
included in clinical trials may have skewed the overall protective effect of RIPC. There is, 
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however, no physiological explanation for the difference between sexes in reducing renal 
IRI by RIPC to date. Besides sex and comorbidity, Chapter 2 showed that the protective 
effects of IPC were larger for the smallest animals, i.e. mice, compared to rats, dogs and 
pigs. Although no strong experimental evidence is available, it has been suggested that 
a higher metabolic rate in smaller animals could result in a larger effect of IPC [9]. This 
might explain why humans, having a slower metabolic rate compared to mice, benefit 
less from the protective effects of IPC.
In addition to the differences between humans and animals, methodological choices 
made by researchers are also likely to contribute to translational difficulties. An important 
issue in this respect is the relatively small amount of renal damage inflicted in clinical 
trials when compared to animal studies. This difference is reflected in a much higher 
rise in serum creatinine levels in animal models when compared to the amount of renal 
injury that is observed after for example major cardiovascular surgery. The differences in 
serum creatinine rise indicate that the amount of renal injury in animal models does not 
necessarily represent clinical practice. Another methodological issue is related to the use 
of anesthetics, which can have strong protective effects against (renal) IRI. Anesthetics are 
mandatory in animal experiments and interfere with the amount of renal IRI inflicted in 
the experiment. It has also been shown that anesthetics can interfere with the protective 
effects of RIPC [10]. For animal experiments regarding RIPC, the ideal anesthetic has no 
influence on RIPC or IRI. Currently, little evidence indicates that barbiturates have little 
or no influence on RIPC and IRI, and therefore, could be the anesthetic of choice for 
future animal experiments [11]. The protective effects of anesthetics have also been 
described in human trials [12, 13]. The use of these agents in clinical trials investigating 
the effectiveness of RIPC may partially explain the discrepancies between animal and 
human studies. 
The interval between RIPC and index ischemia is often well defined in animal studies 
and crucial for its efficacy. The meta-analysis of Chapter 2 demonstrated that IPC in 
the second window of protection provided better protection against renal IRI in animal 
studies when compared to the first window of protection. In human studies the efficacy 
of RIPC in the second window of protection has not been established yet. Another, 
more recent and extensive meta-analysis on cardiac IPC in animal models [14] revealed 
that there is an interval between the first and second window of protection in which 
IPC is less effective, ranging from 45 minutes to four hours prior to the index ischemia. 
Although this ‘ineffective’ window of protection may also exist for RIPC in models of 
renal IRI, this could not be confirmed in our meta-analysis of animal studies reducing 
renal IRI by IPC due to insufficient data for this timeframe. An ineffective window may 
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also have played a role in our randomized trial, where the mean interval between RIPC 
and contrast administration was 46 minutes. Therefore, a substantial number of patients 
were possibly preconditioned in the ineffective window, providing a possible explanation 
for the fact that RIPC did not significantly affect the primary endpoint in this study. This 
can be considered a design error that future researchers should take into account. Our 
human meta-analysis could not show the existence of an ineffective window because 
the interval between IPC and index ischemia was not well defined in most trials. IPC 
is usually started directly after induction of anesthesia. As induction is not the start of 
renal IRI, the exact timing of IRI remains unclear, which means that the RIPC stimulus 
could fall within the ineffective window of protection and diminish the effectiveness of 
RIPC in those clinical trials [15, 16].
Future perspectives
This thesis supports the need for future animal experiments to further explore the 
mechanism of IPC and optimization of the IPC stimulus. Such experiments for example 
could help to provide insight into the ineffective window of protection of RIPC in reducing 
renal IRI. 
With regard to future human studies, this thesis supports further exploration of RIPC as 
an adjunct to standard measures in the prevention of CIN. Support for further studies 
comes from a recent meta-analysis of five randomized clinical trials showing that RIPC 
as adjunct to saline is highly effective in reducing the incidence of CIN [17]. When future 
studies confirm the results of this meta-analysis RIPC as adjunct to saline hydration for 
patients at high-risk of CIN, RIPC should be incorporated in (inter)national guidelines 
for the prevention of CIN. Further optimization of CIN prevention will probably replace 
the saline hydration by the hydration with sodium bicarbonate as it has been reported 
that hydration with one hour sodium bicarbonate, and hydration with four hours 
administration of saline before and after contrast administration are equally effective 
[18–20]. As one-hour hydration with sodium bicarbonate does not require hospital 
admission, it is a highly attractive strategy to reduce the burden for patients and 
healthcare costs. Therefore, a future trial should establish whether RIPC as adjunct to 
one-hour sodium bicarbonate provides similar protection in patients with the highest 
risk of CIN when compared to standard hydration with saline.
In conclusion, a wide range of factors influences successful translation of IPC from animal 
studies to clinical trials. This thesis has contributed to the knowledge on factors that 
influence translation of IPC to reduce renal IRI. This knowledge should be taken into 
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account when designing future animal studies and clinical trials. In future animal studies, 
the influence of anesthesia on the efficacy of RIPC should be elucidated by comparing 
the efficacy of RIPC under different types of anesthetic protocols. A future clinical trial 
should study the efficacy of RIPC as adjunct to sodium bicarbonate hydration in patients 
at high risk of CIN.
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This thesis has explored factors that are important for the efficacy of ischemic pre-
conditioning (IPC) to reduce renal ischemia reperfusion injury (IRI) and has presented 
difficulties and possible solutions that arise from the translation of preconditioning 
protocols in animals to patients. 
Chapter 1 provides the current knowledge of the pathophysiology of IRI and working 
mechanisms of all types of ischemic preconditioning (IPC). Although a large quantity 
of (pre)clinical data was present regarding the efficacy of IPC, the translation from 
effective animal studies to clinical practice is still not evident. New animal experiments 
and human trials are necessary to fill the knowledge gaps, however these studies have 
to be performed after a systematic review and meta-analysis is done to identify those 
gaps. Therefore, Chapter 2 gives a systematic review and meta-analysis of IPC in animal 
studies, providing evidence that both local ischemic preconditioning (LIPC) and remote 
ischemic preconditioning (RIPC) are highly effective in reducing serum creatinine levels 
after IRI. It also demonstrated that IPC stimuli in the late window of protection were more 
effective in reducing renal IRI than stimuli applied in the early window of protection. 
In Chapter 3 a systematic review and meta-analysis is presented on local ischemic 
postconditioning (LIPostC) and remote ischemic postconditioning (RIPostC) in animal 
studies. Results showed that both LIPostC and RIPostC are effective in reducing renal 
IRI, as reflected by lower serum creatinine levels, blood urea nitrogen levels and renal 
histological damage scores. A subgroup analysis indicated that the efficacy of IPostC 
increased with the duration of index ischemia. 
To fill important gaps in our knowledge regarding the most effective IPC protocol, we 
conducted two animal experiments in a rat model of renal IRI. In Chapter 4 an experiment 
in which rats underwent a combination of RIPostC and LIPostC directly after renal IRI 
is described. Unexpectedly, renal injury was not significantly reduced by RIPostC or 
LIPostC alone. However, the combined application of RIPostC and LIPostC significantly 
reduced renal injury, indicating that local and remote IPostC act synergistically. Another 
gap in the current knowledge is related to the question whether the efficacy of RIPC 
in reducing renal IRI could be increased by repeating the RIPC stimulus. In Chapter 5 a 
RIPreC protocol was evaluated in which RIPC was repeated daily for seven days prior to 
renal IRI. Daily RIPC was applied in rats under isoflurane anesthesia. This experiment 
did not show an additive protective effect of repeating the preconditioning stimulus. 
However, a control group receiving daily administration of isoflurane anesthesia, showed 
that repeated anesthetic preconditioning (APC) was highly effective in reducing renal IRI. 
The phenomenon of APC is well known; however, repeated administration of isoflurane 
protected against renal IRI to a much larger extent than anticipated.
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Chapter 6 a systematic review and meta-analysis of IPC for the reduction of renal IRI 
in patients undergoing cardiac or vascular surgery is provided. It included twenty-eight 
clinical studies investigating the effect of RIPC on renal function in patients undergoing 
surgery associated with renal IRI. No protective effect of RIPC was found on the primary 
outcome measure: serum creatinine levels in the early postoperative phase. In Chapter 7 
the methods of a randomized controlled trial were described. In this clinical trial, Chapter 
8, RIPC was applied as an adjunct to standard protective measures (i.e. hydration with 
intravenous saline) in patients who were at risk of contrast induced nephropathy (CIN). 
RIPC did not reduce contrast induced renal injury in patients undergoing diagnostic or 
therapeutic intravascular contrast procedures. However, a subgroup analysis indicated 
that patients at very high risk of CIN (Mehran score ≥11) allocated to the RIPC group 
had significantly lower serum creatinine levels 48–72 hours after contrast administra-
tion. In Chapter 9 we presented our view on the current literature and expected future 
developments in the field of IPC. 
In conclusion, both IPC and IPostC are highly effective in reducing renal IRI in animal 
studies. The effectiveness of IPostC may be improved by combining local and remote 
postconditioning. Repeating RIPC does not provide additive protection, where the 
repeated administration of isoflurane anesthesia provides strong protection against 
renal IRI. Available human data do not confirm the efficacy of RIPC in reducing renal IRI 
in patients undergoing major cardiac or vascular surgery. However, RIPC as adjunct to 
standard measures to prevent CIN might be effective in patients who are at high risk 
of CIN.
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Nierschade kan op verschillende manieren ontstaan en kan variëren van een tijdelijk, 
subklinisch nierfunctieverlies tot blijvend nierfalen. In het kader van dit proefschrift 
zijn wij geïnteresseerd in de nierschade die optreedt door een tijdelijke, ontoereikende 
doorbloeding. Dit wordt ook wel ischemie reperfusie-schade (IRI) van de nier genoemd 
en kan optreden bijvoorbeeld na grote hart- en vaatoperaties, niertransplantaties, sepsis 
en na het toedienen van jodiumhoudende contrastvloeistof voor radiologisch onderzoek 
en/of behandeling. De huidige methoden om IRI te verminderen, namelijk het verkorten 
van de duur van de schade of het koelen van de nier, zijn beperkt toepasbaar en veelal 
onvoldoende effectief. 
Een nieuwe manier om IRI te beperken is enkele malen kortdurend de doorbloeding van 
de nier te blokkeren; dit heet ischemische preconditionering (IPC). De nier wordt als het 
ware voorbereid op een periode met onvoldoende bloedvoorziening. Uit onderzoek blijkt 
ook dat het onderbreken van de doorbloeding van een ander orgaan of lichaamsdeel 
de IRI van de nier reduceert; dit heet ischemische preconditionering op afstand (RIPC). 
Een veel gebruikte methode hiervoor is een bloeddrukband om een arm drie á vier 
keer gedurende vijf minuten op te blazen. Als het moment van IRI niet te voorspellen 
is, bijvoorbeeld bij een hart- of een herseninfarct is ischemische preconditionering niet 
mogelijk. Het beschermende effect van het kortdurend stoppen van de doorbloeding 
werkt echter ook wanneer dit wordt toegepast direct na de periode van ischemie; dit 
heet ischemische postconditionering (IPostC). Ook hiervoor geldt dat eenzelfde bescher-
ming kan worden bereikt wanneer een ander orgaan dan de nier wordt gebruikt voor 
de conditionering; ischemische postconditionering op afstand (RIPostC).
In experimentele diermodellen zijn veel positieve resultaten van bescherming van de 
nierfunctie door conditionering beschreven, bij patiënten zijn de effecten vaak minder 
duidelijk. In dit proefschrift hebben wij onderzoek gedaan naar de effectiviteit van IPC 
in dierstudies en in patiëntenstudies. Daarnaast hebben we ons gericht op het optima-
liseren van de IPC-methode. 
Hoofdstuk 1 beschrijft het probleem van IRI, hoe dit ontstaat en welke processen hieraan 
ten grondslag liggen. Hierbij wordt ook duidelijk hoe het concept van IPC is ontstaan en 
hoe dit idee is vormgegeven in veel verschillende methoden om met IPC orgaanschade 
te verminderen. Een aantal cruciale stappen van IPC is bekend, maar het exacte wer-
kingsmechanisme van IPC is nog niet opgehelderd. Ook de optimale toediening van een 
IPC-stimulus is nog onbekend. 
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In hoofdstuk 2 werden alle dierstudies waarin het effect van IRI door (R)IPC was on-
derzocht systematisch geanalyseerd op de mate van effect en factoren die mogelijk het 
effect bepaalden. Door middel van een systematische zoekstrategie werden 523 studies 
gevonden. Hiervan waren 58 studies bruikbaar voor een meta-analyse. Het bleek dat 
(R)IPC een beschermend effect had op de nierfunctie gemeten aan de hand van het 
serum ureum en creatinine. Dit effect was ook zichtbaar bij microscopische analyse van 
nierschade. Bij subgroep analyse bleek dat muizen meer beschermd worden dan ratten 
en dat een interval van meer dan 24 uur tussen de IPC-stimulus en de IRI effectiever is 
dan een korter interval. Het bleek dat zowel IPC als RIPC effectief zijn en er was geen 
verschil in de mate van effectiviteit. 
In hoofdstuk 3 wordt een systematische analyse van dierstudies beschreven op het gebied 
van (R)IPostC. We vonden 39 artikelen geschikt voor meta-analyse, in vier studies werd 
RIPostC onderzocht, in de overige studies IPostC. Zowel IPostC als RIPostC hebben een 
beschermende werking op de nierfunctie op basis van het serum creatinine en ureum, en 
de histologie. Het beschermende effect is groter naarmate de periode van IRI langer is.
Voor zowel de meta-analyse in hoofdstuk 2 als in hoofdstuk 3 geldt dat de beschrijving 
van de methoden in de geïncludeerde artikelen matig was. Ook zijn subgroepen die be-
langrijk zijn voor translatie van uitkomsten naar de klinische praktijk, zoals vrouwelijke 
proefdieren en dieren met comorbiditeit, ondervertegenwoordigd in de studies. 
In hoofdstuk 4 hebben we de combinatie van IPostC en RIPostC in een rattenmodel 
onderzocht. In dit model werd nierschade veroorzaakt door de niervaten gedurende 25 
minuten af te klemmen. IPostC werd uitgevoerd door zes keer acht seconden de nier-
vaten af te klemmen direct na het langdurig klemmen. RIPostC werd in dit experiment 
uitgevoerd door het opblazen van bloeddrukbandjes om beide achterpoten van de rat 
gedurende drie keer vijf minuten. Het serum creatinine en ureum, de natrium uitschei-
ding en de histologie werden gebruikt als parameters voor optreden van nierschade. 
In de dieren die alleen IPostC ondergingen werd geen beschermend effect aangetoond 
in vergelijking met de controle ratten. Voor de dieren die alleen RIPostC ondergingen 
werd alleen een significant effect in de natrium uitscheiding gevonden. De combinatie 
van IPostC en RIPostC had een beschermend effect op de nierfunctie en niermorfologie. 
Op basis van deze resultaten concluderen we dat de toepassing van IPostC lokaal en 
op afstand elkaars effect versterken. Verder onderzoek moet uitwijzen of de resultaten 
reproduceerbaar zijn en kunnen worden toegepast bij patiënten.
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Eén van de uitkomsten van de meta-analyse beschreven in hoofdstuk 2 was de hogere ef-
fectiviteit bij proefdieren waarbij het interval tussen de IPC-stimulus en IRI lang was (meer 
dan 24 uur). Mede hierdoor ontstond de hypothese dat een herhaalde RIPC-stimulus (Re-
pRIPC), zowel korte als langere tijd voor IRI, effectiever is dan een enkele RIPC-stimulus. 
Deze hypothese werd getest in de dierstudie die is beschreven in Hoofdstuk 5. In een 
aaneengesloten periode van zeven dagen werd iedere dag een IPC-stimulus toegediend 
van drie keer vijf minuten door het afknellen van beide achterpoten, waarna ischemie 
van 30 minuten werd toegediend door tijdelijk een vaatklem op de bloedvaten van de 
nier te zetten. IPC en IRI vonden plaats onder algehele narcose met isofluraan. Om het 
effect van IRI, IPC en narcose goed van elkaar te kunnen onderscheiden werden in totaal 
6 groepen onderzocht: Sham (hier werd alleen een laparotomie verricht, controle (met 
alleen nierschade), herhaalde narcose (RepISO), RIPC, RepISO+RIPC en RepISO+RepRIPC. 
De vier laatste groepen (interventie-groepen) gaven in vergelijking met de controle-
groep een vergelijkbare bescherming tegen IRI van de nier op basis van lagere serum 
creatinine waarden ten opzichte van de controlegroep. In deze studie gaf herhaalde RIPC 
geen extra bescherming ten opzichte van eenmalige RIPC. Het beschermende effect van 
herhaalde isofluraan-anesthesie was groter dan voorzien. Bij toekomstige experimenten 
zal met het beschermende effect van isofluraan en eventueel ook andere anesthetica 
rekening gehouden moeten worden. Het is noodzakelijk om de beschermende effecten 
van verschillende narcosemiddelen verder te onderzoeken, enerzijds om het effect van 
(R)IPC beter te kunnen onderzoeken, anderzijds om te beoordelen in welke mate nar-
cosemiddelen nierschade kunnen verminderen.
In Hoofdstuk 6 worden resultaten beschreven van een systematische review en meta-
analyse van gerandomiseerde klinische studies waarin het klinisch effect en de veiligheid 
van (R)IPC werd onderzocht. Het betrof studies bij patiënten die een operatie ondergingen 
waarbij nierschade kan ontstaan, zoals hartoperaties, open aorta aneurysma operaties en 
nieroperaties. 28 artikelen werden geïncludeerd met in totaal 6851 patiënten. De studies 
waren over het algemeen van goede kwaliteit. Slechts bij vier patiënten werden ernstige 
bijwerkingen van RIPC gezien, dit waren patiënten bij wie met een vaatklem de slagader 
naar het been werd afgesloten. RIPC door een bloeddrukband liet geen relevante bijwerkin-
gen zien. Serum creatinine op dag 1, 2 en 3 na de operatie zijn niet significant verschillend 
tussen RIPC en de controle groep. Ook de secundaire uitkomstmaten: dialysebehoefte, 
opname duur en ziekenhuissterfte, zijn niet significant verschillend. RIPC geeft mogelijk 
wel een iets lagere kans op nierschade zoals gedefinieerd door de AKIN of RIFLE criteria.
Ondanks het gebruik van hydratieprotocollen om de nieren te beschermen tegen intra-
veneus jodiumcontrast komt contrastgeïnduceerde nierschade (CIN) regelmatig voor. 
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Onderzoek laat zien dat CIN voor een deel wordt veroorzaakt door IRI. Op basis hiervan 
zou de incidentie van CIN kunnen worden gereduceerd door RIPC. Er zijn enkele studies 
gepubliceerd met een gunstig effect van RIPC op nierschade bij jodiumcontrasttoedie-
ning. In Hoofdstuk 7 is het protocol opgenomen van de studie waarvan de resultaten 
in Hoofdstuk 8 worden beschreven. Er werden 76 patiënten gerandomiseerd in een 
controle groep en een RIPC-groep. RIPC werd uitgevoerd door een bloeddrukband tot 
een druk van 50 mmHg boven de systolische bloeddruk op te blazen. De band werd vier 
keer gedurende vijf minuten opgeblazen binnen 45 minuten voor de contrasttoediening. 
In beide groepen werd standaard hydratie met fysiologisch zout gehanteerd. Er was 
geen verschil tussen beide groepen in de primaire uitkomstmaat, het serum creatinine. 
Ook de secundaire uitkomstmaten, incidentie van CIN, heropname in het ziekenhuis, 
dialyse en sterfte verschilden niet. Wel was er een beschermend effect van RIPC op de 
nierfunctie in de subgroep met het hoogste risico op nierschade. Het toevoegen van RIPC 
aan een hydratieprotocol met fysiologisch zout voorafgaand aan het toedienen van een 
jodiumhoudend contrastmiddel is mogelijk zinvol bij patiënten voorafgaand aan con-
trasttoediening die een hoog á priori risico hebben op het ontwikkelen van nierschade.
In Hoofdstuk 9 worden de studies in een bredere context bediscussieerd en vergeleken 
met huidige literatuur. Ook worden voorstellen gedaan voor vervolgonderzoek. Hoofdstuk 
10 bevat de Engelse versie van deze samenvatting.  
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Veel dank voor uw kritische beoordeling van mijn proefschrift.
Lieve Dora en Joep, paranimfen, 
Al tientallen jaren staan jullie mij bij, mooi dat dat nu ook zo is. 
Coauteurs; M. Rovers, J.A. van der Vliet, G.A. Rongen, R. Masereeuw, M. Ritskes-
Hoitinga, C.R. Hooijmans, S.J. Jongker, M. Ergun, M.H.D. Bruintjes, R.M.L.M. Lomme, 
D.M.D. Ozdemir van Brunschot, Y. de Waal, R. Donders, M.S. Lemson, J.F. Wetzels, L.J. 
SchulzeKool, T.B. Sterrenborg,
Bedankt voor jullie harde werk, kritische blik en enorme hoeveelheid kennis van zaken. 
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als thuiskomen.
Beste chirurgen Radboud UMC, 
Nevelsteen, niertransplantatie of multi-orgaan donatie, niets was te gek. Ook het geluid 
van de traumahelikopter geeft nog altijd een kick. Ik heb het naar mijn zin gehad en 
heb veel mogen leren. 
Beste chirurgen Rijnstate Ziekenhuis,
Bij jullie mag ik vaatchirurg worden, hoe geweldig is dat! Nog bijna twee prachtige jaren 
voor de boeg, om alles van jullie te mogen leren. 
Collega’s van het Slingeland, Radboud en Rijnstate,
Hard werken en zoveel meer: Cash, Vaatdagen, chirurgencup, cabaret, chirurgendagen, 
skiën, assistentenuitje, Aesculaaf, St. Anneke, Nescio of Ruimzicht. Bedankt voor de 
collegialiteit en gezelligheid. Waar en wanneer is onbekend, maar we komen elkaar 
weer tegen.
Beste prof. dr. R.M.H. Wijnen, dr. T.J. Blokhuis en dr. M. van Deuren,
Mogelijk weten jullie niet meer wie ik ben. Mijn drang om onderzoek te doen begon 
al vroeg in de geneeskundeopleiding, maar was toen nog minder doelgericht. Ik ben 
niet gepromoveerd op congenitale hernia diafragmatica, botgenezing bij osteoporose 
of het complementsysteem. Toch hebben jullie mij warm gemaakt voor het onderzoek, 
bedankt hiervoor.  
Beste Wout en Mark,
Nooit had ik oudere broers, maar in jullie heb ik die toch gevonden. Jullie pad op weg 
naar chirurg-zijn, heeft mede mijn pad bepaald. Iets afspreken met onze vrouwen en 
steeds meer kinderen blijft vreselijk moeilijk en steevast komt de datumplanner zonder 
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geschikte datum, maar zowel in het vak als met datumplanners blijven we doorgaan tot 
succes bereikt is. 
Beste Bart, 
Via onze vrouwen leerden we elkaar kennen, er was eindelijk iemand in Nijmegen die 
niet in de medische wereld zit, fijn om te borrelen en niet over het ziekenhuis te praten. 
Hopelijk kan ik nu het wielrennen oppakken. 
Bram, Joep, John en Pieter; ‘De Mannen’,
Al meer dan 20 jaar Echte Vrienden! Wat had ik jullie nodig; er is niets beter dan samen 
in Kroatië te zeilen of samen een biertje doen. Met z’n vijven weten en kunnen we alles.
Familie van Werven, de koude kant, 
Jullie zijn echt familie geworden. Weekendje Valencia, city-run of diesfeest bij het DSC, 
maar vooral zeilen op Loosdrecht is zoveel waard. 
Dora,
Lieve zus. Leuk dat we, nu er kindjes zijn, elkaar weer zo veel vaker zien. Samen de wereld 
analyseren en belachelijk maken. 
Pa en Ma,
‘Wanneer is dat onderzoekje eens af…’, ik heb het vaak moeten horen. Zonder jullie 
geduld de afgelopen 34 jaar was het niet gelukt. Dank voor jullie enthousiasme, jullie 
stimulerende woorden.
Lieve Linde en Dorus,
Al snapten jullie er vandaag nog niet zoveel van, uiteindelijk draait alles om jullie. 
Allerliefste Hannah,
Wat hebben wij de afgelopen 14 jaar veel moois meegemaakt: de zeeën bezeild, Mount 
Kilimanjaro beklommen, een huis verbouwd. Het begon allemaal met een ijsje eten. 
Laten samen we nog veel ijsjes eten, dan kunnen we elke uitdaging aan. Jij bent de beste.
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one month to Hospital Bezmialem Vakif, Istanbul, Turkey. The last three months of his 
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an ANIOS at the Radboud University Medical Centre, Nijmegen where he started his PhD 
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(2016). Next to his passion for surgery, he loves to sail.
Appendices_Theo.indd   203 14-9-2017   22:16:39
Appendices
204
list of publiCatioNs
menting tp, Wever KE, Ozdemir van Brunschot DMD, van der Vliet DJA, Rovers MM, 
Warlé MC. Ischaemic preconditioning for the reduction of renal ischaemia reperfusion 
injury. Cochrane Database Syst Rev. 2017 Mar 4;3.
Anthonissen N, menting tp, Verkroost M, Morshuis W. Angiosarcoma of the descending 
aorta, diagnostic difficulties. EJVES Short Reports. 2016; 32:4-6.
Jonker SJ, menting tp, Warlé MC, Ritskes-Hoitinga M, Wever KE. Preclinical Evidence for 
the Efficacy of Ischemic Postconditioning against Renal Ischemia-Reperfusion Injury, a 
Systematic Review and Meta-Analysis. PLoS One. 2016 Mar 10;11(3).
Warlé MC, menting tp, Wetzels JF. Response to “Re: Remote Ischemic Preconditioning 
to Reduce Contrast-induced Nephropathy: A Randomized Controlled Trial”. EJVES. 
2015;50(4):540-1.
menting tp, Sterenborg TB, de Waal Y, Donders R, Wever KE, Lemson MS, van der Vliet 
DJ, Wetzels JF, SchultzeKool LJ, Warlé MC. Remote ischemic preconditioning to reduce 
contrast-induced nephropathy: a randomized controlled trial. EJVES. 2015; 50(4):527-32.
Sterenborg TB, menting tp, de Waal Y, Donders R, Wever KE, Lemson MS, van der Vliet 
DJ, Wetzels JF, SchultzeKool LJ, Warlé MC. Remote ischemic preconditioning to reduce 
contrast-induced nephropathy: study protocol for a randomized controlled trial. Trials. 
2014;15:119.
menting tp, Ozdemir van Bronschot DMD, Biert J, Tan ECTH. Pijnlijke zwelling op de 
borst na een ongeval. NtvTraumatologie. 2014; 22(6):151-3.
Wever KE, menting tp, Masereeuw R, van der Vliet JA, Rongen GA, Warlé MC. Local and 
remote ischemic postconditioning have synergistic protective effects on renal ischemia-
reperfusion injury. Transplantion. 2012; 15:94(1)e1-2.
menting tp, Wever KE, van der Vliet JA, Warlé MC. Regarding “remote and local ischemic 
preconditioning equivalently protects rat skeletal muscle mitochondrial function during 
experimental aortic cross-clamping. J Vasc Surg. 2012;56(3):896.
menting tp, Wever KE, Rovers M, van der Vliet JA, Rongen GA, Masereeuw R, Ritskes-
Hoitinga J, Hooijmans CR, Warlé MC. Ischemic preconditioning in the animal kidney, a 
systematic review and meta-analysis. PLos One. 2012;7(2):e32296.
Appendices_Theo.indd   204 14-9-2017   22:16:39
205
Appendices
menting tp, Tan ECTH. Overreden door vrachtwagen, Thiersch plastiek biedt uitkomst. 
NtvTraumatologie. 2012;22(6):151-3.
menting tp, Staal JF. A girl with a painful hip after a splits. NtvGeneeskunde. Ntv-
Geneeskunde. 2012;156(21):A3320.
Appendices_Theo.indd   205 14-9-2017   22:16:39
Appendices
206
riHs pHd portfolio
Name PhD student: T.P. (Theo) Menting
Department: surgery
Research School: Radboudumc Institute for Health Sciences
PhD period: 2011–2017
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Mentor: prof. dr. G.A.P.J.M. Rongen
Training activities eC points
Courses and workshops
Cochrane workshop, AMC Amsterdam, 2012 0.8
PhD training course Hartstichting, Papendal, 2015 1.75
EVAR for dummies, Amsterdam, Medtronic, 2014 0.8
Endovascular surgery, JBZ, ‘s Hertogenbosch, 2015 0.8
Workshop academic writing, Nijmegen, 2016 0.25
Private course academic writing, Amsterdam, 2016 1.75
Themabijeenkomst Vascular Damage, oral presentation, 2012, 2013 2
How to write a veni grant, RIMLS, 2015 0.25
Symposium IRI, 9-4-2015 0.25
EVC Maastricht, 2016 0.25
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Chirurgendagen NVvH, Veldhoven, 2012–2016 0.5
Najaarsvergadering NVvH, 2012–2016 0.5
Najaarsvergadering NVvV, oral presentation 0.25
Vaatdagen, oral presentation, 2012 0.25
Vaatdagen, 2013–2016 0.25
Course Damage control surgery, 2015 0.2
Cash vascular surgery 0.2
TTS, Berlin, 2x poster presentation, 2012 1
ESSR, Lille, 2x oral presentation, 2012 1
Morbidity and mortality conference, 2015–2016 1
Multidisciplinairy complication meeting, 2015–2016 1
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Student meets patient, Nijmegen, 2016 0.5
Vascular anastomosis training on cadaver pigs, 2014 0.4
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Human patient simulator training, Radboud University, 2012–2013 5
Total EC points 32.7
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